













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 






Investigation of Large Protein and 
Multimeric Protein Complex Structures 






















































"In wisdom gathered over time I have found  
that every experience is a form of exploration" 
 





This thesis is submitted in part fulfilment of the requirements for the degree of Doctor of 
Philosophy at the University of Edinburgh.  Unless otherwise stated, this work is my 
own and has not been submitted for any other degree or professional qualification.   
Work which has formed part of jointly-authored publications has been included; my 
contribution and contribution of other authors to this work has been explicitly indicated 
below.  Credit has been given within the thesis where reference has been made to the 
work of others. 
 
Chapter 1:  
This chapter includes work published in “Mass spectrometry based tools to investigate 
protein-ligand interactions for drug discovery”  Pacholarz, K.J., Garlish, R.A., Taylor, 
R.J., Barran, P.E.  Chem. Soc. Rev., 2012, 41, 4335-4355.  I have surveyed the literature 
and written the manuscript.  
 
Chapter 3:  
This chapter includes work published in “Dynamics of intact immunoglobulin G 
explored by drift-tube ion-mobility mass spectrometry and molecular modelling” 
Pacholarz, K.J., Porrini, M., Garlish, R.A., Burnley, R.J., Taylor, R.J., Henry, A.J., 
Barran, P.E. Angew. Chem., Int. Ed., 2014, 53, 7765-7769.  I have designed and carried 
out all the MS and IM-MS experiments, analysed the data and written the manuscript.  
Molecular dynamics presented in this publication were performed by Dr Massimiliano 
Porrini at the Institute Européen de Chimie et Biologie (IECB) in Pessac, France. 
 
Chapter 4:  
This chapter includes work submitted for publication entitled “Distinguishing Loss of 
Structure from Subunit Dissociation for Protein Complexes: a Gas Phase Route for 
Microcalorimetry” Pacholarz, K.J., Barran. P.E.  I have designed and carried out all the 
MS and IM-MS experiments, analysed the data and written the manuscript.   
 
Chapter 6:  
This chapter includes work to be submitted for publication entitled “The application of 
ion mobility mass spectrometry and hydrogen deuterium exchange mass spectrometry 
for probing mechanisms of allosteric inhibition of enzymes” Pacholarz, K.J., Jowitt, T., 
Burnley, R.J., Ordsmith, V., Porrini, M., Larroy-Maumus, G., Pisco, J.P., Garlish, R.A., 
Taylor, R.J., de Carvalho, L.P., Barran, P.E..  I have designed and carried out all MS and 
IM-MS experiments, analysed the data and written the manuscript.  Dr Rebecca J. 
Burnley from UCB has help with set up of HDX-MS experiments and carried out the 
data analysis.  Dr Thomas Jowitt from University of Manchester has performed the AUC 
experiments.  Dr Massimiliano Porrini at the Institute Européen de Chimie et Biologie 
(IECB) in Pessac, France performed the theoretical CCS calculations.  
 
 
         …………………………….. 
 






I would firstly like to thank my supervisor Professor Perdita Barran her constant support, 
help, guidance and opportunities given during the past four years, it has been an exciting 
journey and I’ve learned lots!  I would also like to thank my industrial supervisors Dr 
Rachel Garlish and Dr Richard Taylor from UCB Pharma for their support and insights 
into the biopharmaceutical industry.  
 
I would like to thank fellow group members (PBRG!!!) for everyday companionship 
(well, during the first 3 years), useful discussions, coffee and cake times, PBR(insert 
appropriate letter) times and continuous efforts to fix the MoQToF together: Jason, 
Yana, Hattie, Jude, Ewa, Sophie, Alberto, Bex, Jakub, Ashley, Chris, Ellie, Alex and 
project students, especially Victoria Ordsmith for her great work.  Many thanks go to Dr 
Massimiliano Porrini for running MD and MOBCAL calculations.  
 
As many of the projects I’ve worked on were carried out in collaboration with other 
institutions, I would like to acknowledge all of the collaborators.  Many thanks to Dr 
Alistair Henry from UCB Pharma for useful discussions, Dr Rebecca Burnley (UCB 
Pharma) for help with setting up HDX experiments and data analysis, Dr Shirley Peters 
(UCB Pharma) for providing me with lots of antibody samples and to the entire Physical 
and Analytical Sciences Group at UCB for their help during my research stays down in 
Slough.  I would also like to thank Dr Luiz Pedro Sório de Carvalho from MRC National 
Institute of Medical Research for collaboration on the exciting MtATP-PRT project and 
Dr Thomas Jowitt from University of Manchester for performing the AUC experiments 
and his contribution to the PRT project.  I am also appreciative to Dr Jeff Brown and Dr 
Kevin Giles from Waters Corporation for the instrument time and help with parameter 
optimization while working at Waters site in Manchester.  
 
I am also grateful to everyone in the ex-SIRCAMS lab: Logan, Alan, Sophie and 
Andrew for welcoming me to their office and giving me (and Ultima) space to work in 
the final year.  I would like to acknowledge all technical and administrative support 
provided by the mechanical workshop, the chemistry electronic workshop, the physics 
electronic workshop, the IT, the chemistry stores and the admin office.  
 III 
Finally, I would like to express my gratitude to my parents, grandparents, family and 
friends for their support over years.  Many thanks to my Edinburgh friends (especially 
Anna) and fellow PhD students as well as my wonderful friends far far away for travels 
taken together, emails and chats when I needed them the most: Ewa, Pacuś, Nani and 







The biophysical properties, biological activity and function of macromolecular systems 
are highly dependent on their structure.  Structure-activity relationships of proteins and 
their binding partners are critical for drug discovery, biochemical and medical research.  
While the gas-phase environment might present as an unusual venue from which to 
explore protein structure, for over the past two decades, nano-electrospray ionization 
(nESI) coupled to mass spectrometry (MS) has been recognized as having great potential 
for analysis of protein structure and protein non-covalent complexes.  In conjunction 
with related technique of ion mobility (IM), mass spectrometry (IM-MS) provides 
insights into protein native-like conformations and any structural changes in may 
undergo upon ligand binding or alternations induced via physical parameters such as 
temperature, pressure or solution conditions.  As most proteins tend to exist as multiple 
domains; from the distribution of oligomeric states in the Protein Data Base (PDB) 86% 
of proteins exist as oligomers; the work presented in this thesis focuses on application of 
MS techniques to probe the tertiary and quaternary structure of various large and 
multimeric protein complexes, their dynamics and/or conformational changes.  Wherever 
relevant, the gas-phase studies reported here are complemented by other techniques, such 
as hydrogen deuterium exchange MS (HDX), molecular modelling (MD) and analytical 
ultracentrifugation (AUC).   
 
Firstly, the dynamics of intact monoclonal antibodies (mAbs) and their fragments are 
explored with IM-MS.  Variations observed in conformational landscapes occupied by 
two mAb isotypes are rationalized by differences in disulfide linkages and non-covalent 
interactions between the antibody peptide chains.  Moreover, mAb intrinsic flexibility is 
compared to other multimeric protein complexes in terms of collision cross section 
distribution span.  Secondly, variable temperature MS (VT-MS) and variable 
temperature IM-MS (IM-MS) are used to probe unfolding and dissociation of four 
standard multimeric protein complexes (TTR, avidin, conA and SAP) as a function of 
the of analysis environment temperature.  VT-MS is found to allow for decoupling of 
their melting temperature (Tm) from the protein complex dissociation temperature (TGPD).  
Whereas, VT-IM-MS is used to investigate structural changes of these protein 
complexes at elevated temperatures and provide insights into the thermally induced 
dissociation (TID) mechanism, as well as strength of the non-covalent interactions 
 V 
between subunits.  Thirdly, VT-(IM)-MS methodology is applied to study behaviour of 
three mAbs: IgG1, IgG4 and an engineered IgG4 of increased thermal stability.  Such 
analysis shows to be promising for comparative thermal stability studies for proteins of 
therapeutic interest.  Lastly, the structure of ATP-phosphoribosyltransferase (MtATP-
PRT), an enzyme catalysing the first step of the biosynthesis of L-histidine in 
Mycobacterium tuberculosis, is explored.  Conformational changes occurring upon 
feedback allosteric inhibition by L-histidine are probed with MS, IM-MS, HDX-MS and 
AUC.  Reported results serve as the basis for IM-MS/HDX-MS based screening method 




Lay summary   
 
Proteins are highly important macromolecules in a living organism, responsible for its 
proper functioning.  Each protein has a specific mission to fulfil in the cell, for instance 
some proteins form defence against foreign intruders such as bacteria or viruses 
(antibodies), some catalyze biochemical reactions (enzymes), while others act as 
molecular carriers (transport proteins) or provide support (structural proteins).  The 
building blocks of proteins, called amino acids, form long chains and depending on their 
arrangement in the sequence drive protein to fold in a unique way resulting in variety of 
distinct higher order structures.  This three dimensional shape, referred to as 
conformation, determines the protein function.  Often misfolding, over production of 
certain proteins or their undesired interactions with other molecules may lead to disease.  
Studying shapes of these macromolecules helps understanding of physiological process 
related to disease and facilitates design of potential therapeutic drugs.   
 
Researchers use variety of biochemical and biophysical methods as tools to investigate 
protein structure and obtain a detailed picture their conformations and interactions.  One 
of such tools is mass spectrometry (MS), a method providing mass-to-charge (m/z) 
ratios; experiments can be design to deliver a range of structural, kinetic or dynamics 
parameters.  In conjunction with a hybrid technique of ion mobility (IM), the size of the 
molecule and any conformational changes it undergoes may be determined.  This thesis 
employs MS and IM-MS as central methodology to probe structures and their changes of 
several large proteins.  Firstly, conformations and flexibility of antibodies - molecules 
nowadays more commonly serving as templates for design of therapeutics, are studied.  
Secondly, several protein complexes are exposed to elevated analysis temperature; by 
disturbing the complex structure, more information about the structure itself can be 
obtained.  Subsequently, the same method is used to probe thermal stability of antibody 
therapeutics, which some of were designed to have enhanced stability.  Lastly, the 
structure of an enzyme thought to be a promising anti-tuberculosis drug target is 
investigated.  With MS and related techniques, conformational changes the enzyme 




ADC   antibody-drug conjugate   
AmAc  ammonium acetate 
AMP   adenosine monophosphate 
ATD   arrival time distribution  
ATP   adenosine triphosphate 
AUC   analytical ultracentrifugation  
BPTI   bovine pancreatic trypsin inhibitor  
bsAb   bispecific antibody  
CCS   collision cross section  
CCSD  collision cross section distribution  
CD   circular dichroism  
CH   constant domain of the heavy chain (Ig) 
CID   collision induced dissociation 
CL   constant domain of the light chain (Ig) 
conA   concanavalin A  
CEM   chain ejection model  
CRM   charge residue model  
CS   charge state 
CSD   charge state distribution  
CV   collision cell voltage  
Da   Dalton  
DAR   drug-to-antibody ratio 
DC   direct current  
DNA   deoxyribonucleic acid  
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DSC   differential scanning calorimetry  
DT   drift tube  
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EDDA  ethylenediammonium diacetate  
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EHSS  exact sphere scattering (method)  
ELISA   enzyme-linked immunosorbent assay  
EM   electron microscopy  
ESI   electrospray ionisation  
Fab   Fragment antigen binding (Ig)  
FAE   Fab arm exchange  
FAIMS  field asymmetric waveform ion mobility spectrometry  
Fc   Fragment crystallizable (Ig) 
FPOP  fast photochemical oxidation of proteins  
FT-ICR  Fourier transform ion cyclotron resonance 
GPCR  G-protein coupled receptor  
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IMP   integral membrane protein  
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NMR   nuclear magnetic resonance (spectroscopy)  
NOE   nuclear Overhauser effect 
NOESY  nuclear Overhauser enhancement spectroscopy 
PA   projection approximation  
PDB   protein data bank  
PPAR-α  peroxisome proliferator-activated receptor alpha 
pI   isoelectic point  
PLIMSTEX protein-ligand interactions by MS, titration and hydrogen/deuterium 
exchange 
PISA   protein interfaces, surfaces and assemblies (online server) 
PLGS  ProteinLynx Global Server  
PRPP   phosphoribosyl pyrophosphate 
PSA   projected superposition approximation 
PTM   post transitional modification   
Q-ToF  quadrupole time-of-flight  
RF   radio frequency  
Rg   radius of gyration  
RMSD  root mean square deviation  
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SLS   static light scattering 
SPR   surface plasmon resonance 
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SUPREX  stability of unpurified proteins from rates of HD exchange 
SV   sedimentation velocity 
tATD   total arrival time distribution 
TCEP  tris(2-carboxyethyl)phosphine  
TEA   triethanolamine 
TEAA  triethylammonium acetate  
TEM   transmission electron microscopy  
TIC   total ion count  
TID   temperature induced dissociation  
TJM   trajectory method  
ToF   time of flight  
TOCSY  total correlation spectroscopy 
TTR   transthyretin  
TWIG  travelling wave ion guide  
TWIMS  travelling wave ion mobility spectrometry  
UPLC  ultra performance liquid chromatography  
UV   ultraviolet  
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zave   average charge  
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Physical Constants and Quantities 
 
a  acceleration  
d  distance 
e   elementary charge, 1 e = 1.6021765 × 10-19 C 
E   electric field strength 
f  frictional coefficient 
K   mobility 
K0   reduced mobility 
kB   Boltzmann constant, kB = 1.3806488(13) × 10
-23 JK-1 
L   drift cell length 
m   mass 
MR   relative molecular weight 
m/z   mass to charge ratio 
N   number density 
P  pressure 
pI  isoelectric point  
q  net charge 
S  Svedberg, 1 S = 10−13 s 
s20,w  sedimentation coefficient (in water at 20 ̊C) 
T   temperature 
t0   dead time 
ta   arrival time 
td   drift time 
Td  Townsend unit, 1 Td = 10-17 Vcm2 
Teq   equilibrium temperature 
TGPD   gas phase dissociation temperature 
Tm   melting temperature 
v   velocity 
V   potential difference 
vd   drift velocity 
z   nominal charge 
μ   reduced mass 
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ν   radio frequency  
ω  angular velocity  
Ω        momentum transfer integral 
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Protein interactions are a key element of cell signalling and intracellular 
communication.  Loss or change in protein function is associated with disease; hence, 
studying their structure and interactions is a critical aspect of drug discovery process.  
For over 20 years, mass spectrometry has gained increased application to study intact 
bio-macromolecules in a solvent free environment. This chapter discusses the use of 
native mass spectrometry alone and in conjunction with related techniques such as ion 
mobility, hydrogen-deuterium exchange or chemical cross-linking, to provide insights 
into protein structure. Furthermore, fundamental principles of mass spectrometry are 
explained and other commonly used biophysical techniques are briefly presented. 
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1.1 Why Study Proteins and Their Structure? 
 
Proteins are highly important macromolecules in living cells, responsible for proper 
functioning of the host organism.  Protein functional classes have specific missions to 
fulfil in the cell, for instance some proteins form defence against foreign intruders such 
as bacteria or viruses (antibodies), some catalyze biochemical reactions (enzymes), while 
others act as molecular carriers (transport proteins) or provide support (structural 
proteins), among many others.1,2  The behaviour, biological activity and function of these 
macromolecular systems is dependent on their structure.  Any changes to protein 
structure, either due to post-translational modifications (PTMs), mutations or protein 
denaturation might alter protein function and properties, and often leads to disease.3-5  
The structure-function relationship studies are fundamental for drug discovery, 
biochemical or medical research.6-8   
 
Protein interactions represent an attractive axis for therapeutic intervention as targets in 
drug discovery.  Discovery and design of chemical or biological entities that interact 
with the target proteins is aimed to prevent undesired actions of proteins; done for 
example by inducing conformational changes and disabling further interactions or 
blocking binding sites and prohibiting substrate binding involved in the signal cascade.  
Drug candidates are targeted at variety of proteins such as receptors,9,10 enzymes,11,12 ion 
channels,13-15 or structural proteins16,17.  For example, molecules targeted specifically at 
protein transmembrane receptors - so called G-protein coupled receptors (GPCR) - 
account for the majority of the best-selling drugs and around 50 % of all prescription 
pharmaceuticals.18-20  Moreover, proteins themselves may be used as therapeutics, these 
entities are known as biologics.  The worldwide sales of all biologics approached the 
$US100 billion in 2010, and it is expected that more than 50 % of new drug approvals by 
2015 will be biologics, reaching even 70 % by 2025.21,22  Progress in drug discovery and 
development relies, in part, on structural analysis of complexes formed upon 
introduction of compounds that bind to the protein target in a specific manner as well as 
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1.1.1 Levels of protein structure 
 
The four levels of protein structure can be distinguished; these are referred to as the 
primary, secondary, tertiary and quaternary structure.  Proteins are biological polymers 
composed of monomeric units called α-amino acids, which consist of an amino group (-
NH2), a carboxyl group (-COOR), a hydrogen atom (H) and a variable side chain group 
(R).  All eukaryotic proteins are built of combination of amino acids from 20 commonly 
occurring amino acid with specific R groups.  A list of properties and structures of these 
amino acids are provided in Appendix 1 and 2, respectively.  These protein building 
blocks are held together by covalent peptide bonds to form a polypeptide chain 
terminated by amino terminus (N-terminus) and carboxyl terminus (C-terminus) on the 
other site.  The unique linear sequence, referred to as the primary structure, folds into 
highly regular local structures - the secondary structure.  This ‘local’ fold, governed by 
hydrogen bonds and interactions between closely spaced amino acids, gives rise to α-
helices and β-sheets, firstly proposed by Pauling and co-workers in 1951.23,24  Spatial 
arrangement of these secondary motifs, gives protein its tertiary structure.  This three 
dimensional structure is maintained by hydrophobic interactions (amino acid with 
hydrophilic R-groups seek to interact with water molecules, while hydrophobic R-groups 
avoid contact with aqueous environment and ‘hide’ towards protein centre), hydrogen 
bonds, ionic bonds (which form between positively and negatively charged R-groups), 
and potential disulfide bonds (covalent bonds formed between two cysteine R-groups).  
If the protein is composed of more than one polypeptide chain, arrangement of there 
subunits with respect to each other to form a multimer is considered as the quaternary 
structure.  Similarly to tertiary structure, this highest level of spatial organisation in 
proteins is also stabilized by non-covalent interactions and disulfide bonds.  The 
statistical distribution of quaternary structural types in Protein Data Bank (PDB)25 shows 
more than 65 % of proteins exist as multimers (as of August 2014).  This underlies need 
for development of methodologies allowing to preserve weak interactions and probe 
proteins’ highly important architectures.  
 
1.1.2 Why use mass spectrometry to study protein structure? 
 
A range of biophysical techniques are available for investigation of proteins at all 
structural levels; each possessing certain advantages and some limitations, but when 
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used in combination they can provide a coherent picture of protein structure and 
properties.  Several review articles list and compare these tools, some of which will be 
briefly introduced later.26-28  Despite a plethora of available techniques, the gold standard 
for structural information of protein complexes at atomic resolution remains x-ray 
crystallography.  Improvements in synchrotron radiation facilities and the development 
of automated data acquisition have left the main challenge in x-ray crystallography to be 
the sample preparation.  Optimisation of protein crystallisation can be a lengthy process, 
if indeed achievable at all.29  To date calorimetry and NMR are the methods of choice for 
data collection in the liquid phase; however, both are time consuming, protein size 
limited and may only work effectively under solution or substrate concentration 
conditions that may be unfavourable for the formation of stable protein complexes and 
which do not mimic physiological conditions. 
 
Mass spectrometry (MS) is a technique which measures the mass to charge ratio (m/z) of 
ions in the gas-phase; however, it is able to solve protein complexity at various structural 
levels, addressing questions ranging from protein-ligand binding30-32 to characterisation 
of intact therapeutic proteins.33-38  Its contribution to macromolecular system studies and 
biological research overall is widely reviewed in the literature.31,39-44  A great advantage 
of electrospray ionisation mass spectrometry (ESI-MS) is its non-destructive nature 
which preserves protein tertiary and quaternary structure and non-covalent interactions 
with other proteins or molecules.  With appropriate sample preparation and suitable 
tuning of the instrument, it is possible to transfer weakly associated complexes from 
solution into the gas-phase inside the mass spectrometer source.  Analysis of ESI mass 
spectra obtained under non-denaturing conditions (usually achieved with volatile 
ammonium acetate or bicarbonate buffers) provide insights into protein topology and 
stoichiometry.  Hence, besides delivering the exact mass measuring of proteins, MS 
experiments can be designed to obtain an array of information, such as: peptide sequence 
and protein identification,45-47 dissociation constants of protein-ligand complexes48,49; 
conformational changes upon binding;50 location of the binding site;51 binding 
stoichiometry and binding specificity;52 isotopic information such as oxidation states of 
binding metal ligands;53 subunit exchange that can occur within multicomponent protein 
complexes;54 or protein dynamics55-58 just to name a few.  
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In contrast to x-ray crystallography and NMR, mass spectrometry also offers the 
opportunity for solvent free/independent investigations of interactions that are intrinsic 
to the given protein system.  A gas-phase environment can be in one sense considered 
more similar to that which certain proteins occupy in biological systems.  This is because 
the dielectric constant of a vacuum (εvacuum = 1) is more similar to the membrane receptor 
environment (εpeptide/protein = 2 – 4) than for water (εwater = 80);
59 the gas phase serves as an 
appropriate medium to study structures of proteins in the conditions more closely 
resembling their natural membrane habitat.60  Moreover, MS offers unsurpassed upper 
mass analysis limit in comparison to the other higher resolution techniques.  Minor 
modifications of commercially available MS instruments61,62, has been shown to  greatly 
enhance transmission of large ions and permit analysis of mega-Dalton (MDa) 
complexes such as ribosomes63, transcriptomes and virus capsids up to 18 MDa64-68, or 
even detection of intact viruses as large as 40 MDa.69  
 
 
1.2 Principles of Biological Mass Spectrometry 
 
The history of mass spectrometry goes back to the beginning of 20th century;70 however, 
it was in late 1980’s when John Fenn’s discovery of electrospray ionisation to transfer 
biological macromolecules into the gas-phase revolutionized the application of mass 
spectrometry to biological systems.71  The fate of ions travelling through a mass 
spectrometer starting from sample preparation to detection is depicted in Figure 1.1.  
These basic components of a mass spectrometer (highlighted in purple) as well as 
methods used of conjunction (highlighted in blue) for structural studies of proteins will 
be discussed in more detail in the following sections. 
 
Prior to mass spectrometry analysis, proteins can be covalently labelled via strategies 
such as hydrogen deuterium exchange (HDX), footprinting or chemical cross-linking.  
The sample contained in volatile buffer is loaded into a thin glass capillary.  Application 
of a voltage to the capillary allows charging of the molecules and their transfer into the 
gas phase.  Ions travel through vacuum via series of focusing lenses and a hexapole to 
reach further compartments of the mass spectrometer.  When conducting an ion mobility 
experiment, ions will travel through a drift cell where they are separated by charge, 
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shape and size.  Subsequently, ions reach mass analyzer where separation is governed by 
mass to charge (m/z) ratio.  Here, tandem MS experiments can be performed allowing for 
dissociation or fragmentation of proteins or protein complexes.  Finally, ions hit the 
detector.  The impact of those ions induces an electron cascade and enables to measure 
the total ion current with is later converted to a spectrum.  Example mass spectra of 12.3 
kDa cytochrome C (a), 55 kDa tetrameric transthyretin (b) and 148 kDa immunoglobulin 
G4 (c) are shown in Figure 1.2.   Use of volatile buffers and gentle dissolvation 




Figure 1.1  Mass spectrometry workflow for structural studies of proteins.  Diagram showing 
ions’ path through the basic compartments of a mass spectrometer from sample preparation to 
the detector.  
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Figure 1.2  Nano-ESI mass spectra of monomeric cytochrome C (a), tetrameric transthyretin (b) 
and intact immunoglobulin IgG4, along with graphical representation of structures based on the 
x-ray crystal structures, 2B4Z, 1BMZ and 1IGT, respectively.  Use of aqueous buffers, such as 





1.2.1 Ionisation methods 
 
A crucial step of the MS measurement is ionisation of the analyte.  Several methods of 
sample ionisation exist and are chosen accordingly to the properties of the sample and 
desired type of information to be obtained.  Due to the large number of bonded and non-
bonded interactions in proteins, only ‘soft’ ionisation methods are suitable, namely 
MALDI (matrix assisted laser desorption ionisation) and ESI.  ESI is described in detail, 
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1.2.1.1 Electrospray ionisation 
 
Electrospray ionisation (ESI) is a widely used technique in biological, biochemical, 
pharmaceutical and medical research, as it allows for fast analysis of various molecules 
without fragmentation during ionisation. It is a soft ionization technique that can 
conveniently couple MS to liquid separations and enables MS detection even of large 
non-volatile molecules such as proteins, producing multiply charged ions.  Electrospray 
ions are commonly formed by addition of a proton [M+H]+, or cations like sodium 
[M+Na]+, sometimes by removal of a proton [M-H]-.   
 
The initial conception of producing ions by means of electrospray was first proposed by 
Dole in 1968;72 however, it was Fenn et al. who presented convincing experimental 
results nearly two decades later and was subsequently awarded a Nobel Prize in 2002 for 
the application of electrospray to the analysis of biological macromolecules.71  During 
the ionisation process, the electrolytic analyte solution is pumped through the conductive 
end of a capillary, such as coated fused silica or stainless steel emitters with a typical 
diameter of 100 µm and flow rates 1-100 µL/min.73,74  Since the solvent volume exiting 
the emitter is relatively large, a nebuliser gas and/or thermal heating has to be applied for 
aerosol formation and stable spray sustention; this has to be done especially for highly 
aqueous liquids.  The high potential of a capillary (2-4 kV) induces a strong electric field 
and draws the liquid towards the inlet; cations move towards the liquid surface and 
anions move towards the conductive tip.  Repulsions between adjacent cations combined 
with the pull of the cations towards the MS inlet due to the potential difference cause 
surface to form a Taylor cone, from which droplets with initial diameter of about 1 µm 
are released.73  Each droplet is charged due to presence of excess ions that can include 
H+, NH4
+, Na+ or K+, or removal of H+.  In order to enhance ionisation efficiency, 
compounds that increase conductivity (such as formic acid or acetic acid) can be added 
to the solution.  Evaporation of the solvent from the droplets increases charge density.  
As the Rayleigh limit is passed, where repulsion between cations equals surface tension, 
Coulomb explosions produce even smaller droplets.  Figure 1.3 depicts a nano-ESI 
(nESI) process, a miniature version of ESI, which will be described later. 
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Figure 1.3   Schematic representation of nano-electrospray ionisation in the positive mode, 
showing Taylor cone formation, production of multiply charged droplets, droplet fission, 
dissolvation and entry of the ions into the source of a mass spectrometer.  Image reproduced 
from the Royal Society of Chemistry web site.75 
 
 
ESI process can proceed via different mechanisms.  Currently, three prevailing theories 
on the gas-phase ion formation are proposed; however, “there is still much debate on the 
mechanism(s) by which…gaseous ions are formed” (J.Fenn, 2007)76.  Low molecular 
weight analytes are thought to follow an Ion Evaporation Model (IEM) (Figure 1.4a).77  
In IEM, droplet reaches a certain radius at which its surface field strength becomes 
sufficient to support field desorption of solvated ions.77  The departing ion initially 
remains connected to the droplet via a solvent bridge, which then ruptures as the ion is 
released.78  The solvent solute cluster eventually looses its solvation shell as it travels 
through the source of the mass spectrometer and experiences collisions with background 
gas ultimately resulting in the solvated ion product.79  
 
Large globular species such as folded proteins are charged and released into the gas-
phase via the Charged Residue Model (CRM) (Figure 1.4b).72,80-82  Droplets undergo 
evaporation and fission cycles, producing droplets that finally contain one analyte ion.72  
The solvent shell evaporates to dryness and the charge of the disappearing droplet is 
transferred to the analyte.80,82  As the Rayleigh limit is approached, droplets can shed 
charge upon the shrinkage process by IEM ejection of solvated protons and small ions.83  
It was found that the ESI protonation state predicted by CRM is independent of intrinsic 
protein charge or amino acid composition.80,84-87   
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Figure 1.4  Summary of proposed ESI mechanism: (a) IEM – small ion ejection from a charged 
nanodroplet, (b) CRM – release of a globular protein into the gas phase, (c) CEM – ejection of an 
unfolded protein.   Image adapted with permission from Konermann et al.87 Copyright 2013 
American Chemical Society. 
 
 
The third model, Chain Ejection Model (CEM), has been proposed for disordered 
polymers (Figure 1.4c).87  Molecular dynamics (MD) simulations revealed that unfolded 
protein undergo ESI mechanism somewhat different from the two discussed above.88,89  
Disordered conformations, either intrinsic or solvent triggered, contain solvent 
accessible non-polar residues with hydrophobic character as opposed to globular proteins 
where these residues tend to be buried within the hydrophobic core.  This makes it 
unfavourable for the unfolded protein to reside within the droplet and as a result the 
chain is sequentially ejected from the droplet.  CEM ejection of hydrophobic chains 
occurs on a ns time scale leading to enhanced ion yield and signal intensity as compared 
ions produced via CRM mechanism which is relatively slow and inefficient process 
occurring on a μs time scale.88,90-92  
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In 1994, Wilm and Mann miniaturised Fenn’s ESI technique obtaining improved 
sensitivity.73,93  So called nano-ESI (nESI) produces droplets approximately 10 times 
smaller (about 150 nm) than droplets obtained with the traditional ESI rendering the 
desolvation process more efficient even under very gentle combinations of applied 
pressure and temperature.  This simple variant of ESI with its much lower potentials 
between capillary and sampling orifice (1-1.5 kV cf 3-5 kV for ESI) is less destructive to 
non-covalent interactions.  The lower flow rates mean that less sample material is 
required for analysis allowing interrogation of more limited protein samples, and the 
potential for multiple high throughput measurements.  This invention had a notable 
impact on mass spectrometry studies of proteins and their complexes.94 
 
The purpose of using non-denaturing solution and source conditions is to preserve, as 
much as possible, the solution phase ‘native’ conformation of proteins.  The effective 
charge acquired by a compact globular protein when undergoing electrospray ionisation, 
buffered in an aqueous solution to a suitable pH, close to its isoelectric point, is 
significantly lower when compared with that presented by the same protein that is 
electrosprayed from an acidified solution.  In the former case there are fewer surface 
accessible sites available for protonation.  This results in native proteins being observed 
at higher m/z ratios and imposes a requirement for mass analyzers with extended m/z 
ranges, particularly for study large multimeric protein complexes.  Theoretically, the m/z 
range of time-of-flight (ToF) analyzers is unlimited making them the most appropriate 
for large native protein studies (often commercially available as quadrupole-ToF 
hybrids) offering high sensitivity, specificity and rapid analysis.95,96,97   
 
Optimisation of several instrument parameters is essential to preserve non-covalent 
interactions, native conformation and to obtain high transmission efficiency.  Adjusting 
the pressure of the mass spectrometer’s interface and accelerating voltage will have an 
effect on the efficiency of collisions and kinetic energy of the ions in the source of the 
instrument, this so called collisional cooling, disfavours complex disruption.98  Bespoke 
modification of commercial instruments has allowed for better source pressure control 
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1.2.1.2 MALDI 
 
Matrix assisted laser desorption ionisation (MALDI), a soft ionisation method 
principally introduced by Karas and Hillenkamp,99-101 uses UV laser beam to trigger 
desorption.  Samples are mixed in large excess with a small molecule matrix (usually 
cinnamic aid derivatives for protein analysis), and spotted into a conducting plate.  When 
solid, the mixture is irradiated with a laser under vacuum and sublimates into the gas-
phase.  The matrix absorbs excess energy protecting protein from fragmentation and also 
provides protons for ionisation.  As this method produces mostly singly charged ions 
(with a small population of doubly charged species) and uses acidic conditions for 
sample preparation, it is not a common method of choice for analysis of very large and 
non-covalent protein complexes. Nevertheless, more recently Zenobi and co-workers 




1.2.2 Mass analysers 
 
After the ions pass though a series of focusing lenses, the beam enters the mass analyser 
where ions are separated based on their m/z ratio.  There are several types of mass 
analysers displaying different properties: compatibility with various m/z ranges, 
resolving powers, accuracies, sensitivity, ease of use and operational costs. All 
advantages and disadvantages should be considered prior to choosing an appropriate 
type.  The following sections will present two types of the mass analysers employed in 
this work i.e. quadrupole mass analyser followed by the time-of-flight (ToF) mass 
analyser.   
 
1.2.2.1 Quadrupole mass analyser  
 
Quadrupole mass analysers are the most commonly used type due to their relative low 
cost, easy maintenance and ability to function as both: a mass filter and a full mass 
analyser.  Developed by Paul and Steinwedel in the 1950’s, a quadrupole consist of four 
(usually cylindrical) parallel rods to which a fixed direct current (DC) potential is 
applied along with an alternating radio frequency (RF) potential (Figure 1.5).106   
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Figure 1.5  Schematic of a quadrupole mass analyser.  Opposite rods have the same polarity.  
The ions with a stable trajectory (blue) are transmitted through the quadrupole and pass further 
to the detector.  The ions with an unstable trajectory (pink) collide with the rods, discharge and 
are not detected.  
 
 
The opposite rods are in-phase while the adjacent rod pairs are 180° out-of-phase with 
respect to their RF field.  This produces an oscillating electric field.  High frequency 
polarity switching between adjacent rods, superimposed on the constant electric field, 
drives ions through the analyser.  Ions are drawn towards the oppositely charged rods 
and change directions upon polarity switching to continue travelling through the 
analyser.  The trajectories of these ions are dependent on the spacing of the rods, the 
frequency of the RF and the amplitude of the applied potential.  These factors determine 
the influence of the electric field on an ion and can be expressed by the following 
equations: 
 
+ Ф0 = + (U + V cosωt)    and     - Ф0 = - (U + V cosωt)     (Equation 1.1) 
 
where Ф is the total potential on the rods, U is the DC potential, V is the RFzero-to-peak 
voltage, and ω is the angular frequency of the RF (with ω = 2πv, v = frequency).  For an 
ion of given m/z there is a set of unique combinations of U, V and ω that will give rise to 
a stable trajectory allowing it’s transmission towards the detector.  In Figure 1.5, a 
schematic of a typical quadrupole is shown; the blue ions are able to oscillate between 
the rods and reach the detector, whereas the pink ions have an unstable trajectory and 
discharge during the transmission due to collisions with one of the rods.  By fast 
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scanning the RF amplitude, a range of ions with differing m/z can follow a stable 
trajectory resulting in generation of a mass spectrum, where m/z values are calculated 
based on the potential and frequency applied and known geometry of the quadrupole.  
 
Quadrupole analysers are often used as mass filter in tandem mass spectrometers with 
other types of mass analysers such as time-of-flight (ToF).  The ability to select an ion of 
a specific m/z is exploited in the tandem MS experiments, during which the selected 
precursor is transmitted and subsequently fragmented via collision-induced dissociation 
(CID).   
 
1.2.2.2 Time-of-flight analyser  
 
The time-of-flight (ToF) mass analyser was first described by Stephens107 in 1946, but it 
was not until 1955 when Wiley and McLaren demonstrated its practical usage for 
commercially available instruments.108  In the ToF instrument, a packet of ions is 
accelerated by a potential difference and subsequently enters a field-free region and 
drifts through it at a velocity dependent on the m/z ratio (Figure 1.6).  The m/z can be 
easily determined as it is directly proportional to the ions flight time (tf) through a fixed 
distance.  The relationship between an ion acceleration potential and the flight time can 





mvEk                                             (Equation 1.2) 
 




















                                       (Equation 1.4) 
 
where v is the ions velocity, m is mass, Ek is kinetic energy, tf is flight time, V is 
acceleration potential, q is the charge on the ion, z is the integer ion charge, e is electron 
charge, and df is flight distance.  According to Equation 1.2, for a given kinetic energy, 
the velocity of an ion is dependent on its mass.  Kinetic energy is given to an ion in the 
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acceleration region (pusher) and it varies linearly with the charge as described by 
Equation 1.3 (the higher the charge the more kinetic energy the ion receives).  
Combining those two equations results in Equation 1.4, which directly enables to find 
m/z based on the flight of time (tf).  There is no theoretical upper limit to the mass range 
which can be analysed by ToF analyser. 
 
The original ToF instruments used linear ToF analyzers (Figure 1.6a); however, 
nowadays, many instruments are composed of a reflectron ToF analyser (Figure 1.6b), 





Figure 1.6  Schematic of a linear (a) and a reflectron (b) ToF mass analyser;  (a) ions with lower 
m/z are depicted by smaller circles.  Ions of the same m/z can be distributed along a flight path, 
broadening the response peak and resulting in poor resolution.  (b) Ions of the same m/z values 
are shown, the green ion has higher initial kinetic energy and travels further into the reflectron.  
Use of this ‘ion mirror’ enhances analyser resolution by increasing the flight path length and 
correcting for the initial potential energy differences.  
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affect the potential difference it experiences; hence, ions of the same m/z could enter the 
field-free drift region with differing kinetic energy causing them to arrive at the detector 
at slightly different times jeopardizing the resolution.  In the 1970’s, Mamyrin developed 
an electrostatic mirror called a reflectron.109,110  A series of electrostatic lenses deflects 
ions with a given m/z values back towards the detector.  Ions with higher kinetic energy 
penetrate further into the reflectron what allows species of the same m/z to arrive at the 
detector simultaneously, regardless of the initial kinetic energy greatly improving 
resolution.111  Figure 1.6 compares both types of these ToF mass analysers.  Moreover, a 
single ToF analyser can be coupled with another ToF analyser (ToF-ToF) or quadrupole 
(Q-ToF).  Often, the first analyser is used to isolate an ion of interest (parent ion) and the 





The final stage of a mass spectrometry experiment is ion detection.  Most of the MS 
detectors use incident ions to produce a secondary beam of electrons which is further 
amplified to create a detectable current.  There are three common types of detectors 
available: electron multiplier, photomultiplier and microchannel plates.   
 
1.2.3.1 Electron multiplier and photomultiplier detectors 
 
Electron multipliers are commonly coupled to quadrupole and ion trap analysers.  This 
type of the detector consists of a series of dynodes held at sequentially increasing 
potential.  Ions from the mass analyser are accelerated and collide with the surface of a 
first conversion dynode producing electrons which are accelerated further.  Collisions 
with the subsequent dynodes produce more electrons until the final dynode is reached 
and the signal is detected as an ion current with significant signal amplification (up to 
106 greater intensity).112   
 
The photomultiplier detector operates on a similar principle to the electron multiplier.113  
The ions are incident on a conversion dynode and generate electrons.  Subsequently, 
these electrons collide with a phosphor screen resulting in generation of photons which 
are then detected by a photomultiplier.  If the hybrid Q-ToF instrument used in the 
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‘quadrupole only’ mode, ions are detected by the photomultiplier on their entry to the 
ToF tube.    
 
1.2.3.2 Microchannel plates detector  
 
Most ToF instruments are coupled to microchannel plate (MCP) detectors which have a 
quick time response and high sensitivity (<1 ns and single ion signal of 50 mV).113  
Microchannel plates, firstly implemented in 1960’s, consist of thousands of miniature 
electron multiplier enabling the detection of large number of ions at the same time.114  
An ion incident on one side of the channel will eject electron upon the collision.  This 
process is repeated inducing a cascade of electrons resulting in measurable current.  
Figure 1.7, shows a schematic of a microchannel plate (a) and the process of ion 




Figure 1.7  Microchannel plate detector (MCP): (a) MCP design featuring an array of channels, 
(b) MCP in action – an incident ion starts a cascade of electrons upon impact, amplifying the 
signal.  Images adapted from Hamamatsu web site.115  
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1.3 Mass Spectrometry Methods for Elucidation of Protein 
Structure and Interactions  
 
1.3.1 Ion mobility mass spectrometry 
 
Ion mobility mass spectrometry (IM-MS) can provide useful insights into the structures 
of biological macromolecules and their complexes and has been applied to study 
peptides and proteins, carbohydrates, lipids, nucleotides as well as other natural 
products.28,116  Ion mobility separations performed with an inert background gas are 
based on the charge, size and shape of an ion and are proportional to the ion surface area 
i.e. to the rotationally averaged collision cross section (CCS).  When coupled to a mass 
spectrometer, separation of ions in the gas-phase becomes two dimensional – based on 
the mobility (K) and mass to charge ratio m/z.  It is possible to separate coincident m/z 
species based on their oligomeric order and protein conformations as illustrated 
schematically in Figure 1.8.   
 
Significant developments of IM-MS for biological applications occurred in the mid-
1990’s, results of the first IM-MS structural studies of peptides were published by 
Bowers et al.117 and on intact proteins by  Jarrold, Clemmer et al.118,119.  About 10 years 
later, Robinson, Heck, Ashcroft, Loo, Barran, Leary and other groups extended the scope 
of IM-MS to the study quaternary structure of protein complexes.120,121-135  Much of this 
work has been possible due to the remarkable technical developments made by Bateman  
and co-workers136,137 in their development of the first commercial IM-MS instruments, 
which possess a vastly superior transmission efficiency for IM separation, as well as 
much better m/z resolution compared with most homemade IM-MS devices.  
 
Uetrecht et al. have written an excellent review on the application of IM-MS to protein 
and protein-assembly studies.138  IM-MS allows the study of protein unfolding and 
conformational changes upon ligand binding.  Protein ions can unfold in the gas phase, 
most likely driven by Coulombic repulsion.  Ions with fewer charges retain more 
solution-like structure than highly charged ions of the same species.138  IM-MS is able to 
resolve distinct conformational families for particular ions and to recognize structural 
diversity from compact to extended conformational states.  For example, Hopper and 
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Oldham have studied structural stability (unfolding and dissociation) of compact proteins 
such as the FK-binding protein, lysozyme and myoglobin as a function of ligand 
binding.139  IM-MS has also been applied to study 11-membered structure of oligomeric 
tryptophan RNA binding attenuation protein complex (TRAP) to show retention of its 
ring-like topography after the electrospray ionisation process and its transition to the gas 
phase as well as increase of stability upon ligand binding.121,140  
 
In comparison to atomic structural resolution methods such as x-ray crystallography or 
NMR, IM-MS provides relatively low-resolution structural information; however, only 
small quantities of sample are required, gas phase separations are rapid and solvent 
effects are not present.141  Hill et al. have prepared an extensive review on milestones in 
the development of IM-MS.142  There are three principal types of ion mobility 
instrumentation that have been successfully coupled with mass spectrometry: drift tube 
(DT), travelling wave (TWIMS), and field asymmetric waveform ion mobility 
spectrometry (FAIMS) which will be presented in the following sections.   
 
Despite differences in the configuration of IM-MS instruments; there are some common 
features.  A pulse of ions is injected into a chamber filled with a known inert gas at a 
known pressure.  An electric field is applied across the chamber and the time taken for 
the ions to travel though is measured.  The ions are actively transported through the cell 
by the electrostatic force; at the same time this force is opposed by collisions of ions 
with buffer gas.  The mobility K is dependent on the molecular shape, charge of the 
species and the buffer gas pressure.  Only DT-IM-MS instruments allow for direct 
determination of collision cross sections (CCS) by recording the drift velocity of an ion 
through a linear drift field.143   
 
1.3.1.1 Linear DT-IM-MS  
 
Measuring the time it takes for the ions to transverse through a buffer gas (usually 
helium) filled drift cell under a weak electric field, allows for determination of CCS.  
The electric field (E) is defined in terms of the length of the drift cell (L) and the voltage 
applied across the cell (V) by Equation 1.5:  
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L
V
E                                              (Equation 1.5) 
 
The ratio of the electric field across the cell (E) to the buffer gas density (N); expressed 
in Townsend (Td); determines the transmission of ions through the cell.  Ions align in the 
electric field and their mobility becomes dependent on E at high E/N values (> 10 Td).  
At lower E/N values (≤ 10 Td), known as the low field limit, ion’s velocity is constant 
and linearly proportional to the electric field: 
 
EKvd                                          (Equation 1.6) 
 
where vd is the drift velocity and K is the low field mobility.  In turn, K is proportional to 
buffer gas pressure and inversely proportional to Ω.  Since K is dependent on N, to 
decouple it from experimental variables of pressure and temperature, and allow for data 
comparison, K is converted to reduced mobility K0 by Equation 1.7; where normalized 








0                                    (Equation 1.7) 
 


















                       (Equation 1.8) 
 
The arrival time (ta) measured during an IM experiment, is equal to the sum of time 
taken for the ions to drift through the cell (td) and the time ions spent outside the drift 
cell until detection (dead time, t0).  By maintaining a constant temperature during the 
measurements, a graph of ta versus P/V will provide a linear relationship with an 
intercept equal to t0.  The slope gradient of this line is equal to the inverse of the reduced 
ion mobility; hence, Ω can be determined using Equation 1.9, which is approximated to 
the ion’s CCS.  
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Figure 1.8  Principle of ion mobility separation.  Ions are pulsed into the drift cell and travel 
through a uniform electric DC potential against the gas flow to be separated based on their 
conformation and charge.  Arrival time distributions (ATD) are acquired and can be converted 
to collision cross sections (CCS).    
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Mobility K is inversely proportional to CCS according to the following relationship: 
 



















                             (Equation 1.9) 
 
where K0 is the reduced mobility (the measured mobility K standardized for pressure and 
temperature to 273.15 K and 760 Torr), z is the ion charge state, e is the elementary 
charge, N is the gas number density, µ is the reduced mass of the ion-neutral pair, kB is 
the Boltzmann constant and T is the gas temperature and Ω is the momentum transfer 
collision integral (approximated to the CCS of the ion by kinetic theory). 
 
 IM allows for separation of coincident m/z ions by charge and conformation.  As can be 
seen from Equation 1.9, K and Ω are inversely proportional to each other, hence small 
and more compact ions (of the same m/z) will travel faster through the cell than more 
extended ions (separation by conformation, Figure 1.8).  Whereas, z and Ω are directly 
proportional, therefore ions carrying more charge will have shorter arrival time than 
those with less charge but coincident m/z value what enables separation by oligomeric 
order. 
 
1.3.1.2 Travelling wave ion mobility spectrometry (TWIMS) 
 
The application of IM-MS for structural studies of biological macromolecules has 
greatly increased since the introduction of a commercial quadrupole/travelling wave ion 
mobility time of flight mass spectrometer.136  Although the transmission efficiency of 
ions through a traditional drift cell is low, the physical aspects are well 
understood.142,144,145  This is not yet the case for ions transmitted through ion mobility 
cells with travelling wave technology136,146 where CCS cannot be directly determined 
and drift times calibrated for ions of interest against those measured for ions of known Ω 
values.120,147,148  Jurneczko et al. have compared CCS for several monomeric proteins 
investigated with different ion mobility techniques and found good agreement, although 
they also note the consistent reduction in CCS compared to theoretical CCS extrapolated 
from crystal structure data.147,149 
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The first commercial available integrated IM-MS instrument was introduced by Waters 
MS Technologies in 2006, and called the Synapt G1 HDMS.136  Later, upgraded versions 
of this instrument with improved resolution and sensitivity were released (SynaptG2 in 
2009 and G2S in 2012).  Synapt HDMS instruments, based on the travelling wave 
(TWIMS) technology, use stacked ring ion guides (SRIG) for mobility separations 
located between the quadrupole and the ToF analyser.  Ions are released from the first 
ion guide of T-wave cell as a packet into the IMS T-wave cell filled with nitrogen gas 
(process analogous to the injection of ions into the drift cell in the DT-IM-MS type 
instrument).  Here however, mobility separation is performed as the repeating DC pulses 
drive ions through the cell.  Application of opposite phases of RF voltage to adjacent 
rings and superimposed transient DC pulse, creates a moving electric field – the 
travelling wave, on which ions ‘surf’.  The ions roll over the wave and the separation 
occurs based on their mobility and due to collisions with the buffer gas.  The 
fundamentals of travelling wave are not fully understood yet.146 
 
A shortcoming in the use of TWIMS-MS devices is that this type of IM-MS device does 
not directly provide CCS from drift time data.  Instead a number of different calibration 
approaches have been suggested, which all are based on the use of protein standards, 
whose CCS has been measured in DT-IM-MS instruments.147,150,151  Whilst this approach 
has been used to good effect in a number of studies, there are some less satisfactory 
elements to it.  The first is that the DT-IM-MS standards are usually measured with 
helium as the drift gas, whereas in TWIMS-MS instruments the drift gas is usually 
nitrogen.  This means that TWIMS CCS measurements are made in one gas, but 
converted to another.  For small molecules it is well known that CCS are strongly buffer 
gas dependent.152,153  This effect is less for larger macromolecules, but still apparent, 
which means that standards must be chosen carefully to be ‘similar’ to the unknown 
systems under study.   
 
In addition, a problem with applying a calibration method to determine the CCS of an 
unknown system is that different sampling conditions (including solvent, source 
temperature, ion transmission settings) all can affect the actual conformation of ions in 
the mass spectrometer, which in turn may be distorted by the calibration.  Further to this 
there have been reports that the temperature of ions in TWIMS instrumentation may be 
higher than ambient, whereas for DT-IM-MS, drift cell temperature is a carefully 
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recorded experimental parameter, essential for the evaluation of a CCS from a given 
ion’s mobility (Equation 1.9).154,155  The ions of course are thermalised in these 
experiments having undergone many millions of collisions in the first few mm of drift.  
None-the-less, in the absence of an exact solution for the relationship between the 
mobilities of ion in TWIMS-MS instruments the calibration methods are still useful, and 
have produced a number of interesting results.  Despite issues with determining absolute 
CCS from TWIMS-MS data, the ability of these instruments to provide understanding 
how conformational changes relate to the modulation of protein function is beneficial to 
structural biology and enabled number of research groups to utilize IM-MS 
methodology. 
 
1.3.1.3 Field asymmetric waveform ion mobility mass spectrometry (FAIMS) 
 
High-field asymmetric waveform ion mobility spectrometry (FAIMS), also knows as 
differential mobility, separates ions based on their mobility differences in high and low 
field at the atmospheric pressure.156  Because at a high field electric field (E/N > 10 Td), 
the mobility of the ion is influenced by the electric field, this method cannot be used to 
derive CCS.  In a FAIMS device, ions drift between two parallel planar electrodes 
through a buffer gas flowing in the same direction as the ions.  One of the electrodes is 
kept at ground potential, while an alternating electric field (asymmetric wave) is applied 
to the other electrode consisting of short high-voltage components and long low-voltage 
component of opposite polarity.157  The asymmetric wave applied is orthogonal to the 
gas flow and causes ions to oscillate between the two electrodes moving them towards 
the detector (analogous to the quadrupole analyser).  To prevent ions from discharging 
against the electrode, a compensation DC voltage is applied to correct their trajectory.  
Ions of different size and conformation require specific compensation voltage values for 
successful transmission, hence, it is scanned across a range of values or fixed at a 
specific value to select a specific ion population (similarly to mass filter approach in 
quadrupole mass analysers).  Use of high fields may cause distortion to conformations 
and unfolding of labile biomolecules, hence FAIMS is not a method of choice for studies 
of native-state protein structures.  Nevertheless, FAIMS is a powerful tool for the 
analysis and separation of peptide mixtures158-161 and also finds vast application in 
detection of chemical warfare agents and explosives.142  Commercial instruments were 
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made available by a number of manufacturers, also as a front-end device which can be 
coupled to a mass spectrometer. 
 
 
1.3.2 Probing structures via induced dissociation 
 
Information on subunit composition and topology of multimeric protein complexes is 
often obtained by activating protein ions in the gas-phase to induce structural changes 
and often dissociation of these subunits.  The most commonly used activation method is 
collision induced dissociation (CID) achieved via energetic collisions of the ion with 
neutral gas.  Nevertheless, other activation methods exist, such as surface induced 
dissociation (SID), blackbody infrared radiative dissociation (BIRD) or the application 
of elevated injection or acceleration voltages; these methods and their application to 
study of biomolecules are summarized in Figure 1.9.  Since proteins are capable of 
adopting more compact or extended states both in vivo and also in the gas-phase upon 
activation, including the IM-MS in this repertoire will provide an experiment that 
provides conformational information and enables structural changes to be directly 
followed.  
As protein activity is greatly dependent on the solution temperature, several research 
groups have designed variable temperature nESI (VT-nESI) capillary holders that allow 
for control of the sample solution temperature.  These devices have been applied to 
address variety of questions and study conformational changes in monomeric proteins 
such as ubiquitin,162,163 denaturation of ribonuclease S164 or DNA destabilization,165,166 
protein-carbohydrate binding,167,168  unfolding and dissociation of thermally activated 
proteins such as small heat-shock proteins (sHSPs),169,170  solution-phase thermal 
disassembly of co-chaperonins GroES and gp31,171 or probing early stages of heat-
induced protein aggregation172.  
Activation of proteins can be induced not only in-solution prior to transfer into the gas-
phase, but also in the vacuum of a mass spectrometer.  Raising voltages in the source 
region of the mass spectrometer, such as cone or extractor cone voltages, affects the 
acceleration of the ions through the source.  Increased collision energy with the 
background gas is transferred into the internal energy of the sample ion and might  
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Figure 1.9  Methods of protein activation in an (ion mobility) mass spectrometry experiment.  
The chart lists MS based techniques used to induce protein activation along with the type of 
information that can be obtained via each method and references to research groups 
specializing in application of these techniques for studies of protein complexes. 
 
disturb protein structure and induce protein unfolding and protein complex dissociation.  
With the use of IM, Benesch et al., showed how the in-source complex activation affects 
protein structure.123  Raising the cone voltage, resulted in an initial decrease in drift time 
of ions and a subsequent increase in drift time as well as a notable broadening of the 
arrival time distributions (ATD) for a 197 kDa small heat shock protein Arc1.  This was 
attributed to collision induced reconstructing (collapse of the central cavity) followed by 
collision induced unfolding.123  Similar effects have been noted for a ring-shaped 
tryptophan RNA-binding attenuation protein.121  Ruotolo et. al studied homotetrameric 
transthyretin (TTR) (56 kDa), and showed how the in-source activated complex 
undergoes unfolding transition states that are stable on a millisecond time scale prior to 
dissociation.122   
Protein dissociation can be induced in the later stages of a mass spectrometer via the 
insertion of a collision cell allowing for collision induced dissociation (CID).  In a CID 
experiment, molecular ions are accelerated by an electric potential to higher kinetic 
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energies.  Upon collision with neutral gas molecules, some of the kinetic energy is 
transferred into internal energy leading to dissociation.  CID is a widely used tandem MS 
method to study protein interactions and arrangement of subunits within a complex.  The 
first reports of CID on tetrameric streptavidin, dimeric cytochrome c or tetrameric TTR, 
had shown asymmetrical charge partitioning upon dissociation.173-175  Due to statistical 
reasons, one subunit might carry slightly more charge than others.  This asymmetrical 
charge partitioning results in a marginally destabilized subunit, resulting from 
intramolecular Coulombic repulsions.176  Upon collisional activation of the complex, one 
or possibly multiple subunits begin to unfold.  As the new surface area is exposed, 
charge migration occurs to that region and drives further unfolding which eventually 
results in release of highly charged monomer (Figure 1.10).177  This dissociation pathway 
is referred to as the ‘typical’ route.178  The addition of ion mobility separation probed 
conformational changes that occur during collisional activation process.  Several 
proteins, such as TTR, (and mutants and ligand bound forms) and  heat shock protein 
16.9 (HSP16.9) have been studied to show a series of conformationally diverse transition 
states undergoing unfolding prior to dissociation as the CID energy is increased.124,179,180  
Moreover, CID-IM and molecular dynamics (MD) studies on SAP and TTR showed that 
the protein complex compaction and dissociation are greatly dependent on the charge 
state, where the highly charged species require less energy to cross the dissociation 
energy barrier.179,181  Hall et al. reported that high charge states of protein complexes 
with low subunit flexibility, higher charge densities, fewer salt bridges and smaller 
interfaces are likely to be involved in promoting dissociation routes without unfolding, 
the ‘atypical’ dissociation route.178  Moreover, recent findings show that addition of 
Hofmeister salt-based solution additives that stabilize the complex, increase the energy 
dissociation barrier.182-185  
The multistep protein complex activation occurring on a millisecond time scale in the 
CID experiment and resulting in asymmetric ejection of unfolded monomer from the 
complex, might be somewhat limiting the amount of information on the sub-oligomeric 
architecture.186,187  Wysocki et al. have employed surface induced dissociation (SID) and 
demonstrated conditions that can achieve dissociation of complexes without any 
significant unfolding of subunits prior to dissociation (‘atypical’ dissociation).188-190  
Although the concept of SID has been introduced long time ago,191,192 more recently this  
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Figure 1.10  The effect of activation techniques on the structure of multimeric proteins.  
Skimmer-cone, CID and BIRD activation occur on a long time scale and proceed via asymmetric 
charge partitioning followed by subunit unfolding and dissociation - the ‘typical’ dissociation 
route.  SID activation (occurring at much shorter time scale (ps)) or modulation of charge states 
in the CID process results in release of compact subunits – the ‘atypical’ dissociation route.  
Graphical representation of the activation process is based on a TTR structure, PDB:1BMZ.  
 
method has been used to study dissociation of peptides and non-covalent protein 
complexes such as TTR, SAP, phosporylase B (PHB) and glutamate dehydrogenase 
(GDH) or even 801 kDa GroEL. 190,193-198  In a typical CID experiment, energy is 
deposited into the complex by multiple low-energy collisions, whereas SID deposits 
energy into the complex by a single collision with a surface on a picosecond time scale.  
SID experiments show more symmetric charge partitioning upon dissociation and release 
of compact subunits yielding meaningful information on native-like topology of protein 
complexes (Figure 1.10).190,195,196,199,200 
Additionally, in IM-MS experiments, ions can be activated via higher energy collisions 
which occur as ions are injected into the drift cell region of the IM mass spectrometer.  
High injection energies can induce structural changes and/or fragmentation of the ions if 
desired.  Jarrold et al. have first presented this principle on bovine pancreatic trypsin 
Chapter 1                                                                                                                                                   Introduction  
 
 
- 29 - 
inhibitor (BPTI) and cytochrome c.119  It was found that BPTI retains in its compact form 
when collisionally activated attributed in part to the presence of three disulfide bridges, 
unlike cytochrome c with no disulfide bridges which gradually unfolds through a series 
of well defined intermediates.119  By increasing the ion injection energy, peaks at short 
arrival times disappear and the intensity shifts to the peak at longer arrival times 
illustrating the annealing of ions to more open conformations by collisions with the drift 
gas at the entrance to the drift cell.  Injection energy induced unfolding and dissociation 
has been demonstrated on oligosaccharides, monomeric protein such as ubiquitin, 
lysozyme and amyloidogenic proteins like α-synuclein, amyloid β-protein and its 
aggregates.201-207   Furthermore, an increase of temperature of the buffer gas during the 
IM experiments by direct application of heat induces protein unfolding and dissociation, 
however this method will be discussed in more detail in Chapter 4.208  
An alternative approach to ion activation is blackbody infrared radiative dissociation 
(BIRD) technique, which is usually implemented on ion trap type mass spectrometers.  
In BIRD, isolated ions are activated by absorption of infrared blackbody photons emitted 
from the walls of a heated vacuum chamber of a Fourier-transform mass spectrometer,209  
enabling the measurement of the temperature dependence of dissociation rate constants 
and subsequent determination of the Arrhenius activation energy (Ea) and preexponential 
factor (A) for gaseous ions.  Williams and co-workers have widely investigated the 
dissociation of monomeric proteins,210-212 and later the first application of BIRD on 
multimeric protein complexes was reported by Klassen et al. on a pentameric Shiga-like 
Toxin I.213  Asymmetric dissociation into monomers and tetramers was observed along 
with remarkably large A, being an indicative of the mechanism proceeding via the 
unfolding of a monomeric subunit prior to dissociation.  Further BIRD experiments, 
found that the dissociation pathway is dependent on temperature, with the loss of a 
single subunit dominant at higher reaction temperatures, and fragmentation of the 
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1.3.3 Hydrogen deuterium exchange mass spectrometry (HDX) 
 
1.3.3.1 Principles of HDX 
 
Hydrogen deuterium exchange experiments (HDX) are used to examine the structure and 
dynamics of proteins by replacing a covalently bound hydrogen atom of amides in the 
backbone of a protein by a deuterium atom and detecting the change spectroscopically in 
the deuterated form.  HDX was explored by a Danish protein scientist Kaj Ulrik 
Linderstrøm-Langand and it has been used most frequently in conjunction with NMR.217-
220  In 1991, the first successful coupling with a mass spectrometer as the detector was 
reported by Katta and Chait.221,222  HDX-MS has been used to study structural changes 
involved in physiological processes such as viral infections, 223-225 blood coagulation226-
228 or conformational changes in GPCR rhodopsin229.  Apart from its application in 
probing binding interaction, HDX-MS has been used mapping unstructured regions of 
intrinsically disordered proteins (IDP)230-232, dynamics of enzymes233,234, or 
conformations of hydrophobic integral membrane proteins (IMP)58,235-239.  Furthermore, 
HDX-MS has been used to investigate protein aggregates associated with formation of 
amyloid fibrils such as Aβ240,241, and exploration of the higher order structure and 
dynamics of protein based therapeutics242-245. 
 
Some of the protein hydrogen atoms are capable of being replaced by the molecules 
from the solvent.  There are three types of hydrogen atoms in proteins: hydrogen atoms 
bonded to hetero atoms on side chains with fast forward and backward exchange rates 
(Type 1), hydrogen atoms on the backbone amide nitrogen that exchange at rates ~100 
times slower than those on the side chains (Type 2) and hydrogen atoms covalently 
bound to carbon that do not exchange (Type 3), these generally occur in aliphatic or 
aromatic side chain containing amino acids (Figure 1.11).246  When using deuterium 
oxide in the solvent system, the heavy deuterium becomes incorporated into the protein 
and this change can be detected by mass spectrometry.  As each amino acid has one 
Type 2 amide hydrogen (except proline) this method can be used to probe the exchange 
rates along the entire length of the protein and provide information about protein 
structure and dynamics.247,248  The exchange rate of these amide protons is related to the 
structural characteristics based on the extent to which the exchangeable protons are 
shielded from the solvent i.e. buried in the protein interior, or occluded as part of a  
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Figure 1.11  Classification of hydrogen atoms in polypeptides: Type 1 - hydrogen atoms (blue) 
bound to hetero atom undergo rapid reversible exchange under all buffer conditions, Type 2  -  
hydrogen atoms (green) bound to an amide of the peptide backbone exhibit solvent dependent 
behaviour (low pH and temperature slow down the exchange rate), Type 3 - aliphatic and 
aromatic hydrogen atoms (red) show no exchange within the timeframe of an HDX experiment.   
 
surface involved in binding interaction.  The location and relative amount of deuterium 
uptake along the backbone chain can be subsequently determined by digestion of protein 
and analysis of individual peptides by tandem mass spectrometry (MS-MS).  As the 
hydrogen exchange is acid or base catalyzed, the rate is greatly dependent on the pH.  
The minimum exchange rate occurs at approximately pH 2.6; therefore, the reaction is 
quenched by lowering pH to prevent back-exchange and allowing sufficient time for 
mass spectrometry measurements.221  
 
1.3.3.2 Direct HDX 
 
There are two main types of direct HDX experiments that allow investigation of protein 
conformational changes upon ligand binding: on-exchange and off-exchange 
experiments.249  In the on-exchange experiments (Figure 1.12a), HDX is performed on 
the protein-ligand complex in addition to the unbound protein which acts as a control.  
Ligand binding is expected to occlude the HDX in specific regions due to steric 
hindrance at the binding site and resultant changes in conformation (which may be 
remote from the ligand binding site).  After HDX and subsequent reaction quenching to 
minimize back exchange, proteins are proteolysed and the peptide fragments are 
analyzed by mass spectrometry.  Alignment of the peptides with the primary amino acid 
sequence of the protein identifies the location of the binding site and any conformational 
changes from differential mass uptake of deuterium between the complex and the 
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control.  This approach has recently been fully automated in a commercial instrument 
coupling the HD on-exchange experiment with the quenching step, followed by on-line 
digestion using a pepsin column, chromatographic separation of the resulting peptides 
and their analysis by MS-MS.  In unattended operation this system can generate a time 
course of deuterium uptake mapped onto the protein sequence to elucidate subtle 
changes in solvent exposure not just at the ligand binding site but at remote sites subject 




Figure 1.12  Workflow of an HD on-exchange (a) and off-exchange (b) experiments for probing 
ligand binding sites and any conformational changes induced.  Measuring differences in 
deuterium uptake between apo protein and ligand bound protein helps to map the binding site 
and probe any conformational changes induced upon ligand binding. 
 
 
In the off-exchange experiments (Figure 1.12b), protein and ligand hydrogen atoms are 
allowed to exchange separately with deuterium atoms prior to complex formation.  After 
the time allowed for the complex to form, the deuterium atoms are off-exchanged by 
dilution with water.  Again, the complexes are proteolysed and the peptides analysed 
with mass spectrometry are compared with those from control experiments performed 
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using each binding partner in isolation.  The proteolysed peptides that show extensive 
residual incorporation of deuterium are assumed to be at the ligand binding interface or 
involved in conformational changes associated with the binding event.  On- and off-
exchange experiments have been successfully applied to study inhibition of an essential 
blood coagulation protein thrombin,248,250 or structural stability in gas phase of 
myoglobin,251 bovine cytochrome c252 and bradykinins253.  The usefulness of information 
obtained with HDX on protein-ligand interactions has led to the development of  
automated HDX-MS systems254 and semi-automated data processing applications such 
as HX-Express255, or DynamX from Waters Corporation. 
 
1.3.3.3 PLIMSTEX, SIMSTEX and SUPREX 
 
HDX-MS experiments can be implemented in various ways depending upon the type of 
information required.  Gross et al. have developed a LC-MS technique that allows 
monitoring of protein-ligand interactions termed PLIMSTEX i.e. protein-ligand 
interactions by MS, titration and hydrogen/deuterium exchange.256,257  PLIMSTEX 
experiments enable the measurement of the binding affinities of protein-ligand 
complexes.  The target protein is equilibrated with an increasing concentration of ligand 
to create complexes at various protein-ligand ratios.  Next, each sample is diluted into 
deuterated buffer and HDX is allowed to proceed for a set period of time.  Samples are 
cleaned up on-line by reverse-phase chromatography and the amount of deuterium 
uptake is determined by mass spectrometry.256,258,259  It is predicted that the difference in 
mass due to deuterium uptake will be decreasing with an increasing ligand concentration 
as a result of an increased protection of the backbone amine upon ligand binding.  
Protein-ligand ratios are plotted against the deuterium uptake where the shape of the 
curves is directed by binding affinity and stoichiometry.260  More recently, PLIMSTEX 
has been adapted for determination of self-association equilibrium constants for proteins.  
This methodology has been termed SIMSTEX (self-association interactions using MS, 
self-titration and HD exchange) and has been applied to study insulin analogues and is 
likely to be a valuable tool to study self-assembly of other large proteins.261 
 
Fitzgerald et al. have also developed an alternative method that uses MALDI-MS and is 
referred to as SUPREX (stability of unpurified proteins from rates of HD exchange) and 
allows for determination of free energy values (ΔGu) associated with protein unfolding 
Chapter 1                                                                                                                                                   Introduction  
 
 
- 34 - 
mechanisms.262-265  SUPREX uses denaturing agents (such as guanidinium chloride or 
urea) to measure protein thermodynamic stabilities and as the name suggests it can be 
applied to protein mixtures.  Proteins or protein-ligand complexes are diluted into a 
series of deuterated HDX buffers containing increasing concentrations of chemical 
denaturant.  After a set incubation time, the mass of each denatured protein sample is 
determined with MALDI-MS.  The number of exchanged hydrogen atoms is plotted 
versus denaturant concentration resulting in sigmoidal curves reflecting the transition 
from folded to unfolded protein as more backbone amides are exposed with increasing 
denaturant concentration.  Higher denaturant concentrations are be required to induce 
unfolding of protein-ligand complex due to its increased stability.247  Application of the 
SUPREX protocol can be also expanded to large multimeric protein systems by 
incorporation of protease digestion step.266   
 
As all methodologies, various HDX techniques display advantages and downsides.  
Continuous HDX experiments might be time consuming and not inherently high-
throughput; however, they yield wide range of information on different solution-phase 
conformations.  Recent developments of automated systems have greatly increased the 
throughput rate.  HDX experiments can provide a broad picture of protein dynamics and 
conformational changes induced by ligand binding, mutation or aggregation.  SUPREX 
experiments provide very little structural information about protein folding and ligand 
binding in contrast to the continuous HDX; however, they allow for the use of unpurified 
proteins as long as the other components of the sample mixture do not suppress the 
signal of protein of interest.  This advantage eliminates the need for time-consuming 
high purity sample preparation and makes SUPPEX more amenable towards high-
throughput analysis.  Although PLIMSTEX produces much of the same thermodynamic 
data on protein-ligand binding, it does not involve the use of denaturant which can alter 
or even prevent ligand binding.  In their recent review, Fitzgerald and West, offer more 
details on those methodologies as well as comparison of the advantages and 
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1.3.4 Chemical cross-linking and mass spectrometry 
 
Chemical cross-linking in combination with mass spectrometry has become a useful tool 
in the study of protein structures and non-covalent protein complexes.  It involves a 
covalent reaction between complementary functional groups within the protein or 
between protein and ligand molecules under investigation.  The covalently linked 
proteins and their binding partners are digested and analyzed with mass spectrometry.  
The location of newly formed cross-linked peptides in the primary amino acid sequence 
identifies the location of the respective side chains and is useful in structure 
determination of protein geometry.  Top-down and bottom-up approaches and a wide 
range of available cross-linkers targeted towards certain functional groups, help to map 
those interactions.268   
 
Cross-linking and mass spectrometry have been successfully used to study many non-
covalent protein systems such as human serum albumin and its corresponding 
antibody,269 calmodulin-melittin,270 17β-estradiol and estrogen receptor-α,271 or various 
peptide ligands with its G protein-coupled receptors272, or peroxisome proliferator-
activated receptor alpha (PPAR-α) and small molecule ligands.273  This hybrid technique 
has also been applied to study large protein assemblies and protein-protein interaction 
networks to understand their physical organisation.274  Architecture of a signalling 
complex A-kinase anchoring protein 79275, RNA polymerase II276, GroEL-GroES 
chaperonin complex277, conformational changes of sugarcane chaperone Hsp70278, 
retinal guanylylcyclase-GCAP-2279 interaction or dynamics of ribosomal protein S1280 
have been successfully probed with cross-linking mass spectrometry.  In combination 
with other techniques such as electron microscopy (EM) or IM-MS, cross-linking data 
can be integrated to provide insights into interactions between subunits and overall 
topology to generate three-dimensional models of protein complexes.281,282 
 
Moreover, cross-linking has been even used to covalently link binding partners directly 
in the cell by incorporating the reactive groups into the protein using cell’s own 
biosynthetic mechanisms.283  A number of reviews have been published either on the 
cross-linking reagents and protocols284-286 or protein-protein interaction studies using 
cross-linking mass spectrometry approach287-289.  A great advantage of this method is the 
ability to provide spatial information on proteins and protein complexes that are too 
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large or too flexible for x-ray crystallography or NMR studies.290  The sections below 
will briefly describe two different approaches to analysis of cross-linked proteins and 
protein-ligand complexes as well as types and classification of chemical cross-linking 
reagents available.  
 
1.3.4.1 Bottom-up and top-down approaches  
 
To perform cross-linking experiments two possible approaches exist: bottom-up and top-
down (Figure 1.13).  When conducting cross-linking experiments one must know the 
amino acid sequence of the protein system under investigation as control samples (i.e. no 
cross-linker added) need to be used.  In the bottom-up approach, after cross-linking of 
functional groups, the covalently bound complex is purified by gel electrophoresis or 
size-exclusion chromatography and enzymatically digested either in-gel or in solution 
and the resulting proteolytic peptide mixtures are analyzed by MALDI or ESI-MS.  
Comparison of the mass spectra from cross-linked and non-linked peptide mixtures 
reveals which individual peptides are cross-linked in the complex providing information 
on relative spatial orientation of the binding groups.  This approach has been 
successfully applied to study protein interfaces and has been valuable to low-resolution 





Figure 1.13  Top-down and bottom-up cross-linking approaches.  Functional groups within 
proteins or between proteins and their binding partners are covalently linked via cross-linking 
reagents to provide information on spatial proximity of these groups, hence insights into the 
structure.  Intact proteins are fragmented either via enzymatic digestion (bottom-up) or inside of 
a mass spectrometer (top-down) prior to identification and analysis of resultant peptides.  
Chapter 1                                                                                                                                                   Introduction  
 
 
- 37 - 
The top-down approach exploits the capability of a multistage mass spectrometer to 
fragment intact cross-linked proteins and their complexes.293  High resolution ESI 
Fourier transform ion cyclotron resonance mass spectrometry (ESI-FTICR-MS) is the 
most commonly used tool for this approach.  The cross-linking mixture is introduced 
into the FT-ICR mass spectrometer, isolated in the ICR cell and subsequently 
fragmented with one of the various fragmentation techniques such as electron caption 
dissociation (ECD), infrared multi-photon dissociation (IRMPD), or sustained off-
resonance irradiation collision-introduced dissociation (SORI-CID).  The superior mass 
accuracy of FT-ICR-MS allows determination of the number of incorporated cross-
linkers in the intact protein and the number of possible modifications caused by cross-
linking reagents.   
 
This approach has been applied to study for example intramolecular cross-linked 
products of bovine rhodopsin294 or ubiquitin295.  The major advantage of top-down over 
bottom-up approach is the freedom from a chromatographic separation of the cross-
linking mixture prior to mass spectrometric analysis as this is achieved in the mass 
spectrometer itself.  However, FT-ICR-MS becomes less sensitive and lower resolution 
as the mass of the complex increases; hence, it is challenging to study large protein 
assemblies using this MS method.  
 
1.3.4.2 Classification of cross-linking reagents  
 
Covalent cross-links can be formed either inter-moleculary between different molecules 
or intra-moleculary within parts of the same molecule.  The cross-linking reagents can be 
classified either by their reactivities or their functional design.  Sinz, in her review, offers 
an excellent summary on the classification of the many cross-linkers described in the 
literature. 268,296   
 
Based on the functional groups, three main types of cross-linkers can be distinguished: 
amine-reactive, sulfhydryl reactive and photoreactive cross-linkers.  N-
hydroxysuccinimide (NHS) esters, one of the amine-reactive cross-linkers, are most 
widely used reactive acylating agents.  NHS esters react with nucleophiles to produce the 
NHS group and to subsequently form a stable amide and imide bonds with primary and 
secondary amines (ex. free N-terminus and ε-amino groups in lysine side chains).  NHS 
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esters can react with sulfhydryl groups of cysteine, hydroxyl groups of serine or 
threonine, and imidazole nitrogens of the histadine; however, their reactivity and 
stability can be influenced by the pH conditions and the solvent system.268  The other 
two types of amine-reactive cross-linkers are imidoesters,297 considered one of the most 
specific acylating groups, and carbodiimides298 which form an amide bond between 
spatially close groups; however, they were found to have only a modest cross-linking 
efficiency compared to NHS esters.299   
 
Sulfhydryl-reactive cross-linkers such as maleimides, are targeted at the SH groups of 
cysteine residues; unfortunately due to their reductive capabilities, they might have a 
distorting effect on the protein confirmation.  Another large group of cross-linkers are 
photo-reactive cross-linkers, which react with the target proteins upon irradiation with 
UV light.  Most of these reagents are based on nitrene or carbene chemistry with 
photolabile presursors such as aryl azides, diazirines and benzophenones.  Often those 
reagents also possess an amide- or sulfhydryl-reactive group.268  When choosing an ideal 
photoreagent one should consider its reactivity, stability in the dark and capability to 
react at the wavelength that does not cause damage to the biological sample.268 
 
Cross-linking reagents can be further classified by their functional design into sub 
classes including homobifunctional, heterobifunctional, trifunctional and zero-length 
cross-linkers.  Homobifunctional cross-linking reagents contain two identical reactive 
sites and react with the same complementary protein functionality, their proximity being 
determined by a carbon-chain spacer of a defined length in the cross linker.  Similarly, as 
the name suggests, heterobifunctional reagents incorporate two different reactive groups 
which react with  different functional groups on the proteins and trifunctional cross-
linkers acting as heterobifunctional reagents with additional functional group.300  The 
smallest available chemical cross-linking reagents called zero-length cross-linkers, 
mediate a cross-link between two proteins by formation of a bond without an intervening 
linker; carbodiimides are the most widely used linkers of this type.  Despite a large 
number of cross-linking reagents available there is still need for an improvement and 
gaining better understanding of their reactivates. 
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1.4 Selected Complementary Biophysical Techniques to 
Study Protein Structure 
 
A vast array of biophysical techniques for study of protein structure and interactions is 
available.26,28,37,301,302  High resolution techniques like x-ray crystallography and nuclear 
magnetic resonance (NMR) spectroscopy can provide structural information at the 
atomic level.  Lower resolution techniques such as analytical ultracentrifugation (AUC), 
electron microscopy (EM), static light scattering (SLS), surface plasmon resonance 
(SPR), size-exclusion chromatography (SEC), circular dichroism (CD), infrared 
spectroscopy (IR), ultraviolet (UV) spectroscopy, Raman spectroscopy and others are 
able to present information on the global structure and properties of proteins and trace 
any conformational changes.  In conjunction with MS, they serve as complementary 
tools for solving the puzzle of protein structure.  Some of these techniques, which have 
been employed to study biological systems discussed in this thesis, are briefly 
overviewed below. 
 
1.4.1 Solution-phase techniques  
 
1.4.1.1 NMR spectroscopy  
 
Nuclear magnetic resonance (NMR) spectroscopy is a non-destructive method exploring 
protein structure and dynamics in their ‘natural’ habitat – the solution-phase.303-306  Upon 
exposure to strong magnetic fields and RF signals certain kinds of atomic nuclei (1H, 
13C, 15N) absorb the RF radiation.  The resonance of each nucleus, represented as a 
chemical shift, is very sensitive to the local molecular environment and can provide 
information about covalent and non-covalent protein structure.  Peaks observed in an 
NMR spectrum can split into finer structures (doubles or triplets) as a result of magnetic 
coupling between adjacent nuclei (J coupling).  Furthermore, nuclei can also transfer 
energy to each other though bonds and though space, a phenomenon known as the 
nuclear Overhauser effect (NOE), that is used to identify hydrogen atoms in proximity to 
each other either due to primary sequence or the tertiary protein fold.307 
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Due to a large number of atoms present in a protein molecule, thousands of signals are 
overlapping and multidimensional experiments must be performed to allow correlating 
frequencies of distinct nuclei.  A series of 2D and 3D NMR experiments are carried out 
to collect sufficient amount of data so every NMR resonance can be assigned to every 
NMR detectable atom in a protein.  Common homonuclear NMR experiments include: 
total correlation spectroscopy (TOCSY) allowing identification of individual amino 
acids by their chemical shifts308, nuclear Overhauser enhancement spectroscopy 
(NOESY) detecting interactions between protons within 5 Å of each other309; or 
heteronuclear NMR experiments on isotope-labelled proteins: heteronuclear single 
quantum correlation (HSQC) correlating nuclei other than 1H; or triple resonance 
experiments such as HNCO, HN(CA)CO, HNCA, HN(CO)CA, or NHCABA.  Detailed 
description of various NMR experiments can be found elsewhere.303-305,310  Data are used 
to derive distances, angles and torsions between atoms and to construct three 
dimensional models.  NMR data can be further used to gain insights into protein 
interactions and conformational dynamics on a picosecond to second time scale; 
however, the spectra reveal only the average state of a protein complex.305,311-313  As 
NMR spectroscopy is nucleus specific, also HDX experiments can be performed 
monitoring amide proton exchange and reflecting on the solvent accessible protein 
regions.314-317 
 
As any other technique, NMR spectroscopy presents a number of drawbacks.  Firstly, a 
large quantity of protein sample is required (typically 300-600 μL, concentration of ~1 
mM) and the time needed for data acquisition might vary from hours to several days.  
Additionally, this technique is size limited to small proteins or protein domains and tends 
not to exceed 100 kDa for atomic resolution318; nevertheless, improvements in the 
method development allowed studying protein complexes such as chaperone GroES-
GroEL.319 
 
1.4.1.2 Analytical ultracentrifugation (AUC) 
 
Analytical ultracentrifugation (AUC) is a non-destructive low resolution technique 
measuring the rate at which macromolecules sediment in response to centrifugal force, 
allowing their hydrodynamic and thermodynamic characterisation in the solution-
phase.320  There are two types of AUC experiments: sedimentation velocity (SV-AUC) 
Chapter 1                                                                                                                                                   Introduction  
 
 
- 41 - 
based on hydrodynamic theory and used to define the size, shape and interaction of 
macromolecules; and sedimentation equilibrium (SE-AUC), a thermodynamic method 
used to determine molecular mass, assembly stoichiometry or association constants.321-
323  AUC methods are used to probe shape and size of large proteins and their complexes 
within 100 kDa to 10 GDa range, and find application in detection of aggregates or 
probing of conformational changes.324-328  Here, the basic principles of SV-AUC will be 
presented briefly.  
 
In a SV-AUC experiment, the sample is spun at a high velocity (40-60 K rpm) in an 
analytical centrifuge.  The centrifugal force depletes molecules from the meniscus near 
the centre of the rotor forming a boundary which migrates towards the outside of the 
rotor.  An optical system (absorbance, interference and fluorescence) monitors the 
concentration distribution across the cell in real time.  Proteins can be characterised in 
their native state under biologically relevant solution conditions at protein concentrations 
typically of 0.1 to 1 mg mL-1.  Additionally, a wide range of pH and ionic strength 
conditions can be used at temperatures ranging from 4 to 40 ̊C.  
 
Through the SV-AUC experiments sedimentation coefficient (s, expressed in svedberg 
(1 S = 10−13 s)) is determined, which is defined as ratio of a particle's sedimentation 




s                                          (Equation 1.10) 
 
The sedimentation coefficient is dependent on the molecular weight and conformation of 




s b                                        (Equation 1.11) 
 
where Mb is the buoyant molar mass and f is the frictional coefficient.  Derivation of 
Equation 1.11 can be found elsewhere.321  Sedimentation coefficients quoted in the 
literature usually relate to sedimentation in water at 20 ̊C (s20,w).  As can be seen from 
Equation 1.11, s is directly proportional to mass; hence, larger protein species have 
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higher sedimentation coefficient.  The sedimentation coefficient is however, inversely 
proportional to f; therefore unfolded proteins or ones with highly elongated 
conformations will experience more hydrodynamic friction and have smaller 
sedimentation coefficients than folded, globular proteins of the same molecular weigh 
 
1.4.2 Solid-phase techniques  
 
1.4.2.1 X-ray crystallography  
 
The number of macromolecular structures deposited into the Protein Data Bank (PDB) 
now exceeds 100 000 with over 88% of them determined using crystallographic 
methods.329  X-ray crystallography is a powerful atomic resolution technique considered 
as the gold standard for protein structure determination.  Protein samples are purified and 
crystallised, then subjected to intense beam of x-ray radiation usually generated by a 
synchrotron.  Electrons in the molecule scatter x-rays to provide a characteristic 
diffraction pattern.  The crystal is gradually rotated to collect multiple data sets with 
diffraction patterns recorded at every crystal orientation.  Due to structural motifs in the 
unit cell repeating throughout the crystal, the scattering in amplified in selected 
directions.  These patterns are then analysed to provide the electron density map which is 
used to build a model of protein structure, whose sequence has been determined by other 
means.330,331   
 
X-ray crystallography provides very detailed structural data of proteins along with any 
other molecules (ligands, ions or inhibitors) that have been incorporated into the crystal.  
The single electron of the hydrogen atom is always involved in the formation of bonds; 
therefore, these atoms lack the electronic core and are the weakest x-ray scatterers.  For 
those reasons, hydrogen atoms are often not present in electron density maps and their 
localisation must be calculated based on the positions of the heavier atoms.  
Furthermore, as the diffraction pattern is dependent on the formation of highly ordered 
crystals, this method lacks dynamic information and is challenging with regards to 
structure determination of flexible and/or disordered protein regions.  Although, there is 
no analyte size limit and large protein assemblies such as viruses can the analysed,332,333 
the crystallisation process can be very demanding if achievable at all in some cases.334  
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1.4.2.2 Electron microscopy  
 
Electron microscopy (EM), a method for structure determination of large 
macromolecular complexes, uses an electron beam to create molecular images and is 
particularly useful for studies of difficult to crystallise proteins.  The type of EM 
typically used in life sciences is transmission electron microscopy (TEM).335  Samples 
deposited on an EM grid are stained (to enhance contrast by absorbing electrons 
otherwise projected onto the image), and then exposed to high electron beam.  The 
electron beam that has been partly transmitted through the sample carries structural 
information with attainable resolution of ~20 Å.  Preservation of native-like structure has 
been a challenge in terms of TEM use for studies of biological macromolecules. 
 
Visualisation of protein molecules became possible with the development of negative 
stain techniques which aid contrasting and prevent collapse of macromolecules by 
replacing the surrounding water with dried solution of heavy metal salt.336  Nevertheless, 
it can still lead to denaturation of protein structure.  Limitations of the technique were 
solved by introduction of cryo-electron microscopy.337  In cryo-EM, samples are rapidly 
frozen in liquid nitrogen-cooled ethane and embedded in a layer of amorphous ice 
preserving near-native structure in the hydrated state.338  Multiple copies of cryo-EM 
images are acquired at low temperatures by low intensity electron exposures, where even 
resolution of 3.5 Å can be achieved.339  Furthermore, freeze-trapping allows capturing 
proteins in different conformational states providing insights into structural 
dynamics.340,341  Despite being a time consuming method, EM and cryo-EM are useful 
options for structure determination of large biomolecules.  
 
1.4.3 Computational methods  
 
Protein behaviour can be studied in solution or in vacuo by means on molecular dynamic 
(MD) simulations.  MD enables to follow dynamic evolution of proteins in the gas-phase 
and the output files are used for determination of theoretical CCS.  Information provided 
by IM-MS can be enhanced with computational approaches and vice versa.  
Experimentally determined CCS can help to discriminate between different predicted 
models where several structures with similar energy minima are possible.  A number of 
algorithms have been developed using different theoretical assumptions342-346 however, 
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three of them are commonly used: hard sphere projection approximation (PA)347, 
trajectory method (TJM)348 and exact hard sphere scattering (EHSS)349,350.   
 
Based on a set of coordinates derived via x-ray crystallography, NMR spectroscopy or 
MD simulations, mobility and buffer gas specific CCS can be calculated using 
MOBCAL software.342,348,349,351  The PA treats each molecular atom as a hard sphere, 
and similarly the interactions between buffer gas and ions are perceived as hard sphere 
collisions.  The resulting CCS is based on averaging the geometric projection areas over 
all possible orientations of the ion.  PA was found to underestimate CCS for large 
molecules by up to 20 %.149  The EHSS method is an improved version of PA, which 
accounts for multiple collisions and scattering but still does not consider the effects of 
long range potentials between the buffer gas and the ion.  For systems with a molecular 
weight greater than 1.5 kDa the most reliable results can be estimated by a trajectory 
method calculation.138,352  The TJM model considers the analyte ion as a collection of 
molecules, and accounts for possible multiple collisions and the long range interactions 
which occur between drift gas atoms and the ion.  This comprehensive evaluation of the 
momentum transfer integral that is achieved via the TJM method, is computationally 
very expensive, in addition the code has been found to not scale particularly well for 
very large extended systems.  Recently Bleildholder et al. have developed the projected 
superposition approximation (PSA), a reworked version of the PA which accounts for 
the dramatic underestimation this rapid method provides.353-356  By rescaling the CCS of 
input co-ordinates based on extensive empirical training of this new code, a more 
computationally amenable answer to translate CCS from crystal structure or NMR co-





Mass spectrometry has come of age as a recognised, predictive tool in the analysis of 
protein structure and protein interactions with certain benefits for structural biology and 
drug discovery.  The molecular weight of proteins can be determined even for very large 
systems on MDa scale.  Intact proteins and their complexes can be analysed and related 
to data obtained via other biophysical techniques and create a fuller picture of their 
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architecture, dynamics and interactions.  Recent developments in the use of IM-MS, 
dissociation techniques, HDX-MS and chemical cross linking mean that mass 
spectrometry is evolving into a powerful tool for protein structural characterisation.   
 
The work presented in this thesis employs mass spectrometry based methods to probe 
higher order structure of several large proteins and multimeric protein complexes 
representing various functional protein classes.  Chapter 3 explores flexibility and gas-
phase dynamics of therapeutic antibodies; Chapters 4 and 5 set out to probe thermal 
stability of protein complexes with implication to therapeutic antibodies; whereas 
Chapter 6 aims to identity and map subtle conformational changes of an enzyme induced 
by binding of an allosteric inhibitor. 
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Instruments used in experiments presented in the following chapters are described here, 
along with typical tuning parameters.  An example of ion mobility mass spectrometry 
data acquisition and processing is provided.  Information on nano-electrospray 
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2.1 Biological Mass Spectrometry 
 
All of the mass spectra presented in this thesis were obtained using quadrupole time-of-
flight mass spectrometers: either Ultima API US (Waters, Manchester, UK); in-house 
modified IM-Q-ToF 1; Synapt G2 HDMS or Synapt G2S HDMS (Waters, Manchester, 
UK); with nano-electrospray ionisation source. 
 
2.1.1 Reagents and general sample preparation  
 
Intact IgG and Fc-hinge fragment samples, used in experiments presented in Chapter 3 
and Chapter 5, were provided by UCB Pharma.  Antibody-drug-conjugates (ADC) were 
provided by Piramal Healthcare.  Standard protein complexes studied in Chapter 4 i.e. 
avidin from egg white (A9275) was obtained from Sigma Aldrich (St. Louis, MO, USA), 
concanavalin A from Canavalia ensiformis (C2010) was obtained from Sigma Aldrich 
(St. Louis, MO, USA), human TTR was obtained from SCIPAC (Sittingbourne, UK); 
and human SAP was obtained from CalBioChem (Darmstadt, Germany).  ATP-
phosphoribosyltransferase investigated in Chapter 6, was provided by Dr. Luiz Pedro 
Sório de Carvalho from MRC National Institute for Medical Research (London, UK).  
Detailed information on sample preparation, concentration and conditions can in found 
in the relevant chapters.  
 
Ammonium acetate (AmAc) was obtained from Fisher Scientific (Loughborough, UK).  
On the day of analysis, buffer was exchanged to ammonium acetate (Fisher Scientific, 
Loughborough, UK) using micro Bio-Spin Chromatography columns (Micro Bio-Spin 6 
Columns, Tris) following the instructions specified by the manufacturer. The desalting 
procedure was performed one to four times to achieve desired sample purity.  The 
majority of experiments were carried out at pH 6.8 (pI of all proteins are provided in the 
Appendix 3).  Otherwise (Chapter 6), pH of the buffer was adjusted with hydrochloric 
acid or ammonia supplied by VWR International Ltd (UK).  Solution pH readings were 
taken using a pH meter (Jenway 3305).  High purity water was obtained from an Arium 
611 water purification unit (Sartorius, Göttingen, Germany) fitted with a 0.2 µm filter or 
supplied by Fisher Scientific Ltd (Loughborough, UK).  Solids were weighed with a 
Mettler AC100 balance to an accuracy of ± 0.0001 g.  Charge reduction experiments 
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were carried out by addition of 10% (v) triethylammonium acetate buffer (TEAA) 
(Fluka, Steinheim, Switzerland) prior to MS analysis. 
 
2.1.2 Nano-electrospray ionisation and sample introduction 
 
All MS and IM-MS instruments utilized in the presented studies were fitted with nESI 
sources.  Samples were ionised using nESI method, where protein species were charged 
and transferred from solution into the gas phase.  NanoESI capillaries were prepared in-
house from thin-walled borosilicate capillaries (inner diameter 0.9 mm, outer diameter 
1.2 mm, World Precision Instruments, Stevenage, UK) using a Flaming/Brown P-97 
micropipette puller (Sutter Instrument Company, Novato, CA, USA).  These were then 
filled with sample using micro-loading tips (Eppendorf, Hamburg, Germany). A positive 
voltage was applied to the solution via 0.125 mm platinum wire (Goodfellow Cambridge 
Ltd., Huntingdon, UK) inserted into the capillary.  Capillary voltage applied via 
platinum wire was adjusted to give optimum spraying conditions and ranged from 1.0 to 
2.0 kV which was dependent on the solvent composition and protein species under 
investigation, as well as tip geometry.    
 
2.1.3 Ion transfer, mass analysis and detection  
 
Ions generated by the nESI enter the mass spectrometer via a ‘Z-spray’ source.  The axis 
of the sample capillary is orthogonal to the sampling orifice i.e. the cone, which in turn 
is perpendicular to the following extractor cone, as shown in Figure 2.1.  This 
architecture results in increased sensitivity by allowing transmission of ions and 
reduction in transmission of neutral species. To aid the desolvation process, the 
temperature of the source region may be increased.  For work presented in Chapters 3-5, 
the source temperature was set to 80 °C, unless otherwise stated.   The work presented in 
Chapter 6, required application of lower source temperatures (30 °C) to prevent 
aggregation of protein species in the glass capillary.   
 
Post the extractor cone, ions travel through a transfer hexapole.  On the Ultima API US 
instrument, this region has been modified to include a flow-resisting sleeve.   
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Figure 2.1   Schematic representation of a Waters Quadrupole Time of Flight (Q-ToF) mass 
spectrometer modified for analysis of large molecules; modification carried out by MS Vision.  
Inclusion of the hexapole pressure sleeve allows for use of increased pressure and enhances 
the transfer of large molecular species to the mass analyser.  Items indicated in dark blue are 
modifications included.  Yellow circles indicate differential pressure stages: P1 – regulated by 
the pumping efficiency of the rotary pump to 9 × 10-1 mBar; P2A -  hexapole pressure within a 
flow-restricting sleeve estimated to be about 8 × 10-3 mBar; P2 – pressure in the hexapole 
chamber maintained ~4 × 10-3 mBar;  P3 – pressure in the quadrupole chamber ~7 × 10-3 mBar; 
P4 – pressure in the collision cell ~2 × 10-2 mBar; and P5 – pressure in the ToF chamber ~3 ×10-7 
mBar.  The image has been reproduced from van den Heuvel et al. 2006.1 
 
 
It has been shown, that the application of increased pressure in the first and second 
vacuum chamber of the mass spectrometer is a requirement for the analysis or large 
proteins. 1-6  Increased pressure leads to collisional cooling and focusing of large ions in 
the ion guides, hence improved transmission to the quadrupole analyser and later ToF.  
Pressure can be controlled with two Speedivalves (Edwards, West Sussex, UK), located 
along the vacuum line between the source rotary backing pump and the source block.  
Partially closing the Speedivalve, and throttling the source backing pump, enables the 
source pressure to rise.  Source pressure used typically varied from 3 and 9 × 10-1 mBar 
dependent on the species under investigation and these values will be reported in the 
relevant chapters.  The instrument modification has been carried out by MS Vision (The 
Netherlands).   
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Eventually, ions reach the quadrupole analyser.  Here, collision-induced dissociation 
(CID) can be performed by selecting ions of a particular m/z and increasing the kinetic 
energy by collisions with an inert gas such as argon, causing complex dissociation or 
fragmentation as described in Chapter 1.  The Ultima API US instrument has been 
modified to allow for ion selection up to m/z 30374.  Moreover, the quadrupole can be 
used as a mass filter where ions are not subjected to high collision energies what allows 
for preservation of intact species, as it has been done for the majority of experiments 
presented in this work.  Post the collision cell, ions pass though a transfer hexapole into 
the ToF region.  Here, the pusher accelerates the ions into the ToF tube until they reach 
the reflectron where they are refocused and reflected back towards the microchannel 
plate (MCP) detector.  The velocity of each ion is inversely proportional to its m/z.  Ion 
signals are converted by a 1 GHz time-to-digital converter, resulting in a total ion count 
(TIC) chromatogram which can be deconvoluted into a mass spectrum using MassLynx 
software (Waters, Manchester, UK).  
 
A typical QToF mass spectrometer has three stages of differential pumping: the source, 
the quadrupole analyser and the ToF chamber; to create a decreasing gradient along the 
length of the instrument.  Each compartment is kept under vacuum by a turbomolecular 
pump, backed by a rotary pump.  Typical pressure values for the QToF Ultima API US 
in each region are as follows: source ~ 2-9 × 10-1 mBar (regulated with the Speedivalve), 
analyser ~7 × 10-3 mBar; and ToF ~3 × 10-7 mBar.  
 
2.1.4 Mass calibration 
 
External mass calibration was carried out using a 2 mgmL-1 solution of caesium iodide 
(Sigma Aldrich, Dorset, UK) in 49.5 % water, 49.5 % isopropanol and 1 % formic acid.  
The metal salt calibrant provides a series of monoisotopic cluster peaks corresponding to 
Csn+1In ions, covering an appropriate m/z range.  
 
2.1.5 Typical instrumental parameters   
 
Typical instrument settings for Ultima API US used in the presented work are shown in 
Table 2.1.  Optimisation of the source parameters is crucial for preservation of non-
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covalent complexes.  Particular attention must be paid to the influence of the source 
pressure on the ion transmission and to the cone voltage effecting protein tertiary and 
quaternary structure and non-covalent interactions.   
 
 
Table 2.1   Typical instrumental parameters for the Q-ToF Ultima API US in the positive mode.  
Parameter  Value Comment 
Capillary /kV 1.0 – 2.0  
Cone /V 20 – 200 adjusted accordingly to the sample 
and experimental design   
Extractor /V 1.0 – 3.0  
RF Lens1 /V 2.0  
Apperture1 /V 5.0  
RF Lens2 /V 0.0  
Source Temperature /°C  25 – 80 adjusted accordingly to the sample 
LM Resolution /V 5.0  
HM Resolution /V 5.0  
Collision Energy /V 10 raised stepwise for CID  
Ion Energy /V 1.0  
Steering /V -1.10  
Entrance /V 65.0  
Pre-filter /V 4.0  
Transport /V 5.0  
Aperture3 /V 15.0  
Acceleration /V 200  
Focus /V 0  
Tube Lens /V 60  
Offset1 /V 0  
Offset2 /V 0  
Pusher /V 980  
ToF /kV 9.10  
Reflectron /V  35.0  
Pusher Cycle Time / µs 70 – 200 adjusted accordingly to m/z range 
Multiplier /V 650  
MCP /V 2000- 2400  
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2.1.6 Use of buffers to reduce charge  
 
Application of elevated voltages in the source region of a mass spectrometer to aid 
desolvation process may lead to non-covalent complex dissociation and/or structure 
perturbation.  Addition of different buffer salts, such as triethylammonium acetate 
(TEAA) to the sample buffer, has been reported not only to reduce the charge of the ions 
but also to increase the stability of protein complexes in the gas phase.7-9  The charge-
reducing nature of alkylated ammonium ions is mainly based on its higher gas-phase 
basicity relative to ammonium acetate, which is commonly used as a buffer in the native 
MS experiments.  The gas-phase basicity of the ionic species present in the solution 
controls how much charge is emitted during the electrospray process.  Small ionic 
electrolytes with higher gas-phase basicity will compete for charges with ionized sites of 
the protein and effectively remove the charge from protein species.10-13  Moreover, 
reducing the charge increases the energy barrier of unfolding and subsequent complex 
dissociation.9,14 Even with use of an elevated acceleration voltages in the source region, 
non-covalent complexes may remain intact in the presence of such additives.  
 
Figure 2.2   Use of charge reducing agents, such as TEAA, not only decreases the charge of 
ions detected but also helps to preserve non-covalent interactions.  Antibody-drug-conjugates 
(ADC) can undergo dissociation when high acceleration voltages are applied to aid desolvation 
for enhanced resolution (a).  Addition of 10 % TEAA to the sample buffer (b) helps to keep these 
non-covalent complexes intact making the drug-to-antibody ratio (DAR) determination simpler.  
Both mass spectra shown here were acquired under identical instrumental conditions.  
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Figure 2.2 illustrates how addition of TEAA to the sample helps to preserve non-
covalent interactions by using an antibody-drug-conjugate (ADC) as an example.   
 
ADCs are a new class of anticancer biopharmaceutical drugs composed of an antibody 
(also know as immunoglobulin) linked via a stable chemical linker to a biologically 
active cytotoxic small molecule drug.15,16   One of the most important properties of an 
ADC is the average number of drug molecules attached to an antibody as it determines 
the amount of drug delivered to the tumour cells and affects safely and efficacy.  Mass 
spectrometry is currently emerging as a tool of choice for drug-to-antibody ratio (DAR) 
determination.17-20  The immunoglobulins of the G isotype (IgG), which are commonly 
used as templates for ADCs, are ~150 kDa protein complexes composed of two light 
chains and two heavy chains covalently linked though disulfide bonds (for details see 
Chapter 3).  When the cytotoxic drug is being conjugated via the cysteine of the 
interchain disulfide bond, the ADC molecule becomes a non-covalent tetramer as the 
disulfide bridges are broken.  Since the mass of the drug conjugate and its linker is 
relatively small (~1 kDa) in comparison to the antibody molecule, high acceleration 
voltages are applied to aid desolvation process and enhance the resolution at higher m/z 
to allow accurate peak assignment and mass determination.  Often, use of elevated 
acceleration voltages leads to dissociation of non-covalent complexes.  In Figure 2.2a, an 
experimental ADC provided by Piramal Healthcare, was sprayed from 100 mM AmAc 
with the sample cone held at 200 V potential.  Peaks corresponding to an intact ADC are 
observed in the ~ m/z 5500 – 7000 region; however, there is a significant amount of 
dissociation products present: one light chain + 1 drug molecule fragment (m/z 1800 – 
3500) and two heavy chains + one light chain + n drug molecules fragment (m/z 7800 - 
11000), making the DAR determination challenging.  As 10 % (by volume) of TEAA is 
added to the sample (Figure 2.2b), only the intact ADC species are observed (m/z 7800 - 
10500) as the complex does not undergo dissociation.  Moreover, charge reduction shifts 
the peaks to a higher m/z region and as a consequence spectra interpretation and DAR 
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2.2 Ion Mobility Mass Spectrometry (IM-MS) 
 
Ion mobility mass spectrometry (IM-MS) experiments presented in this work were 
performed on an in-house modified Q-ToF 1 (Waters, Manchester, UK), known as the 
‘MoQToF’21 and on Synapt G2 HDMS and Synapt G2S HDMS instruments (Waters, 
Manchester, UK).  Samples for IM-MS measurements were ionised by nESI in positive 
mode as described in section 2.1.2.   A description of these instruments, as well as data 
acquisition and analysis of ‘MoQToF’ data is described in the subsequent sections.  
 
2.2.1 Linear drift tube IM-MS – MoQToF 
 
2.2.1.1 Instrument description   
 
The linear drift tube IM-MS instrument (MoQ-ToF) is an in-house modified Q-ToF 1 
which contains a 51 mm copper drift cell with temperature control capabilities.  The drift 
chamber filled with a buffer gas is situated between the first transfer hexapole and the 
quadrupole analyser as highlighted in yellow in Figure 2.3.  Typically, the drift cell is 
filled with helium gas at a pressure of 3.2 – 4.0 Torr (4.3 – 5.3 mBar) and a weak electric 
field is applied to propel the ions through the cell.  The MoQ-ToF instrument can be 
operated either in MS or IM-MS mode.  In the MS mode, ions formed in the nESI source 
are guided through a series of ion lenses and the drift cell towards the detector.  In the 
IM-MS mode, analysis relies on trapping and then injection a pulse of ions to drift 
through the cell.  A continuous beam of ions is produced by nESI source, the DC voltage 
on the ‘top hat’ ion gate lens (d in Figure 2.3) is raised to trap ions which are then pulsed 
out of hexapole in discrete “ion packets”.  At regular intervals, this trapping voltage is 
lowered for several microseconds (40-100 µs) to inject the pulse into the drift cell.  The 
frequency of this pulse is set using a Stanford DG535 digital delay generator (Stanford 
Systems, Sunnyvale, CA, USA) and is dependent on the ToF pusher period which in turn 
is dependent on m/z required for the ion species.  For example, a pusher period of 160 µs 
is used to cover m/z range up to 8000.  Therefore, any two mobility events occur every 
200 x 160 µs = 32 ms, or at a frequency of 31.3 Hz (v = 1/t = 1/32 ms = 31.3 Hz).  Ions 
drift through the cell and separate due to mobility.  The small compact ions traverse 
faster than the large extended ions.  On exiting of the drift cell, ions are refocused in the 
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post-cell hexapole and travel though the quadrupole mass analyser to the ToF analyser 
and the MCP detector.  Ion arrival time distributions (ATD) i.e. mobility spectra are 
recorded by synchronized release of ions into the drift cell, with one mobility separation 
event sampled 200 times i.e. pushes by the ToF. 
 
 
Figure 2.3   Schematic of the linear drift tube ion mobility mass spectrometer ‘MoQToF’ 
illustrating the source region, the drift chamber, the quadrupole and the time-of-flight 
analysers.  The drift chamber, highlighted in yellow, has been modified in-house to include the 
linear drift cell (e).  The ion flight path is shown in red dotted line.     Labelled instrument 
elements are: a - sample cone, b – extractor cone , c – pre-cell hexapole, d – top hat lens, e – 
drift cell, f – post-cell hexapole, g – quadrupole,  h – collision cell, i – post-collision cell 
hexapole, j – acceleration and focusing lenses, k – pusher, l – reflectron, m – point detector (for 
quadrupole analyser), and n – MCP detector (for ToF analyser).   
 
 
The drift chamber is filled with the CP Grade helium gas (99.999%, BOC Speciality 
Gases Ltd, Guildford, UK) at a pressure of ~3.75 ± 0.02 Torr measured using a MKS 
Barotron (MKS Instruments, Andover, Massachusetts, USA).  A precise pressure is 
recorded at the start and end of each measurement and is used in the calculations of CCS 
(± 5 % error).  In addition to the differential pumping regions as in the Q-ToF Ultima 
API US described in the section 2.1.3., the MoQToF contains an additional vacuum 
chamber pumped by a 500 Ls-1 Pfeiffer TMH520 pump (Pfeiffer Vacuum Ltd., Newport 
Pagnell, UK), backed by a dual state Edwards E2M40 rotary pump (Edwards Vacuum, 
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Crawley, UK) and an additional mechanical booster pump when the drift cell is filled 
with gas.  Optimisation of pressure in the source region for improved transmission of 
large molecules, is achieved by throttling of the source rotary pump (Edwards E28) and 
the introduction of argon gas (99.998 %, BOC Speciality Gases Ltd, Guildford, UK) to 
the pre-cell hexapole chamber and control of its flow with a metering bellows-sealed 
valve.  The typical pressures in each region, with the buffer gas in the cell, are: source ~ 
3-8 × 10-1 mBar (adjusted by controlling the argon flow), analyser ~ 3 × 10-3 mBar, ToF 
~ 5 × 10-7 mBar.  
 
2.2.1.2 The drift cell and the temperature control of the drift cell region 
 
The design of the drift cell is based on the previously reported by Bowers et al. at the 
University of California Santa Barbara, CA, USA.22-24  The cell contains five copper drift 
rings separated by ceramic spacers housed within a copper block and the end cap which 
is also separated by a ceramic space ring (Figure 2.4).  A potential difference between 
those elements is applied to achieve a linear drift field with a total drift length of 51 mm.  
Ions enter and exit the drift cell though 0.8 mm orifices in molybdenum discs enclosed 
on each site of the cell.  
  
 
Figure 2.4   A photograph of the MoQToF drift cell showing: a - the Einzel lens stack, b – the 
buffer gas inlets, c – the buffer gas outlet, d – the ceramic heaters and e – the cooling lines.  
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The design of the drift cell allows for temperature control of the buffer drift gas and 
determination of temperature dependant absolute CCS.  The cell can be heated up to 700 
K via tantalum wire (0.25 mm diameter, Goodfellow Cambridge Ltd., Huntingdon, UK) 
wound ceramic rods (Kimball Physics Inc., Wilton, NH, USA) located in both the cell 
body (8 heaters) and the end cap (2 heaters).  A current is supplied to the heaters by two 
external variable transformers, resulting in resistive heating of the cell copper block.  
Cooling of the cell is accomplished by passing chilled nitrogen gas though the channels 
inside the copper block.  The nitrogen gas is cooled by passing it though a stainless steel 
tubular coil contained in a thermally insulated Dewar flask filled with liquid nitrogen.  
The temperature of the drift cell is carefully monitored using three k-type thermocouples 
(one situated on the cell body and two on the end cap) read on an Omega CN1001TC 
thermocouple controller.  Temperature is recorded before and after each measurement, 
and the average value is used in the calculations of CCS.    
 
The voltages applied to the drift cell and associated optics (Figure 2.5a) are supplied via 
an in-house build power supply.  As the ions are pulsed from the ‘top hat’ (TH1) lens, 
they are focused into the entrance orifice of the cell via a stack of three stainless steel 
cylindrical lenses (L1, L2 and L3) referred to as the Einzel lens stack.  The pre-drift cell 





Figure 2.5  (a) Schematic of the MoQToF drift cell with surrounding lenses.  H1 – the pre-cell 
hexapole, H2 – the post-cell hexapole, TH1 – the pre-cell ‘top hat’ lens, TH2 – the post-cell ‘top-
hat’ lens, L1, L2 and L3 – the pre-cell lenses, L4 – the post-cell lens, C1 – the ‘cell body one’, C2 
– the cell body two – end cap. (b)  The potential gradient along the drift cell and associated 
optics.  The potential difference between H1 and C1 is the energy with which ions are injected 
into the drift cell (IE) indicated here with a red double-headed arrow.  
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the post-drift cell lens L4 is referenced to the end cap voltage (C2).  H2 and TH2 float 
above the collision cell voltage (CV) which is set from the instrument tuning page in the 
MassLynx software;  C2 and H1 are referenced to this and the source, respectively.  
Typically used drift cell voltages and their working ranges are reported in Table 2.2 
below.   
 
Table 2.2   Voltage requirements and typical drift cell lens stack settings used in a IM-MS 
experiments on the MoQToF instrument. *The C1 voltage is decreased in 5-10 V intervals to 
acquire IM data at several distinct drift voltages.   
Lens Voltage range Potential wrt. C1 or 
C2٭ / V 
Actual voltage/ V 
H1 0 to 200 30 - 35 C1 + H1 
TH1 0 to 200 2 - 30 C1 + TH1 
L1 0 to -350 -50 - (-5) C1 + L1 
L2 0 to -350 -180 - (-80) C1 + L2 
L3 +50 to -50 23 - 30 C1 + L3 
C1* 0 to 200 70 C1 
C2 0 to 75 10٭ C2 
L4 +50 to -50 -4 – 5٭ C2 + L4 
 
 
The kinetic energy with which ion are injected into the drift cell in defined as the 
potential difference between the pre-cell hexapole (H1) and the first drift cell lens, 
depicted in red arrow (IE) in Figure 2.5b.  This energy can be varied within 25 V to 54 
V, and is adjusted dependent on the ion species analyzed and experimental design.  The 
injection energy is kept low to preserve the native protein structure and to minimise the 
shortening of the drift region as ions injected from higher energies will penetrate deeper 
into the drift cell before starting to drift.  In the work presented here the values were kept 
between 31-36 V dependent on the ion species.   
 
2.2.1.3 Typical instrumental parameters  
 
The typical instrumental settings used in the work presented in this thesis are tabulated in 
Table 2.3.  
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Table 2.3   Typical instrumental parameters for the MoQToF IM-MS instrument in the positive 
mode.  
Parameter  Value Comment 
Capillary /kV  1.3 – 2.0  
Cone /V 40 – 200 adjusted accordingly to the sample 
and experimental design   
Extractor /V 110-140 at the drift voltage of 60 V (this 
value is decreased as the DV is 
lowered during the IM-MS 
experiment) 
RF Lens /V 2.40  
Source Temperature /°C 25 – 80 adjusted accordingly to the sample 
LM Resolution /V 4.4  
HM Resolution /V 4.4  
Collision Energy /V 4.0  
Ion Energy /V 0.5  
Steering /V -2.0  
Entrance /V 43.3  
Pre-filter /V 5.0  
Transport /V 3.0  
Aperture2 /V 5.7  
Acceleration /V 200  
Focus /V 0  
Tube Lens /V 90  
Guard /V 44.1  
ToF /V 7.20  
Reflectron /V 35.00  
Pusher Cycle Time / µs 70 – 200 adjusted accordingly to m/z range 
Multiplier/ Hz 6250 at pusher cycle time = 160 µs 
MCP /V 2400 or 3000* * higher MCP voltage used prior 
to the instrument maintenance 
service 
TDC Start /mV 300  
TDC Stop /mV 40  
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2.2.1.4 Data acquisition and analysis: an example  
 
The following IM-MS experiment is provided as an example of data acquisition and data 
analysis obtained from the in-house modified MoQToF instrument.  An Fc-hinge 
fragment of an immunoglobulin G4, IgG4 (~54 kDa) was analysed by ion-mobility mass 
spectrometry.  In-depth description of immunoglobulin classification and structure can 
be found in Chapter 3.  The protein sample was kindly provided by UCB Pharma, and on 
the day of analysis the sample buffer was exchanged to 100 mM ammonium acetate, pH 
6.8.  40 µM IgG4 Fc-hinge sample was ionised by nESI as described in section 2.1.2.  
The mass spectrum shown in Figure 2.6, displays a narrow charge state distribution 
centred at the 13+ charge state (m/z 4130). 
 
 
Figure 2.6  nESI mass spectrum of 40 µM IgG4 Fc-hinge fragment in 100 mM ammonium acetate 
at pH 6.8, acquired on MoQToF instrument at 300 K.  The theoretical mass calculated based on 
the amino acid sequence is 52 167 Da, measured mass is 53 454 Da; the deviation from the 
theoretical mass can be assigned to the presence of two N-glycans and residual solvent. 
 
 
In the IM-MS experiment, a total arrival time distribution (tATD), corresponding to one 
mobility separation, is generated every 200 MS scans (Figure 2.7).  Spectra are acquired 
for at least fifteen pulses per each drift voltage.  Some ion species, usually large 
molecules with poorer transmission, require more pulses to be collected for enhanced 
signal intensity once summed.   Several IM experiments are performed at various drift 
voltages applied across the drift cell, ranging from 60 to 15 V in 5-10 V intervals, 
typically measurements are carried out at 60, 45, 35, 30, 25, and 15 V.  As the drift 
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voltage is lowered, the extractor cone voltage is adjusted by the same number of volts to 
preserve the field integrity between source and drift cell.  Along with tATD, pressure 
and temperature is recorded at the start and end of each set of scans and averaged for 




Figure 2.7  Total ion ATD at a drift voltage of 35 V for the IgG4 Fc-hinge fragment.  Each peak is 
a collection of 200 scans.   
 
From the tATD, a mass spectrum can be generated and a deconvoluted ATD for each 
m/z peak can be extracted.  Deconvoluted ATD peaks are summed to enhance data 
quality.  An ATD extracted for the most intense charge state (13+) of the IgG4 Fc-hinge 
fragment is shown in Figure 2.8a.  The average scan number is calculated in Origin 8.5.1 
graphing software (OriginLab, Northampton, MA, USA) by fitting a Gaussian 
distribution and determining the midpoint value.  For many species, especially the 
dynamic and flexible systems, the individual ATD are broad and peaks are not base line 
resolved indicating the presence of potential multiple closely related conformers.  The 

















                             (Equation 2.1) 
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where offset y0 = 0, A is the area, xc is the centre of the fitted peak and w is the peak 
width; to resolve these distributions.  The maxima values for the resulting peaks are used 





Figure 2.8  The ‘raw’ ATD extracted for the +13 charge state of the IgG4 Fc-hinge fragment 
[M+13H]13+ (~m/z 4130) at 300 K and DV – 35V (a), along with the Gaussian fitting to the ATD data 
points to elucidate average ATD for population of ions (b); the cumulative peak fit (blue line) is 
the sum of the Gaussian fits (red and green lines) and closely approximates the experimental 




An average arrival time (ta) is obtained by multiplication of the average scan number (xc 
from Equation 2.1) by the MS pusher period used in the experiment.  Average arrival 
time (ta) corresponds to the time ions take to travel through the drift cell (the drift time, 
td) plus the time ions spent outside the drift cell (known as the dead time, t0).  Next, the 
arrival time (ta) is plotted as function of pressure over drift voltage (P/V) and a linear fit 
to the data-points is made (Figure 2.9), which should have a high R2 value (> 0.999).  
The y-intercept of this fitted line provides the instrumental ‘dead time’ (t0), and the slope 








0                               (Equation 2.2) 
 
where L is the length of the tube (0.051 m), V is the drift voltage, P is the pressure, P0 is 
760 Torr, T is the temperature and T0 is 273.15 K.  The rotationally-averaged collision 
cross section (Ω) can be then calculated from K0 knowing that:  
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where z is the integer ion charge, e is electron charge (1.602 × 10-19 C), N is the number 
density of the buffer gas, µ is the reduced mass of the analyte (in kg) and the buffer gas 
and kB is the Boltzmann constant (1.381 × 10
-23 J K-1).  Each complete IM-MS 
experiment is performed at least twice and the average collision cross sections are 






Figure 2.9  Plot of average arrival times (µs) versus P/V  (Torr Volt-1) for the IgG4 Fc-hinge 
fragment [M+13H]13+ ion at 300 K.  The slope of the linear fit is inversely proportional to the 
reduced mobility K0, and the intercept gives the instrument dead time, td. 
 
 
Protein complexes investigated in the work presented in this thesis are large and/or 
multimeric dynamic systems displaying broad ATD.  In the literature, CCS are often 
reported as discrete values.  Here however, the resulting ATD show broad and complex 
profile due to presence of a number of closely related dynamic conformational families 
not resolvable at this experimental time scale and temperature.  Assigning two or more 
discrete arrival time maxima (hence CCS) would not reflect the experimentally observed 
conformation occupancy and would risk biasing interpretation towards the presence of 
Chapter 2                                                                                                                                  Experimental Methods 
 
 
- 74 - 
more defined structures.  Instead experimental results are reported as the entire arrival 
distributions acquired for each charge state.  To make comparison of the results obtained 
at different experimental conditions possible, ATD are converted into CCS distribution 
profiles (CCSD).  To make such conversion possible, the instrumental dead time (to) 
needs to be known.  Instead of using the strategy described earlier of fitting individual 
Gaussian peaks to match the cumulative peak with the experimental data to obtain the 
maxima for each conformational family, a median scan number value of the total 
distribution is used to determine to from the P/V plot .  Next, all the experimental data 





Figure 2.10  Collision cross section distribution profiles (CCSD in nm2) for the three charge 
states of highest intensity for the IgG4 Fc-hinge fragment acquired at 300 K,  DV = 35 V, and 
normalized to the spectral intensity. 
 
Figure 2.10 shows such CCSD for three charge states of the IgG4 Fc-hinge fragment.  
Immunoglobulins are known to be highly dynamic molecules somewhat hindering full 
structural characterization using classical methods such as NMR spectroscopy (due the 
size of the intact molecule) or x-ray crystallography (due to the need for sample 
crystallisation).  IM-MS provides shape defining parameters, a very high mass limit of 
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the analyte and no need for crystallisation, rendering it highly suitable to study the 
higher order structure of large dynamic proteins such as IgGs.  Gas-phase conformations 
of the IgG4 Fc-hinge fragment probed with linear DT-IM-IM show broad CCSD 
populated from ~22 to 46 nm2 suggesting multiple indistinguishable conformations, 
and/or dynamics in the time scale of the experiment.  In comparison to other proteins of 
similar size, the CCSD width is significantly broader for the Fc-hinge fragments as well 
as the intact IgG molecules.  Insights into antibody gas-phase dynamics from IM-MS 
and molecular dynamics (MD) as well as the effect of the buffer gas temperature on the 
CCSD of intact IgGs will be discussed in Chapters 3 and 5, respectively.    
 
2.2.2 Travelling wave IM-MS – Synapt G2 HDMS 
 
TWIM-IM-MS experiments on ATP-phosporibosyltransferase presented in Chapter 6, 
were performed on Synapt G2Si HDMS (at Waters Corporation, Floats Road, 
Manchester, UK) and Synapt G2 HDMS (at the Manchester Institute of Biotechnology, 
Manchester, UK).  Samples for IM-MS measurements were ionised by nESI in positive 
mode as described in section 2.1.2.    
 
2.2.2.1 Instrument layout and operation 
 
In 2006, Waters Micromass Technologies introduced the first commercially available 
ion-mobility mass spectrometer called the Synapt HDMS.  In the subsequent years, 
upgraded versions of the higher resolution instrument mediated by an altered drift cell 
with higher pressure and drift voltage by inclusion of a helium-filled entry cell prior to 
the T-wave IMS cell (Synapt G2 HDMS, Figure 2.11) and the StepWave device (Synapt 
G2S, Figure 2.13) were released.  Synapt HDMS instruments have hybrid 
quadrupole/IM/ToF geometry where the T-wave i.e. travelling wave ion guide (TWIG) 
technology is used to separate ions based on their conformations.  Unlike the MoQToF 
described above the TWIG is located after quadrupole analyser.  Ions generated using 
nESI pass via a ‘Z-spray’ and are subsequently transferred though a T-wave ion guide 
and a quadrupole mass filter to the IM section of the instrument composed of three 
travelling wave ion guides.  The first compartment, the trap T-wave, accumulates ions as 
the previous mobility separation is taking place.  Next, the ions are released in a packet 
into the IMS T-wave filled with nitrogen gas as visualized in Figure 2.12.   
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Figure 2.11   Schematic of the Waters Synapt G2 HDMS instrument.  Image adapted from the 
Waters web page 25.    
 
 
This event is analogous to the injection of ions from the pre-cell hexapole into the drift 
cell on the MoQToF instrument.   Here however, the following mobility separation is 
performed as the repeating DC pulses drive ions through the cell.  Increased mobility 
resolution can be achieved by use of higher N2 pressure and higher T-wave pulse 
amplitudes.  Nevertheless, increasing the pressure alone might lead to reduction in signal 
intensity, fragmentation of molecules or distortion of structure while working with native 
state proteins.  For those reasons, the second generation Synapt G2 HDMS (Figure 2.11) 
has been implemented with an interface high pressure helium-filled cell situated just in 
front of the IMS cell.  The helium-filled cell balances N2 pressure in the main cell, 
maximizes the transmission of ions into the mobility cell and promotes ion cooling.  
From there mobility separated ions are delivered to the ToF mass analyzer though the 
transfer T-wave.  As in the MoQToF instrument, ion arrival time distributions are 
recorded via synchronised mass spectral acquisition with the gated release of ions from 
the trap T-wave cell.  Ion detection is accomplished by a system combining ultrafast 
electron multiplier and with a novel analog-to-digital conversion (ADC) detector 
electronics.   
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Figure 2.12   During the ion mobility experiment on a Synapt HDMS instrument, ions are 
accumulated in the trap T-wave cell and subsequently gate released in ion pockets into the 
TWIM IMS cell, where the mobility separation occurs.   Mobility separated ions are further 
transferred to the ToF mass analyser via transfer T-wave.  This process is continually repeated 
on a ten of millisecond time scale.  Image adapted from one found on the Waters web site 25.    
 
 
Further increase in instrument sensitivity has been achieved with the new off-axis ion 
guide design in the source region, the StepWave introduced with the Synapt G2S HDMS 
instrument.  The new design, based on stacked ring ion guide technology, actively 




Figure 2.13   Illustration of the StepWave device implemented on the Waters Synapt G2S HDMS 
instrument.  The off-axis ion source technology was designed to maximise ion transmission 
from the source to the mass analyser.  Image adapted from one found on the Waters web site 25.     
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and allows for removal of neutral species and excess solvent to the exhaust (in blue).  
This feature not only maximises ion transmission from the source to the mass analyser 
but also increases method robustness as the upper ion guide is protected from the 
majority of contaminants.   
 
Unlike the linear DT based arrival times, the physical relationship between T-wave 
based drift time and CCS have not been fully understood yet and the fundamentals of 
TWIMS have been explained only qualitatively.26  Data obtained from Synapt HDMS 
instrument are commonly externally calibrated against the DT-IM-MS data of molecules 
with similar arrival times and masses.27-29  Normalised CCS for charge and reduced mass 
are plotted versus arrival times (excluding time spent outside of the TWIMS region) 
creating power-series fit calibration curve.  The calibration is valid given that the 
mobilities i.e. corrected arrival times lie within the mobility range observed for the 
calibrant.   
 
The main parameters that allow successful ion transport through the IMS cell are wave 
height (V) and wave velocity (ms-1).  These experimental parameters affect the measured 
CCS.30  In the work presented in Chapter 6, CCS have been determined based on 
MoQToF measurements; whereas T-wave IMS based data is presented in terms of 
arrival time and comparison among the samples is made based on data acquired under 
identical experimental conditions and instrumental parameters.  
 
2.2.2.2 Travelling wave ion guide technology 
 
Synapt HDMS instruments use stacked ring ion guides (SRIG) located between the 
quadrupole and the ToF analyser. The T-wave device, shown in Figure 2.14a, is 
composed of a series of ring-shaped electrodes which are supported on printed circuit 
boards supplying radio frequency (RF) and direct current (DC) voltages.  The ions are 
radially confined within the device by application of opposite phases of RF voltage to 
adjacent rings, as they progress along the axis (Figure 2.14b)31.  The ions ‘surf’ though 
the IMS cell due to application of transient DC pulse superimposed on the RF voltage, 
what creates a moving electric field – the travelling wave.  At elevated N2 gas pressure 
(~0.5 mBar in the first generation and ~2.5 mBar in the second generation instruments),  
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Figure 2.14   (a) A photograph of the T-wave device consisting of series of transmission ring 
electrodes; image adapted from the Waters web page25; (b) Schematic diagram of an RF-only 
stacked ring ion guide (SRIG); image adopted from Giles et al., 200432; (c) ions ‘surfing’ on the 
travelling wave shown with a computer simulation in SIMION software, image reproduced from 
one found on the Waters web site25.  
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ion separation occurs based on their mobility and due to collisions with the buffer gas.  
The ions roll over the wave as shown in Figure 2.14c; species with higher mobility roll 
over the wave less often in comparison to ions with lower mobility; and are propelled 
through the device with shorter drift times.  Ions with lower mobility are displaced over 
the wave crest to the previous potential well, and remain there until the next wave carries 
them forward. 
 
2.2.2.3 Typical instrumental parameters  
 
As with any other nESI-MS instrumentation, optimisation of source parameters 
(capillary and cone voltage) as well as bias potential is essential for preservation of 
native-like protein structures and non-covalent complexes.  As previously, the 
optimisation of source pressure helps the transmission of large ions.  The main 
parameters allowing successful ion transport through the cell are wave height (V), wave 
velocity (ms-1) and gas pressure.  Optimization of the gas flow ratio between the He-
filled pre-cell and N2 IMS cell gas flow allows for improved mobility separation.
33  
Table 2.4, lists the typical experimental settings employed in experiments performed on 
the Synapt G2 HDMS and Synapt G2S HDMS instruments.  The experimental 
parameters were screened to achieve an optimum signal and prevent any instrument-
induced structural rearrangements.  
 
Table 2.4   Typical instrumental parameters for Synapt G2 HDMS and Synapt G2S HDMS 
instruments in the positive mode.  
Parameter  Synapt G2 HDMS Synapt G2S HDMS 
Capillary / kV 1.66 1.67 
Cone /V 99 99 
Extractor /V 3.0 2.5 
Source Temperature /°C 20 20 
LM Resolution /V 2.0 4.9 
HM Resolution /V 15.0 15.3 
Aperture1 0.0 0.0 
Pre-filter /V 2.0 2.0 
Ion energy /V 1.0 1.0 
Trap Collision Energy* /V 10.0 5.6 
Transfer Collision Energy /V 0.0 2.0 
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Parameter  Synapt G2 HDMS Synapt G2S HDMS 
Source Gas Flow / mL/min 0.0 0.0 
Trap Gas Flow / mL/min 0.40 5.0 
He Gas Flow / mL/min 180.0 180.0 
IMS Gas Flow / mL/min 90.0 90.0 
Detector 2875 2700  
Collision Energy /V 4.0 4.0 
Acceleration1 70.0 70. 0 
Acceleration2 200.0 200.0  
Aperture2 40.0 70.0 
Transport1 70.0 70.0 
Transport2 70.0 70.0 
Steering 0.0 0.00 
Tube Lens 45 75 
Pusher  1900.0 1900.0 
Puller 1370.0 1370.0 
Collector 50 50 
Collector Pulse 10.0 10.0 
Entrance 55 62 
Flight Tube /kV 10.00 10.00 
Reflectron /kV 3.780 3.780 
Trap DC Bias 45.0 60.1  
Trap DC Exit 3.0 -4.9 
IMS DC Entrance 25.0 20.0 
He Cell DC 35.0 50.0 
He Cell Exit -5.0 -20.0 
IMS Bias 3.0 5.0 
IMS DC Exit 0.0 0.0 
Transfer DC Entrance 4.0 5.0 
Transfer DC Exit  5.0 15.0 
Trap Wave Velocity/ m/s 508 311 
Trap Wave Height /V 8.0 7.0 
IMS Wave Velocity / m/s 550 617 
IMS Wave Height /V 40.0 40.0 
Transfer Wave Velocity / m/s 508 75 
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Parameter  Synapt G2 HDMS Synapt G2S HDMS 
Transfer Wave Height /V 0.1 5.0 
Step Wave 1 In Velocity / m/s NA 300.0 
Step Wave 1 In Height /V NA 10.0 
Step Wave 1 Out Velocity m/s NA 300.0 
Step Wave 1 Out Height /V NA 1.0 
Step Wave 2 Velocity/ m/s NA 300.0 
Step Wave 2 Height /V NA 0.0 
Backing Pressure /mBar 7.53 8.90 
Source Pressure /mBar 3.86 × 10-3 4.42 × 10-3 
Trap Pressure /mBar 2.74 × 10-2 2.39 × 10-2 
He Cell Pressure /mBar 1.41 × 103 1.32 × 103 
IMS Pressure /mBar 3.65 1.91 
Transfer Pressure /mBar 1.00 × 10-6 2.15 × 10-2 
ToF Pressure /mBar 1.03 × 10-6  1.51 × 10-6 
* increased stepwise in 10 V intervals for the CID experiments 
 
 
2.3 Computational Techniques: Molecular Dynamics and 
Estimation of CCS from PDB Structures  
 
All MD calculations and estimation of CCS from the PDB structures presented in this 
thesis were performed by Dr Massimiliano Porrini at the Institute Européen de Chimie et 
Biologie (IECB) in Pessac, France.  
 
The experimentally derived DT-IM-MS based CCS can be compared to the theoretical 
CCS of protein structures obtained via other biophysical methods such as NMR 
spectroscopy, x-ray crystallography, electron microscopy or molecular dynamics.34  The 
input x-ray crystallography structure coordinate files of intact IgGs (1IGT, 1IGY and 
1HZH – work presented in Chapter 3) and MtATP-phosporibosyltransferase (1NH7 and 
1NH8 – work presented in Chapter 6) were taken from the online database - the Protein 
Data Bank (PDB)35.  
 
Chapter 2                                                                                                                                  Experimental Methods 
 
 
- 83 - 
X-ray crystallography usually cannot resolve positions of hydrogen atoms. As the 
structure and function of proteins and peptides is highly dependent on the protonation 
state of its amino acid building blocks, position of all hydrogen atoms and any protons 
needs to be assigned prior to any molecular modeling.  This can be achieved by using 
platforms such as the H++ server 36-39, or Amber molecular modeling package40 by 
predicting the protonation state (pK) of ionisable groups within the molecule.  Protons 
are added to the output files which are then used for further molecular modeling.  
 
For the MD results reported in Chapter 3, after adding hydrogen atoms, structures are 
minimized in vacuo with the sander module of Amber1140, implementing a radial cut-off 
of 999 Å and Amber99SB-ILDN force field.41  Theoretical CCS are calculated with each 
of the three methods  described in Chapter 1, implemented in the MOBCAL code42,43, 
with the trajectory method (TJM)44 appropriately modified to handle large systems such 
as these studied in this thesis.  The less accurate methods: the projection approximation 
(PA)45 and the exact sphere scattering (EHSS)43,46 are included in this work for 
comparison with other more approximate methods; results from TJM are most reliable 
and most robust with respect to comparison to the coordinates.47  To follow the evolution 
of dynamics in the gas-phase, the structures are firstly gradually heated up to 300 K, 
utilizing a Langevin thermostat (damping coefficient of 2 ps-1) with a time-step of 1.0 fs, 
and then subjected to a constant temperature (300 K) molecular dynamics (MD) run of 
10 ns, again with Langevin thermostat.  Damping coefficient, radial cut-off, force field 
and time-step were the same as these described above, and the simulation software 
package utilized was NAMD 2.9.48  The observables are computed to follow 
conformational rearrangements of the proteins studied are the backbone root mean 
square deviation (RMSD), the radius of gyration (Rg) and the rotationally averaged 
CCS. The latter are calculated with a simulation time increment of every few ns intervals 
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2.4 Hydrogen Deuterium Exchange Mass Spectrometry 
(HDX-MS)  
 
Even though x-ray crystallography and cryo-electron microscopy provide invaluable 
snapshots of static structures; a complementary method reflecting structural dynamics in 
physiologically relevant solvent environment is needed to fully understand protein 
behaviour.  HDX is a chemical phenomenon in which labile hydrogen atoms at backbone 
amide positions in the protein exchange with deuterium atoms in a surrounding solvent 
or gas and these changes can be measured with MS, as it was described in Chapter 1.49  
HDX-MS has been successfully used to study higher order structure of 
biopharmaceuticals,50 epitope mapping,51,52 conformational changes,53,54 protein 
dynamics55,56 or allosteric interactions.57,58 
 
Experimental data presented in Chapter 6 of this thesis was collected on the Waters 
HDX module with nanoAcquity UPLC and Synapt G2 mass spectrometer, equipped with 
a LEAP-PAL robotics system at UCB Pharma, Slough, UK.  Data analysis was 
performed using the ProteinLynx Global Server (PLGS) v2.5 and DynamX Data 
Analysis software v2.0 (Waters Corporation, Manchester, UK).  The deuterium update 
protein maps were created in the PyMOL Molecular Graphics System, V1.5.0.4 
(Schrödinger, LLC., Portland, OR, USA).  Experimental set-up and data analysis were 
performed with help of Dr Rebecca J Burnley from UCB Pharma.  
 
2.4.1 Instrumental set-up 
 
An automated workflow, from sample preparation to data processing, results in optimal 
use of experimental time.  An automated sample injection system (LEAP-PAL robotics 
system) for sample labeling, quenching and digestion on a pepsin column, schedules the 
experiments and allows for three replicas to be run overnight on a protein even of 200 
kDa size, significantly reducing the human labour required.  The workflow of a typical 
HDX experiment using Waters HDX automated system is shown in Figure 2.15.  
Proteins are prepared in the aqueous buffers at a desired pH (usually pH 7 and above), 
then diluted 20 fold into phosphate buffer in H2O (for undeuterated analysis) or D2O (for 
deuterated analysis), with use of the robotics system.  Next, mixtures are incubated at  
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Figure 2.15  Workflow of a hydrogen-deuterium exchange mass spectrometry (HDX-MS) 
experiment using the Waters nanoACQUITY UPLC system with HDX technology.   
 
 
20°C in the deuterated buffer for a specified amount of time to produce a labeling time-
course.  The labeling reaction is quenched at various time points by reducing the pH to 
2.5. Next, the denaturing agents guanidine chloride (Gdn-HCl) and tris(2-
carboxyethyl)phosphine (TCEP) are added to reduce the disulfide bonds.  Once the HDX 
reaction is chemically quenched, the HDX Manger injects samples into the pepsin 
column for peptic digestion; here everything is performed under properly controlled 
temperature and pH conditions.  If intact analysis i.e. global HDX data is required, the 
sample bypasses the pepsin column and proceeds directly onto the trapping column and 
then analytical column.  The non-specific cleaving nature of pepsin produces 
overlapping peptides and increases the sequence coverage of the studied protein.  
Maintaining temperatures at 0 ± 1 °C assures that the back-exchange is kept to an 
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absolute minimum.  Resulting peptides are separated by UPLC and further fragmented 
and identified in the mass spectrometer.  If necessary, IM separation can be used to 
provide additional, orthogonal separation to chromatography and mass dimensions for 
overlapping ion species.  Peptides are identified and the deuterium update is determined 
using the PLGS database search and the DynamX Data Analysis software (Waters 
Corporation, Manchester, UK), respectively.  Each experiment is performed in triplicate 
and the average values are reported.  
 
2.4.2 Data analysis using PLGS and DynamX software   
 
Manual analysis of HDX-MS data produced across multiple time points, multiple species 
and few replicas is a time consuming task.  Deuterium uptake at a peptide level needs to 
be determined for hundreds of peptides.  With the use of automated PLGS search and 
DynamX software, the data processing time is reduced.   
 
Firstly, peptides are identified with the PLGS database search and the output files are 
created.  These output files and the raw MS data are imported into the DynamX 
software.  DynamX software determines deuterium uptake of each peptide from the 
undeuterated data versus the deuterated data at various time-points.  Deuterium update of 
each peptide identified is plotted as a function of exposure time to create the uptake 
curves.  To ensure consistency in monitoring HDX, the software tracks all peptides 
reproducibly found in experimental replicates.  Now, the data can be visualized by 
means of ‘butterfly charts’, difference plots and heat maps (Figure 2.16). 
 
Figure 2.16 shows a workflow of an HDX data analysis in the DynamX software.  The 
list of peptides identified through a PLGS search of a sample protein is displayed (Figure 
2.16a).  The uptake curves (upper right hand corner panel of Figure 2.16a) for the 
selected peptide shows how the extent of deuterium uptake changes with respect to the 
incubation time, as well as the differences between relative deuterium uptake between 
ligand-free (red curve) and ligand-bound (blue curve) species, if such experiment was 
performed.  A spectrum of the selected peptide at a specified incubation time point 
(lower right hand corner panel of Figure 2.16a) can be also viewed.  Here, the raw 
spectrum is shown in red, and the blue lines are overlaid centroid data identified though 
the PLGS search and matched to the peptide.  The data can be also displayed as stacked 
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Figure 2.16  An HDX data analysis and visualisation in the Waters DynamX software. (a) main 
window of the DynamX software showing the list of identified peptides through the PLGS 
search (LHS), deuterium uptake curves (upper RHS) and a mass spectrum of a selected peptide 
at a selected incubation time point; (b) the stacked mass spectra of a selected peptide in a time-
course; (c) a ‘butterfly chart’ comparing relative fractional deuterium uptake between two 
protein batches at various incubation time points; and (d) HDX data visualized as a colour 
coded heat map created in PyMOL Molecular Graphics System.  Images obtained from Water 
Corporation web page.25 
 
spectra in a given time-course (Figure 2.16b) showing the mass shift due to deuterium 
incorporation as a function of incubation time.      
 
To cope with the burden of data processed, results are often presented as a ‘butterfly 
chart’ (Figure 2.16c).59  Here as an example, two different batches of protein sample are 
compared in relative fractional uptake.  Each point along the x-axis corresponds to a 
peptide identified through the PLGS search.  The plot shows relative fractional update at 
specified labeling time-points indicated in different colours.  Such visualisation helps to 
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spot any differences in HOS between the protein batches.  Moreover, when concerned 
with conformational changes due to ligand binding or environmental changes, 
differences in deuterium uptake will help to differentiate between solvent accessible 
regions of the protein and those where uptake is reduced due to structural rearrangements 
or ligand binding.  If structural data obtained via other biophysical techniques exists and 
the atom coordinate file is available, HDX data can be further visualised by exporting the 
deconvoluted data for each residue into PyMOL Molecular Graphics System to build a 
colour coded heat map as the one shown in Figure 2.16d.  
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Dancing Antibodies:  
Exploring the Dynamics of 
Immunoglobulin G  
with DT-IM-MS and MD  
 
Monoclonal antibodies (mAb) are a rapidly growing group of biopharmaceuticals.  Due 
to their intrinsic flexibility, intact mAbs provide a challenge with regards to higher order 
structure characterization.  Intact mAbs and their fragments are explored here using the 
DT-IM-MS and were found to be far more dynamic in the gas-phase than proteins of 
comparable size.  This is rationalised with MD simulations, which revealed dynamics 
between linked folded domains of mAbs.   
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3.1 Introduction  
 
3.1.1 Immunoglobulins – function, classification and structure 
 
Immunoglobulins (Ig), also known as antibodies, are glycoproteins employed by the 
immune system for binding to antigens.1  Antibodies are produced by plasma cells and 
are secreted in response to non-self antigens, often produced by bacteria or viruses, in 
order to bind and remove these intruders.  Antibodies exist in various isoforms which 
differ in their biological function, structure, distribution in the body and antigen 
responses.  These ‘Y’ shaped molecules are composed of four polypeptide chains, with 
the atom density distributed almost evenly into three globular domains linked via a 
flexible stretch of polypeptide chain referred to as the hinge region.  Each of the Ig 
isoforms consists of one or more replicas of the ‘Y’ shaped unit.  In mammals, five 
different isoforms (also known as classes) are identified: gamma (IgG), mu (IgM), alpha 
(IgA), delta (IgD) and epsilon (IgE), shown in Figure 3.1.  These are classified based on 
differences in the amino acid sequence.2  In this chapter, the IgG isotype is investigated 
which constitutes to about 75% of serum immunoglobulins in humans and is commonly 




Figure 3.1   Five isoforms of mammalian immunoglobulins IgD, IgE, IgG, IgA and IgM and their 
main components: constant (C) and variable (V) regions of heavy (H, teal) and light chains (L, 
yellow) and the J chains (red) which merge ‘Y’ subunits in IgA and IgM isoforms.  Image 
reproduced from Rojas, R. et al., 2002.4 
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From a structural point of view, all the isoforms share several similar features:  each ‘Y’ 
unit consists of two identical heavy chains (HC) with covalently attached 
oligosaccharide groups, and two identical non-glycosylated light chains (LC).    There 
are two isoforms of LC, lambda (λ) and kappa (κ), which have not been found to be 
functionally different and can be found in any of the isotypes.5  The two identical half-
molecules, each composed of one HC and one LC, are joined via disulfide bonds.  The 
isotype and effector function of an antibody is determined by the sequence of the HC, 
specifically the Fc portion.  Here, the IgG isoform is investigated, hence further 
description of the structural characteristics will be based on this.  
 
A schematic representation of an IgG molecule is shown in Figure 3.2.  An IgG is about 
150 kDa with each HC ~50 kDa and each LC ~25 kDa.  All chains consist of a series of 
amino acid sequences folded into discrete compact regions known as domains each of 
about 110 amino acids.6,7  Each of the four chains has a variable domain (VL and VH) at 
the N-terminal, which is responsible for the antigen binding.  As the nomenclature 
suggests, the amino acid sequence of these regions varies across antibodies accordingly 
to the antigen binding specificity.  The remaining domains are referred to as ‘constant’ 
domains; the light chain constant domain (CL) domain and heavy chain consisted of 
three constant domains: CH1, CH2 and CH3 (Figure 3.2).   
 
 
Figure 3.2   A schematic representation of the immunoglobulin gamma structure.  Each IgG 
consists of two light chains (yellow) and two heavy chains (teal) joined at the hinge region via 
disulfide bonds.  The Fab arms of an antibody recognize and bind to an antigen, while the Fc 
region interacts with the cell surface receptors.  
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Antibody molecule structure can be divided into two functionally distinct regions.  The 
two identical ‘arms’ of the ‘Y’ shaped structure which recognise and bind to an antigen 
are named Fab fragments (Fragment antigen binding).  Each Fab arm is composed of the 
LC and VH and CH1 domains.  The CH2 and CH3 domains contained within the tail of 
the ‘Y’ unit are termed as the Fragment crystallizable (Fc), with its name originating 
from an early observation of ready crystallization.8,9  This region has no reported antigen 
binding activity; instead it interacts with the cell surface receptors and complement 
proteins.8,9  The CH3 domains are non-covalently bonded as oppose to the non 
interacting CH2 domains which in turn contain N-linked glycans situated within the 
cavity between the two HCs.10 
 
Furthermore, IgGs are categorized into subclasses: IgG1, IgG2, IgG3 and IgG4 (in 
humans) as shown in Figure 3.3.  Apart from variation in the amino acid sequence, the 
most distinct difference among the IgG subclasses is the location and the number of 
disulfide bonds (DSB) in the hinge region.11-15  All IgGs poses twelve conserved intra-
chain disulfide bonds buried within the structure and associated with an individual 
folded domain.16  More importantly, it is the number and properties of the inter-chain 
disulfide linkages that allocate IgGs into various subclasses.17  The two HC are 
covalently associated in the hinge region by two DSB in IgG1 and IgG4, four DSB in 
IgG2 and eleven DSB in IgG3.   
 
More recently, IgG2 and IgG4 subclasses were found to have an alternative DSB linkage 
in the hinge region.  The classical DBS organization in IgG2 referred to as IgG2-A, has 
four inter-chain linkages connecting two half molecules.14  In the non-classical 
arrangement of IgG2-B and IgG2-A/B, one of the inter-chain DSB is linked to a cysteine 
residue located in the CH1 domain instead to a cysteine in the hinge region, either for 
one half molecule or both, respectively.18-21  Distribution of these DSB isoforms is 
directed by the type of light chain present; λ LC constitutes to formation of the IgG2-A, 
κ LC favours the IgG2-B, while IgG2-A/B is considered as a structural intermediate 
between both.19  Likewise, IgG4 subclass also displays non-classical linkage system.  It 
is capable of forming a stable intra-chain DSB in the hinge region allowing for the 
antibody to part into two half-molecules.22-24  This dissociation is recognized as the first 
step in the Fab arm exchange (FAE) process during which an IgG4 exchanges half-
molecules with another IgG4 of different antigen binding specificity to form a bispecific 
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IgG4 (bsAb).24-27  An additional structural difference among the IgG subclasses, setting 
IgG1 apart from other isoforms, is the location of the disulfide bonds between the LC 
and HC.  In IgG1, the C-terminal cysteine residue of the LC is linked to the fifth cysteine 
residue of the HC.  In case of the IgG2, IgG3 and IgG4 subclasses, the LC is linked to 
the third cysteine residue of the HC located in the Fab portion of the antibody near the 
N-terminal of the CH1 disulfide loop.28  
 
 
Figure 3.3   Schematic representations of four IgG subclasses: IgG1, IgG2, IgG3 and IgG4, 
showing the major differences location and number of the inter-chain disulfide bonds among 
the subclasses (marked as solid black lines). The IgG4 subclass is capable of forming inter-
chain and intra-chain DSB in the hinge region. The IgG2 subclass consists of further three 
disulfide bond isoforms.  
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Early studies on antibody structure have indicated immunoglobulins to be highly flexible 
and dynamic molecules.29-34  This segmental flexibility allows antibodies to fulfil their 
biological function and effectively extend their arms to identify and bind to the target.  
The upper hinge region allows Fab arms to adopt variable angles with respect to each 
other (Fab-Fab flexibility also know as Fab arm waving)29,35, moreover it also enables 
rotational flexibility of each individual Fab (Fab arm rotation).36-38   The lower hinge 
segment governs the position of the Fab arms relative to the Fc region (Fab-Fc flexibility 
known as Fc wagging).35,37,38  Additional molecular movement, so called Fab elbow 
bending, is observed between the variable domain (VL and VH) and the CL and CH1 
domains.39   
 
The degree of flexibility depends upon the length of the hinge, the number and 
properties of inter heavy chain DSBs present within that region.  In decreasing order, the 
relative flexibility of the hinge regions of the IgG subclasses has been classified as 
follows: IgG3 > IgG1 > IgG4 > IgG2.  Mean Fab-Fab angles were reported to be 136 ± 
53° for IgG3, 117 ± 43° for IgG1, 128 ± 39° for IgG4 and 127 ± 32° for IgG2, where the 
large standard deviations are attributed to a high degree of flexibility.35  In IgG3, the 
elongated hinge gives the molecules a greater flexibility and range of motions, whereas 
flexibility of IgG2 is restricted by a shorter hinge from any other subclass, presence of a 
rigid poly-proline double helix and stabilizing four DSB.40  The hinge of IgG4 is shorter 
than that of IgG1 and places its flexibility as intermediate between that of IgG1 and 




3.1.2 mAbs as therapeutics  
 
Monoclonal antibodies (mAb) and related products form the fastest growing class of 
therapeutic agents with application in the treatment of diseases including cancer, 
immunological and neurodegenerative disorders, and other pathologies.41-49  In the past 
three decades, more than 40 mAbs and their derivatives have been approved for use in 
various indications, and currently many more are in research and pre-clinical trials.50,51  
The approved entities, include not only the ‘naked’ antibodies but also radio-
immunoconjugates,52,53 antibody-drug conjugates (ADCs),54-57 bispecific antibodies 
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(bsAbs),58-61 immunocytokines,59,62,63 Fab fragments,64 and Fc-fusion 
protein/peptides65,66.  Between 2006 and 2010, 13 new mAbs were approved as 
therapeutics, representing over a half of genuinely new biopharmaceuticals to come on 
market in that period.67    The worldwide sales for all biologics i.e. mAbs and other 
protein based therapeutics, is expected to approach US$150 billion mark by 2015, rising 
further to US$170 billion by 2025.67,68   
 
Along with the development of these new biopharmaceuticals, there is a need for rapid, 
sensitive and robust analytical methods for detailed characterization of these complex 
and flexible biological structures.  Additionally, as these therapeutics begin to come off  
patent, opportunities are rising for production of generic copies of these drugs known as 
biosimilars.69,70  Being far larger, naturally more heterogeneous, and produced as a result 
of batch fermentation, protein based drugs provide a significant regulatory challenge 
compared to small molecules.  Regulatory authorities have identified three critical 
characteristics of any protein biopharmaceutical which must be monitored and controlled 
during the development process: post-translational modifications (PTMs), three-
dimensional structure and protein aggregation.69,71  A characterization tool that can 
address all of those needs is mass spectrometry which allows us to probe mAbs at a 
primary and higher order structural level.  MS based approaches are used to provide 
insights into molecular composition, PTMs, glycosylation patterns, mixture 
characterization, oligomerisation and aggregation, conformational changes, DSB 
scrambling, antibody-antigen binding or epitope mapping.69,71-78  
 
3.1.3 Native IM-MS studies of intact immunoglobulins  
 
Ion mobility mass spectrometry (IM-MS) facilitates study of protein higher order 
structure and provides shape defining parameters for each mass (and charge) selected 
species termed their collision cross sections (CCS).  Moreover, since IM-MS is an 
isolated molecule technique, it can delineate structural changes that occur upon antigen 
binding or environmental change, which can be compared with theoretical values 
derived from structures solved with other methods.  Despite an increasing application of 
IM-MS for structural studies, as of now, there is just handful of reports available in the 
literature on use of this technique to study intact mAbs.   
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Application of IM-MS to probe higher order structure of intact mAbs was first reported 
by Schnier and co-workers.79  TWIM-IM-MS was applied to resolve disulfide structural 
isoforms of IgG2 mAbs.  IM-MS revealed presence two to three gas-phase conformer 
populations related to disulfide bond heterogeneity among the IgG2 subclasses 
(described in section 3.1.1, Figure 3.3), as opposed to a single gas-phase conformer 
observed for IgG1 and C232S IgG2 mutant both of which are homogenous with respect 
to the DSB heterogeneity.  Later, Gross et al. used combination of IM-MS, top-down 
fragmentation and protein footprinting to characterize conformational differences among 
IgG2 isoforms and several IgG2 mutants with altered S-S bonding.80  IM-MS studies 
verified that the WT IgG2 presents itself in two major conformations, while the mutants 
display more compact CCSD than the dominant WT component.  Utilization of fast 
photochemical oxidation of proteins (FPOP) approach provided residue-level 
information for the entire mAb also locating the conformational differences determined 
by IM-MS and identifying the hinge region as the origin of these differences. 
 
IM-MS was used to investigate conformation dependent binding of a reference protein 
standard to a specific mAb commonly used in ELISA assays.81  Under native conditions, 
human growth hormone (hGH) was present across two conformational families, while 
additionally two more extended forms were revealed under reduced conditions.  Upon 
addition of the rhGH-specific mAb, none of the most compact rhGH conformer was 
observed in the free rhGH detected in the presence of mAb.  The authors suggested, that 
although extended forms of the protein seemed to be not directly involved in binding 
with mAb, they might constitute an intermediate conformer necessary for mAb-rhGH 
binding rather than the mAb binding exclusively to the compact form of rhGH.  
Furthermore, the rhGH mAb was found to exist in three monomer conformations with 
median CCS values ranging from 61 to 76 nm2 and ~80 % of the mAb sitting primarily 
in the monomer 2 conformation centred at 68 nm2. 
 
Recently, Debaene et al. applied native MS and time resolved TWIM-MS to monitor 
Fab arm exchange (FAE) between two humanized IgG4 and the subsequent formation of 
bsAb.82  Differences observed in the drift time between the mAbs and bsAb are believed 
to arise from the structural differences rather than mass difference which in turn affects 
the drift time.  The FAE process was monitored as a function of time in the presence and 
absence of a reducing agent to demonstrate how IM-MS can differentiate between mAbs 
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and the newly formed bsAb.  This chapter presents application of drift tube ion mobility 
mass spectrometry (DT-IM-MS) supported by molecular dynamics (MD) simulations to 






3.2.1 Sample preparation  
 
Four intact IgG samples and two Fc-hinge fragments were provided by UCB Pharma; 
protein samples were expressed and purified by Dr Shirley Peters.  Two types of IgG1 
and IgG4 antibodies of different antigen binding specificity examined in this chapter are 
denoted here as A and B; the amino acid sequences are available in the Appendix 3.  
Samples were stored in 50 mM sodium acetate (NaOAc) : 125 mM sodium chloride 
(NaCl) at 4 °C.  On the day of analysis, samples were diluted to the concentration of 
40µM and the buffer was exchanged to 100 mM, 200 mM or 500 mM ammonium 
acetate (Fisher Scientific, Loughborough, UK) pH 6.8, using micro Bio-Spin 
Chromatography columns (Micro Bio-Spin 6 Columns, Tris) following the instructions 
specified by the manufacturer. The desalting procedure was performed twice to achieve 
desired sample purity.  High purity water was obtained from an Arium 611 water 
purification unit (Sartorius, Göttingen, Germany) fitted with a 0.2 µm filter.  Charge 
reduction experiments were carried out by addition of 10 % (v) triethylammonium 
acetate buffer (TEAA) (Fluka, Steinheim, Switzerland) prior to MS analysis. 
 
3.2.2 Mass spectrometry 
 
Mass spectra were recorded on a Q-ToF mass spectrometer (Ultima API US, Waters, 
Manchester, UK).  5 µM samples were ionized using positive nESI as described in 
Chapter 2, section 2.1.2.  Source voltages and pressures were tuned to enable maximum 
ion transmission.  The source backing pressure was elevated to 5 × 10-1 mBar.  The 
capillary potential was held at 1.6 kV, the source temperature was set to 80 °C, and the 
cone voltage was varied between 60 and 200 V; low voltages were used for preservation 
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of native-like structure, while high cone voltages were applied in experiments aimed at 
mass determination.  Other instrumental settings for the Ultima API US mass 
spectrometer are listed in Chapter 2, Table 2.1   
 
3.2.3 Ion mobility mass spectrometry 
 
40 µM samples were ionised using positive nESI as described in Chapter 2, section 
2.1.2.  The IM-MS data were acquired on the MoQToF, quadrupole time-of-flight mass 
spectrometer, detailed in section 2.2.1.83  The capillary potential was held at 1.5 - 1.8 kV, 
the source temperature was set to 80 °C, and the cone voltage was set to 80 V.  The 
injection energy used was between 31 and 33 V.  Other instrumental settings for the 
MoQToF IM mass spectrometer are listed in Chapter 2, Table 2.3.  The drift cell was 
filled with helium gas at a pressure of 3.7 – 3.8 Torr at temperature of 302 ± 2 K.  The 
electric potential across the cell was varied from 60 to 20 V for intact IgG samples; and 
60 to 15 V for the Fc-hinge fragments, with measurements taken at six different drift 
voltages.  The rotationally-averaged collision cross-sections (CCS) were determined 
from a plot of arrival time versus P / T and the CCSD were determined as described in 
Chapter 2, section 2.2.1.4.  Each experiment was repeated in triplicate and the average 
values are reported.  
 
3.2.4 Molecular dynamics  
 
The MD simulations, estimation of theoretical CCS and calculation of the secondary 
structure content presented in this chapter were performed by Dr Massimiliano Porrini at 
the Institute Européen de Chimie et Biologie (IECB) in Pessac, France.  
 
The input coordinates files were those taken from the crystallographic structures, PDB 
identifiers 1IGT and 1IGY for: IgG2a and IgG1, respectively.  After adding hydrogen 
atoms, the X-ray structures of the two antibodies were minimized in vacuo with the 
sander module of Amber1184, implementing a radial cut-off of 999 Å and Amber99SB-
ILDN force field85.  The theoretical collision cross sections (CCS) were calculated with 
each of the three methods implemented in the MOBCAL code86 with the trajectory 
method appropriately modified to handle large systems such as mAbs studied here.  The 
less accurate methods PA and EHSS are included here for comparison with other more 
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approximate methods; results from TJM are most reliable and most robust with respect 
to comparison to the co-ordinates.87  To follow the dynamic evolution in gas phase, the 
antibodies were firstly gradually heated up to 300 K, utilizing a Langevin thermostat 
(damping coefficient of 2 ps-1) with a time-step of 1.0 fs, and then subjected to a constant 
temperature (300 K) molecular dynamics (MD) run of 10 ns, again with Langevin 
thermostat.  The damping coefficient, radial cut-off, force field and time-step were the 
same as these described above, and the simulation software package utilized was NAMD 
2.9.88   The observables computed to follow the conformational rearrangements of the 
antibodies were the backbone root mean square deviation (RMSD), the radius of 
gyration (Rg), and the rotationally averaged CCS.  The latter was calculated with a 
simulation time increment of 0.5 ns (plus one computation at 0.25 ns), except for which 
additional random evaluations were done.  The content of the secondary structure was 
determined using AmberTools13 (module cpptraj), which implements the algorithm 
DSSP.89  
 
The Matthews coefficients and solvent content of the asymmetric units were calculated 
using an online Matthews Coefficient Calculator.90 
 
 
3.3 Results and Discussion  
 
3.3.1  Mass spectrometry of intact IgGs 
 
Two types of IgG1 and IgG4 antibodies of different antigen binding specificity 
examined in this chapter, are denoted here as A and B.  nESI-MS of 5 µM IgG1 A, 
IgG4 A, IgG1 B and IgG4 B in 100 mM ammonium acetate at pH 6.8 acquired on the 
Ultima API US Q-ToF mass spectrometer are shown in Figure 3.4.  Mass spectra 
present narrow charge state distributions diagnostic of the native-like nESI-MS 
conditions.  Peaks corresponding to the intact IgG are observed in the ~5700 – 7200 
m/z range; with the charge state envelope ranging from 21+ to 27+ charge state, 
centred at the 24+ charge state.   
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Figure 3.4   nESI mass spectra of intact IgG1 A and IgG4 A (left), IgG1 B and IgG4 B (right) 
in 100 mM ammonium acetate at pH 6.8 acquired on the Ultima API US Q-ToF mass 
spectrometer at a sample cone potential of 200 V.   
 
 
For mass determination experiments, high cone voltages (200 V) were applied.  Raising 
voltages in the source region of the mass spectrometer, such as sample cone or 
extractor cone voltage, affects the acceleration of the ions through the source.  The 
measured mass of protein complexes in the gas phase tends to be higher than the 
mass derived from the sequences of their components.91,92  Theoretical monoisotopic 
masses based on the amino acid sequence of the IgG1 A, IgG4 A, IgG1 B and IgG4 
B are 147106.78 Da, 146776.18 Da, 145246.13 Da and 144915.53 Da, respectively 
(sequences available in the Appendix 3).  The theoretical masses reported here, do 
not include the mass of two N-glycans attached at the Fc domain, each of ~1400-
1700 Da.  Measured masses at lower acceleration voltages (sample cone 50 V) were 
found to be 150450 ± 67 Da, 151486 ± 162 Da, 148908 ± 60 Da and  148442 ± 56 Da 
for IgG1 A, IgG4 A, IgG1 B and IgG4 B, respectively.  Measured masses at high 
acceleration voltage (sample cone 200 V) decreased further to 149666 ± 28 Da, 
149837 ± 138 Da, 147978 ± 17 Da and 147578 ± 31 Da for IgG1 A, IgG4 A, IgG1 B 
and IgG4 B, respectively.  The 2.6 - 3.0 kDa deviation from the theoretical mass can 
be assigned due to the presence of two N-glycans.  Upon gentle increase of the 
accelerating voltage, the peak width decreases along with a variation from the 
theoretical mass, attributed to the loss of residual solvent and salt bound to the 
protein complex.  This collision-induced cleaning is often used to improve the mass 
spectrum quality and parameters are optimized to find a balance between preventing 
in-source dissociation and achieving adequate, well resolved protein ion signal.93,94  
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Increasing collision energy with the background gas transfers energy to the sample 
ion and can disturb protein structure and induce protein unfolding and protein 
complex dissociation.  Therefore for structural studies, such as those presented in the 
next section, care was taken in the optimization of those crucial parameters.   
 
 
3.3.2 Conformational landscapes occupied by intact IgG explored with 
DT-IM-MS 
 
3.3.2.1 Differences in CCSD among IgG isoforms   
 
nESI-IM-MS of 40 µM IgG1 A, IgG4 A, IgG1 B and IgG4 B in 100 mM ammonium 
acetate at pH 6.8 were acquired on the MoQ-ToF ion mobility mass spectrometer.  
Source conditions were optimized and low acceleration voltages were applied to 
preserve protein native-like structure.  Arrival time distributions (ATDs) were 
recorded following mobility separation at 300 K and converted into CCSD as 
described in Chapter 2 section 2.2.1.4.  Figure 3.5 shows the CCSD of four intact 
mAbs, normalized to spectra intensity, where the CCSD are outlined in different 
colours for different charge states observed.  Across the four antibodies investigated, 
all appear flexible with very broad ATDs describing CCS landscapes populated from 
~50 to 100 nm2.  Only CCSD obtained for the most populated charge states, z = 22+ 
to 26+, are shown (Figure 3.5) as the intensity of the lowest (21+) and the highest 
(27+) charge states observable in the MS mode was not sufficient in IM mode.   
 
In Table 3.1, median CCS values from the total occupied space for each charge state 
are reported.  Whilst the trends for each antibody are similar, the range of CCS 
presented over the charge states observed differ.  For the 22+ charge state, the 
median CCS found for IgG1 and IgG4 are the same (~61-62 nm2) as is the width of 
the ATD, suggesting indistinguishable conformations.  As the charge state increases 
so does the median CCS for each mAb.  For the two highest charge states of 
significant intensity (25+ and 26+), the observed median CCS for IgG4 molecules 
are larger than the equivalent for the IgG1 mAbs.  The median CCS of the 26+ 
charge state of IgG4 is significantly larger (82-83 nm2) than CCS of the same charge 
state of IgG1 (76-77 nm2).  The change in median CCS across the charge state range 
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is 15 nm2 for both IgG1s and 20 nm2 for both IgG4s; hence the conformers adopted 




Figure 3.5   Conformational space occupied by intact IgG1 A, IgG4 A, IgG1 B and IgG4 B 
across the charge states in terms of collision cross sections (CCS).  Data shown here was 




Table 3.1   Median collision cross section (CCS) values along with the standard deviation values 
derived from three experimental replicas; for each charge state of IgG1 A, IgG4 A, IgG1 B and 
IgG4 B reported in nm2 across detected charge states. 
 
charge state IgG1 A / nm2 IgG1 B / nm2 
22 + 61.7 ± 1.1 61.1 ± 1.6 
23 + 62.5 ± 1.6 63.3 ± 1.0 
24 + 65.9 ± 1.3 66.7 ± 1.3 
25 + 71.7 ± 0.6 73.9 ± 2.6 
26 + 76.1 ± 1.1 77.4 ± 3.9 
   
charge state IgG4 A / nm2 IgG4 B / nm2 
22 + 61.8 ± 1.6 61.8 ± 1.4 
23 + 64.7 ± 1.4 64.1 ± 0.9 
24 + 68.6 ± 0.5 68.4 ± 0.5 
25 + 76.8 ± 1.9 75.6 ± 1.1 
26 + 83.2 ± 0.6 82.2 ± 0.8 
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3.3.2.2 DT-IM based CCS vs. TWIM based CCS 
 
The median CCS determined with the linear DT-IM-MS on our MoQToF instrument, 
correspond well with the TWIM-MS based CCS reported in the literature.  Ashcroft’s 
group found the rhGH-specific mAb monomer (IgG1) to be present in three 
conformations with median CCS values ranging from 61 to 76 nm2 and ~80 % of the 
mAb sitting primarily in the monomer 2 conformation centred at 68 nm2.81   The span of 
TWIM based median CCS observed for these IgG1s correlates with DT-IM based CCS 
of both IgG1s investigated in this chapter.  Additionally, Debaene et al. reported TWIM 
based CCS of two IgG4 mAbs undergoing Fab-arm exchange (FAE) to be 69.6 ± 0.4 
nm2 and 65.9 ± 0.3 nm2 and the resulting bispecific antibody (bsAb) to have an 
intermediate CCS of 66.9 ± 0.1 nm2.82  Only CCS for the most intense charge states were 
reported.  The observed differences between values reported in this thesis and the 
reported by Debaene et al. could originate from the differences in the amino acid 
composition of these mAbs as well as differences in the experimental procedure, 
instrumentation and CCS determination protocol.  
 
3.3.2.3 The effect of buffer composition on the CCSD of intact mAbs  
 
Aqueous ammonium acetate buffer is the most commonly chosen buffer for protein 
analysis in their native state by MS.  Nevertheless, the concentration of the buffer needs 
to be chosen carefully depending on the target protein.  Non MS compatible storage 
buffer of IgG1 A was exchanged to 100 mM, 200 mM and 500 mM ammonium acetate 
to investigate the effect on buffer ionic strength on mAb charge state distribution and 
CCSD.  Figure 3.6a shows spectra of mAbs contained in the above mentioned buffers.  
No change in charge state distribution was observed; however, increasing the buffer 
strength resulted in broadening of peaks and reduction of S/N ratio.  IM experiments 
showed no differences in CCSD of IgG1 A among the three ammonium acetate buffers 
tested as shown in Figure 3.6b using the most abundant 24+ charge state.  Since 
increased buffer strength was demonstrated not to have an effect on the conformational 
space occupied by IgG1 A and only contributed to lower the signal quality, the 100 mM 
AmAc was chosen as an optimum buffer strength and was used in all experiments 
reported in this chapter.   
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Figure 3.6   (a) Mass spectra of IgG1 A in 100 mM AmAc, 200 mM AmAc, 500 mM AmAc and 100 
mM AmAc + 10 % TEAA (from top to bottom).  Upon the addition of a charge reducing agent, 
TEAA, the charge state envelope shifts it’s centre from 24+ to 17+ ions.  (b) Conformational 
space occupied by the IgG1 A (149 kDa) in 100 mM AmAc, 200 mM AmAc, 500 mM AmAc and 
100 mM AmAc + 10% triethylammonium acetate (TEAA) (from top to bottom) in terms of 
collision cross sections (CCS).  When in the ammonium acetate buffer, IgG1 A 24+ displays the 
same CCS profile regardless of the buffer strength.  Upon the addition of TEAA; charge state 
shift is noted, however no structural stabilization is observed but even further decrease in the 
CCS.  Data shown here was acquired at 300 K and 35 V drift voltage. 
 
Use of charge reducing agents may help to stabilize protein structure and preserve non-
covalent protein complexes in the gas phase.95,96  The effect of triethylammonium acetate 
(TEAA) on the IgG structure was investigated.  Upon the addition of 10% TEAA, IgG1 
A experiences a charge state envelope shift by 7 charge states; from 24+ to 17+ as the 
most abundant state.  Nevertheless, addition of this charge modulator does not induce 
structural stabilization.  Furthermore, the antibody undergoes significant compaction 
with a central CCS of ~55 nm2 for the 17+ charge state (Figures 3.6). 
 
3.3.2.4 mAb flexibility and CCSD 
 
CryoEM and TEM studies have indicated that IgGs are flexible, dynamic molecules,  
capable of Fab arm waving and rotation, as well as Fab elbow bending or Fc 
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wagging.36  Mean Fab-Fab angles have been previously reported to be 117 ± 43° for 
IgG1 and 128 ± 39° for IgG4, where the large standard deviations on these values are 
attributed to a high degree of flexibility.35   Considering this, the wide CCSD 
observed for mAbs could be attributed to a large number of closely related 
conformational families present in the gas phase with dynamic flexibility that cannot 
be resolved by room temperature ion mobility measurements.  Whilst some features 
(notably the tail on the left hand side for the 26+ species) suggests states with very 
different conformations, the lack of baseline resolution means we can surmise that 
the mAbs present interconverting conformers.   
 
It can be speculated as to why the IgG4 subclass can occupy more space in the gas-
phase than IgG1.  The hinge region of the IgG1 subclass is known to be more 
flexible in comparison to the hinge of the IgG4 subclass. 30,35,97  The structure and 
stability of IgG antibodies has been shown to be affected by differences in the inter- 
and intra-disulfide bonds.  The non-classical structure of the IgG2 B has been shown 
to be more compact than that of IgG2 A by SEC and AUC.19  These isoforms have 
previously been also resolved by TWIM-IM-MS.79   Moreover, the disulfide linkages 
between the HC and LC vary among the IgG subclasses resulting in structural 
differences.  This bond links the carboxy-terminal of the LC with the cysteine 
residue at position 220 in IgG1 and at position 131 in IgG2, IgG3 and IgG4 of the 
CH1 sequence of the HC.  The LC of IgG4 being linked further from the centre of 
mass, will allow for more ‘movement’ and have more accessible space dynamics 
which will display broader CCDS as shown experimentally. 
 
 
3.3.3 Fc-hinge fragment CCSD profiles further emphasize differences 
in gas-phase conformations among the IgG subclasses  
 
To test whether the broadness of CCSD of intact mAbs is only attributed to the 
movement of Fab arms with respect to the Fc domain or whether there are other factors 
controlling the conformational diversity, the Fc-hinge fragments of both IgG1 and IgG4, 
were studied with DT-IM-MS.  nESI-IM-MS of 40 µM Fc-hinge mAb fragments in 100 
mM ammonium acetate at pH 6.8 were acquired on the MoQ-ToF ion mobility mass 
spectrometer.  Source conditions were optimized and low acceleration voltages were 
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applied to preserve protein native-like structure.  ATD were recorded following mobility 
separation at 300 K and converted into CCSD as described in Chapter 2 section 2.2.1.4.  
Mass spectra of both Fc-hinge fragments (Figure 3.7a) display narrow charge state 
distribution centred at the 13+ charge state.   Fc-hinge fragments of both mAbs present 
broad CCSD.  Similarly, as in case of intact mAbs, no striking differences are noted in 
CCSD for the 12+ charge states as shown in Figure 3.7b.  The CCSD of 13+ charge state 
of the IgG4 Fc-hinge appears to be slightly broader than the one of the IgG1 Fc-hinge 
fragment.  Interestingly, the highest 14+ charge state of IgG4 Fc-hinge displays two 
conformational families, with the larger one centred at 37.5 nm2 being more abundant as 





Figure 3.7   (a) Mass spectra of the IgG1 Fc-hinge fragment (top) and the IgG4 Fc-hinge 
fragment (bottom) in 100 mM ammonium acetate. (b) Conformational space occupied by the 
IgG1 Fc-hinge fragment (left) and IgG4 Fc-hinge fragment (right).  Data shown here was 
acquired at 300 K and 35 V drift voltage and was normalized to spectral intensity.  *CCSD of 
IgG4 Fc-hinge fragment have been already shown in Chapter 2, Figure 2.10; here it is shown 
again to ease the comparison and pinpoint differences in CCSD between IgG1 Fc-hinge 
fragment and IgG4 Fc-hinge fragment. 
 
 
It can be speculated that the distinct features in the hinge region and the non-covalent 
interactions between the CH3-CH3 domains are potentially responsible for the 
experimentally observed differences.98-100  These and/or other interactions may 
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dictate how the intrinsic flexibility varies in the absence of solvent.  The 
characteristic core sequence of the IgG4 hinge (residues 226-230 of the HC) and 
presence of a serine rather than a proline at position 228 permits formation of intra- 
and inter- HC disulfide bonds (a process essential for FAE to occur); whereas an 
arginine at position 409 at the CH3-CH3 interface weakens the non-covalent 
association between these domains.  Both of these features are prerequisite for the 
FAE process in which IgG4 dissociates into half-molecules and re-assembles with 
half-molecule of another IgG4 of different specificity to form a bsAb.25,98,101-103  
Recently Davies et al. presented the first high-resolution crystal structures of 
recombinant and serum-derived IgG4-Fc fragments.100  The study revealed how 
Arg409 can adopt two different conformations affecting the stability of the CH3 
interface.  One of these conformations is similar to those observed in IgG1, whereas 
the other conformation weakens the interface by disrupting the water molecule 
network resulting in reduced hydrogen bonding what might also be an early snapshot 
to the dissociation process.  Only the latter conformation was observed in the CH3 
domain crystal structure; however, authors believe that the two conformers are 
equally populated.  Similar conclusions can be draw from the DT-IM-MS 
experiments presented here.  Over 60 % of the 14+ charge state of the IgG4 Fc-hinge 
fragment populates the larger conformational family of the two observed.  Larger 
CCS would suggest the structure to be more open and hence could be corresponding 
to the conformation with destabilised interactions between the CH3 domains of the 
HC described by Davies et al..100  In contrast, the 14+ charge state of the IgG1 Fc-
hinge fragment occupies mainly one – the smaller conformational family centred at 
31.6 nm2, hinting at the presence of a more compact structure held tightly via strong 
CH3-CH3 interactions.27  
 
 
3.3.4 Comparison of mAb’s CCSD to CCSD of other protein complexes 
as a measure of structural flexibility  
 
The conformational spread observed for mAbs was compared to that found for 
similarly sized proteins (Figure 3.8).  The CCSD of both, IgG1 and IgG4 as well as 
the Fc-hinge fragments were compared to those of several multimeric protein 
complexes, namely: tetrameric transthyretin (TTR, ~55 kDa), tetrameric 
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concanavalin A (ConA, ~102 kDa), pentameric human serum amyloid P component 
(SAP, ~128 kDa) and hexameric ATP-phosporibosyltransferase (ATP-PRT, ~190 
kDa) (these complexes will be further described in the following chapters).  In Figure 
3.8, the CCSD are plotted as a function of molecular mass (kDa); coloured blocks are 
used to represent the span of baseline CCSD observed, whereas points represent the 
median CCS determined for each of the charge states observed.  As expected, the 
median CCS increase with increasing protein mass, however IgGs display a notably 
wider range of conformations, which can be attributed to dynamic and flexible 
structures.  Whilst, the 24+ IgG species with a median CCS of ~65.9 - 68.6 nm2 
follow a trend line set by other multimeric protein complexes, it is the higher charge 






Figure 3.8   Collision cross sections distributions (CCSD) of the detected charge states vs. 
molecular mass of mAb Fc-hinge fragments, transthyretin (TTR, PDB:1BMZ), avidin (PDB:AVE), 
concanavalin A (ConA, PDB:1DQ0), human serum amyloid P component (SAP, PDB:1SAC), 
IgG1s and IgG4s (PDB:1IGY), and MtATP-phosporibosyltransferase (ATP-PRT, PDB:1NH7) 
along with structures based on crystal data deposited into the Protein Data Bank.  The coloured 
blocks represent CCSD width, and points represent median CCS determined for charge states 
observed for each protein complex; ▲ are used to represent the IgG1 subclass and ■ for the 
IgG4 subclass. 
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This deviation can also be illustrated by comparing the CCS profiles of each protein. 
Figure 3.9a, shows CCSD for the most abundant charge state of each of protein 
complexes considered here.  Clearly, the intact IgG1 and IgG4 present significantly 
wider CCSD and populate more conformational space than other multimeric complexes.  
The CCSD width of Fc-hinge fragments (~54 kDa) is slightly broader than the one of 
similarly sized tetrameric TTR (~55 kDa).  The 24+ charge state of intact mAbs (~147 - 
149 kDa) display considerably larger CCSD than 128 kDa SAP or 190 kDa ATP-PRT.  
When CCSD width is plotted in function of molecular mass, mAbs and their fragments 




Figure 3.9   (a) Conformational space occupied by the most intense charge states of IgG1 Fc-
hinge, IgG4 Fc-hinge, transthyretin (TTR), avidin, concanavalin A (ConA), serum amyloid P 
component (SAP), IgG1, IgG4 and ATP-PRT protein complexes.  Both, intact IgGs and Fc-hinge 
fragments present considerably broader CCSD containing closely related conformational 
families.  Data shown here was acquired at 300 K and 35 V drift voltage. (b) Collision cross 
section distribution (CCSD) widths across charge states of IgG1 Fc-hinge, IgG4 Fc-hinge, 
transthyretin (TTR), concanavalin A (ConA), serum amyloid P component (SAP), IgG1, IgG4 and 
ATP-PRT plotted as a function of molecular mass. Both, Fc-hinge fragments and intact IgGs are 
outliers from the other protein complexes investigated. 
 
It is worth mentioning that the CCSD profile of avidin appears to be slightly broader in 
comparison to proteins of alike size.  Similarly to intact IgGs and their Fc-hinge 
fragments, avidin is a glycoprotein what suggest that presence of glycans could be 
contributing to broader CCSD profiles.  Performing IM-MS experiments on 
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deglycosylated IgGs and Fc-hinge fragments would help to predict how much of the 
CCSD peak width can be attributed to presence of glycans.  At the same time, 
deglycosylation of IgGs could lead to collapse of intra-cavity between CH2 domains and 
contradict the idea of probing native-like structures.  In conclusion, IM-MS reveals the 
intact mAbs to be more structurally dynamic than proteins of comparable size which can 
be attributed to their intrinsic flexibility.   
 
3.3.5 In vacuo molecular dynamics simulations tracing gas-phase 
behaviour of intact IgGs   
  
3.3.5.1 Estimation of theoretical CCS and in vacuo MD simulations  
 
Full structural characterization of antibodies has been hindered by their flexibility 
causing the crystallization step to be a major challenge.32,35  Most of the hundreds of 
IgG structures available at the Protein Data Bank (PDB) are merely fragments of 
antibodies, typically only the Fab arm or the isolated Fc domains.  There are to date 
just three x-ray crystallography based structures of intact IgG molecules deposited 
into PDB, namely: human IgG1 b12 (1HZH), IgG2a (1IGT) and IgG1 
(1IGY).28,104,105   For comparison of the DT-IM-MS based CCS and the theoretical 
CCS, the available structures were protonated, minimized in vacuo to reach the 
lowest energy state structure, and theoretical CCS were calculated with the trajectory 
method (TJM) implemented in the MOBCAL code.86  Calculated CCS were found to 
be 100.3 nm2, 105.6 nm2 and 100.8 nm2 for 1HZH, 1IGT and 1IGY, respectively.   
Experimentaly determined CCS are significanlty smaller than the theoretically 
derived CCS, thus indicating that the protein might have collapsed somewhat in the 
gas-phase in comparison to the x-ray structure.  It is important to keep in mind that 
x-ray crystallography provides only a snapshot of a ‘frozen’ protein conformation.  
Antibodies being  flexible and dynamic molecules display closely related 
conformations, as shown by IM-MS, that x-ray crystallography as a solid state 
technique cannot necessarily capture all.  It can be envisaged that the three atom 
dense linked domains of an IgG i.e. two Fab arms and the Fc, might rearrange to a 
lower energy gas-phase structure. 
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To follow the dynamic evolution of intact mAbs in the gas-phase and gain further 
insights into the IM-MS results, in vacuo molecular dynamic (MD) simulations on the 
crystal structures were performed.  The 1HZH structure was discounted as the deposited 
coordinates have several residues missing including some in the hinge region which play 
a crucial role in mAb flexibility and the range of adopted conformations.  Antibodies 
were first gradually heated up to 300 K, and then subjected to molecular dynamics (MD) 
for 10 ns.  The conformational changes are reported with respect to simulation time in 
terms of the CCS of each mAb using three approximation methods: the projection 
approximation (PA)106, the trajectory method (TJM)107, and the exact hard sphere 
scattering (EHSS)108 with the results listed in Table 3.2.  Whilst the CCS values from the 
PA method appear to agree with experimental measurements, this method is known to 
underestimate the CCS for coordinates from molecules larger than 3 kDa.87,109  The most 
robust method is TJM and only the results from that will be discussed here.   
 
At t = 0, theoretical CCS calculated with the trajectory method are found to be 
105.6 nm2 and 100.8 nm2 for 1IGT and 1IGY, respectively.  The MD simulations 
support the speculated mAb in vacuo structural collapse; over only 2 ns of MD both 
antibodies undergo a significant compaction.  Change in CCS with respect to 
simulation time is shown in Figure 3.10a.  After 10 ns of in vacuo MD simulations, 
theoretical CCS calculated with TJM decreased to 86.5 nm2, and 84.1 nm2 for 1IGT, 
and 1IGY, respectively.  These CCS are still a little higher than median experimental 
values, although Figure 3.5 shows that around 20% of the conformational occupancy 
of the mAbs is at or above these t = 10 ns theoretical values.  Since the millisecond 
time scale of the ion mobility experiments greatly exceeds the simulation time (ions 
take ~12 - 24 ms to transverse MoQToF’s drift cell), further structural compaction is 
anticipated with longer time in vacuo.   
   
During it’s gas-phase evolution represented as a red line in Figure 3.10, 1IGT undergoes 
the highest degree of compaction; from the initial CCS of 105.6 nm2 to 86.5 nm2 after 
10 ns of MD simulation i.e. 18.1 % reduction in CCS.  This very high conformational 
rearrangment is depicted also from the backbone root-mean-square deviation (RMSD) 
trend which plateaus at ~17 Å and again increases after 6 ns to reach ~20 Å after 10 ns, 
suggesting further structural rearangments to be taking place (Figure 3.10b).  RMSD 
measures the average distance between the backbone atoms of superimposed protein  
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Table 3.2  Theoretical collision cross sections (CCS) of 1IGT and 1IGY at various time points (up 
to 10 ns) resulting from the in vacuo molecular dynamic simulations.  Reported CCS were 
calculated with the trajectory method (TJM), the exact hard sphere scattering method (EHSS) 
and the projection approximation method (PA).  
 

















0 105.57 100.84 104.61 98.60 82.03 76.30 
0.156 - - - - - - 
0.250 94.91 87.31 98.28 90.07 75.79 68.60 
0.380 - - - - - - 
0.464 - 90.16 - 89.39 - 68.06 
0.500 95.41 90.05 95.96 89.58 74.23 68.12 
1.000 93.26 87.6 93.75 87.37 72.17 66.28 
1.182 91.3 - 93.31 - 71.84 - 
1.496 90.63 - 91.85 - 70.44 - 
1.500 92.94 84.96 92.05 84.90 70.75 64.30 
1.860 - 85.17 - 85.00 - 64.39 
2.000 89.43 83.77 89.62 84.76 68.52 64.27 
2.500 89.50 83.86 89.39 84.94 68.37 64.35 
3.000 88.26 86.60 89.49 84.93 68.63 64.28 
3.500 91.69 85.50 89.42 84.61 68.25 64.30 
4.000 86.63 84.23 89.14 84.43 68.13 63.88 
4.500 89.88 83.70 89.31 84.17 68.28 63.71 
5.000 88.48 85.34 89.10 84.84 68.17 64.15 
5.500 87.54 84.20 88.96 84.34 68.02 63.86 
6.000 86.37 85.79 88.41 84.15 67.69 63.74 
6.500 88.24 85.00 87.54 84.16 66.78 63.88 
7.000 87.57 85.33 87.31 84.01 66.83 63.72 
7.500 89.15 82.72 87.40 83.23 66.68 63.21 
8.000 88.95 83.27 87.00 83.01 66.59 63.08 
8.500 87.00 83.55 86.74 83.36 66.28 63.26 
9.000 86.67 82.69 87.10 83.21 66.40 63.09 
9.500 85.25 83.95 86.35 83.55 65.85 63.31 
10.000 86.49 84.13 87.00 83.77 66.40 63.40 
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Figure 3.10   (a) Theoretical TJM based CCS in nm2 of 1IGT (red) and 1IGY (green) subjected to 
molecular dynamics (MD) to investigate the in vacuo behaviour of the IgGs.  Significant 
collapse of 1IGT and 1IGY is observed only after 0.25 ns. The points represent calculated CCS 
values reported in Table 3.2.  (b) Backbone RMSD (Å) and Rg (Å) recorded during the 10 ns in 
vacuo MD of 1IGT (red) and 1IGY (green).  
 
 
structures over the simulation time and indicates divergance among the aligned 
structures, hence larger values correlate to greater structural changes.  The root mean 
square distance from each atom of the protein to the centriod expressed as radius of 
gyration (Rg), changes in a similar fashion throughout the simulation of 1IGT.  A sharp 
decrease between 0 ns and 2 ns and subsequent gentle decrease between 2 ns and 10 ns is 
observed as seen in the bottom panel of Figure 3.10b.  The 1IGY mAb (green line in 
Figure 3.10), shows 16.6 % decrease in CCS after 10 ns and its RMSD plateaus at ~12 
Å.  Although changes in CCS, RMSD and Rg are lesser, 1IGY collapses faster in 
comparison to 1IGT; within the first nanosecond it reaches a conformation stable up to 
10 ns, whereas the compaction of 1IGT occurs within a double time scale (~2 ns) to 
conformation that is stable up to 6 ns and experiences further collapse afterwards.  This 
gradual collapse of 1IGT is visualized in Figure 3.11, showing snapshots from the MD 
simulation at t = 0 ns, t = 1 ns and t = 10 ns.  The contraction of three linked domains 
(two Fab arms and Fc fragment) is mainly observed around the hinge region.  
Furthermore it is worth noting that for each antibody, the CCS do not simply decrease as 
the simulation time progresses but fluctuate, being an indicative of flexible molecules, 
present over many interconverting conformers.  This conclusion is also supported by 
wide ATD and the corresponding large CCSD across the narrow charge state range 
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compared with that found for other protein complexes as discussed in the previous 




Figure 3.11   Snapshots from an in vacuo MD simulation at t = 0 ns, t = 1 ns and t = 10 ns 
presenting gradual contraction of an intact IgG2a (PDB:1IGT).  Structural collapse can be 




3.3.5.2 Solvent content and secondary structure content   
 
A significant amount of the volume of a protein crystal is occupied by solvent.  An 
estimation of the number of molecules contained within a crystallographic 
asymmetric unit was first achieved by Matthews in 1968.110  Matthews defined VM, 
now known as the Matthews coefficient, as the crystal volume per unit of protein 






VM                                          (Equation 3.1) 
 
where V is the volume of the unit cell, n is the number of asymmetric units and M is 
molecular weight of contents of the asymmetric unit.  Moreover, it was shown that 
VM has a straightforward relationship to the fractional volume of solvent (VS) in the 







1                                       (Equation 3.2) 
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VM values for 1IGY and 1IGT were calculated to be 2.99 Å
3Da-1 and 3.39 Å3Da-1 
respectively, using an online Matthews Probability Calculator.90  The solvent content 
(VS), based on the Matthews coefficient, was found to be 59 % and 64 % for 1IGY 
and 1IGT, respectively.  In each case this is higher than the average protein crystal 
structure solvent content of ~47% as calculated based on a survey of 10,471 entities 
in PDB.111  As the mAbs desolvate, they lose both solvent and stabilising buffer 
interactions.  Based on the high solvent content of the unit cells used here as a 
comparator, one would predict structural contraction that is experimentally observed.  
The 1IGT mAb having a higher solvent content is also seen to experience higher 
degree of compaction during the 10 ns MD simulation.  Whilst these mAbs are not 
identical to the mAb studied experimentally, structural homology allows us to predict 
which regions of a mAb will contract and also which are unchanged in vacuo.   
 
Despite a significant change in the theoretical CCS, the secondary structure content 
does not change drastically along the MD simulation time.  This content was 
determined using AmberTools13 (module cpptraj), which implements the algorithm 
DSSP.89  The percentage of secondary structure elements i.e. coils, turns, β-sheets 
and helices present at 2 ns intervals of the MD run is reported in Table 3.3 for both 
mAbs.  After 10 ns of in vacuo MD simulation on the 1IGT crystal structure, the 
total helical content decreases from 7.1 % to 6.2 % and the total β-sheet content 
decreases from 47.3 % to 41.7 %.  Similarly in case of the 1IGY crystal structure, the 
total helical content decreases from 6.2 % to 5.0 % and the total β-sheet content 
decreases from 43.3 % to 35.8 %.  It can be seen in Figure 3.11, that structural 
contraction occurs mainly around the hinge region and the antigen binding region 
remains still well preserved in vacuo.  The MD simulation shown how the linked folded 
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Table 3.3  Secondary structure content and theoretical CCS (TJM based) of 1IGT and 1GTY 
prior to and at 2 ns intervals of in vacuo MD simulation.   
 
1IGT       
Simulation time / 
ns 
0 2 4 6 8 10 
TJM based CCS / 
nm2 
106 89 87 86 89 86 
Coil 34.42 37.92 39.82 42.48 40.20 41.95 
Turn 11.25 11.32 10.79 11.63 10.87 10.11 
Parallel-β-sheet 2.13 2.05 2.13 1.52 1.98 1.67 
Anti-parallel-β-
sheet 
45.14 41.64 40.88 39.29 41.11 40.05 
3 10-helix 3.50 3.57 3.80 2.66 3.50 3.80 
α-helix 3.57 3.12 3.20 2.05 1.82 2.28 
π(3-14)-helix 0.00 0.38 0.38 0.38 0.53 0.15 
       
1GTY       
Simulation time / 
ns 
0 2 4 6 8 10 
TJM based CCS / 
nm2 
101 84 84 86 83 84 
Coil 39.57 47.30 46.83 45.52 44.36 47.06 
Turn 10.97 11.90 10.66 11.67 12.67 12.13 
Parallel-β-sheet 2.01 1.47 1.62 1.39 1.39 1.39 
Anti-parallel-β-
sheet 
41.27 34.54 35.01 35.94 35.63 34.39 
3 10-helix 3.94 3.17 4.40 3.63 4.48 4.02 
α-helix 2.24 1.62 1.47 1.85 1.47 1.00 




3.4 Conclusions  
 
IM-MS has revealed intact mAbs to be more structurally dynamic than proteins of 
comparable size which is attributed to their intrinsic flexibility.  This flexibility of 
mAbs is reflected by broad CCSD landscapes and the lack of baseline resolution is 
an indicative of closely related interconverting conformational families present.  
Moreover, the distinct features in the hinge region and the non-covalent interactions 
at the CH3-CH3 interface are potentially responsible for the experimentally observed 
differences in CCSD of intact IgG1 and IgG4 as well as their Fc-hinge fragments.  
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The MD simulations indicate that desolvation causes a contraction in the hinge 
region and loss of the cavities between the folded domains of mAbs; however, still 
preserves much of the secondary structure as well as the tertiary fold.  The subtle 
differences in IM-MS data from the two IgG subclasses, with IgG1 less flexible than 
IgG4 in the absence of solvent, these contrasts with solution evidence which shows 
the IgG4 hinge to be more rigid than that of IgG1, and raises interesting caveats 
about the use of mass spectrometry to probe higher order structure in flexible 
proteins such as mAbs or biosimilars.  Nevertheless, IM-MS and MD simulations 
have shown that the linked folded domains proteins ‘dance’ in the absence of 
solution as they do in the condensed phase.  In future, ‘freezing’ molecules in the 
gas-phase by use of low temperature IM-MS and preferably instruments with higher 
mobility separation capabilities, could provide insights into the conformational 
diversity of mAbs.  
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Variable Temperature (IM)-MS: 
Unfolding and Dissociation of 
Multimeric Protein Complexes 
 
Proteins and protein complexes undergo structural changes depending on the 
surrounding environment, in turn affecting their biological function.  Here, VT-MS is 
applied to study four multimeric protein complexes and allow for decoupling of their 
melting temperature (Tm) from the protein complex dissociation temperature (TGPD).   
VT-IM-MS is used to investigate structural changes of these proteins at elevated 
temperatures and provide insight into the thermally induced dissociation (TID) 
mechanism, as well as strength of the non-covalent interactions between subunits.  
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4.1 Introduction  
 
The biophysical properties, biological activity and function of macromolecular 
systems are highly dependent on their structure.  In turn structure-function analyses 
are critical for drug discovery, biochemical or medical research.1-3  Changes to 
protein structure, either due to post-translational modifications (PTMs), mutations or 
protein denaturation can alter both the function and the biophysical properties of a 
given protein.4-6  The structure of these large complex molecules is not only greatly 
dependent on their amino acid sequence, but also on their surrounding environment, 
and can be altered by changes in solution conditions (pH, ionic strength) or by 
physical parameters like temperature and pressure.  Understanding the molecular 
basis of thermodynamic stability of proteins is a fundamental problem with clear 
practical applications.  Nowadays, with an emerging market for protein based 
therapeutics, improving protein stability has a tangible benefit.7,8  Thermal stability is 
an indicative of global protein stability and is traditionally probed using circular 
dichroism and/or calorimetry techniques such as differential scanning calorimetry 
(DSC).9-11  Data obtained from such analysis can also delineate other properties of 
proteins such as their ease of crystallization for further structural studies.12   
 
4.1.1 Variable temperature IM-MS studies: past and present  
Jarrold et al. were the first to report variable temperature (VT) IM-MS to probe 
temperature dependent conformations adopted by proteins in the gas phase.  Their initial 
study revealed that the effect of increased temperature on the CCS of cytochrome c ions 
was charge state dependent.13,14  Measurements were performed at various temperatures 
over the range 273-573 K; it was reported that lower charge states (5+ and 6+) show 
little change in CCS over the temperature range, whereas higher charge states (7+) 
demonstrate dramatic changes in the CCS attributed to a series of unfolding transitions 
as the temperature is raised.  Later, Bowers and co-workers applied VT-IM-MS to study 
unfolding and dissociation of amyloid β-protein peptide multimers.15  Last year, the 
Barran group reported on the effect of the salt on the conformations of model monomeric 
proteins  (BPTI, ubiquitin and cytochrome c) at temperatures ranging from 260 to 360 
K.16  The study showed that thermally induced unfolding is minimized in the presence of 
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adducted iodide to monomeric proteins, and that at relatively low temperatures, native 
proteins can unfold.   
Currently, there is no commercially available instrument suitable for analysis of large 
biomolecules that would allow drift gas temperature control and variation.  Even though, 
variable temperature technique of selected ion flow tube MS (SIFT-MS) exists, it is 
applied for the study of ion-molecule reaction kinetics in the gas phase yielding reaction 
rate coefficients; this type of instrumentation is commonly used for volatile compounds 
and is not suitable for large protein work.17-19  Our in-house modified linear drift tube ion 
mobility mass spectrometer20 features heating and cooling capabilities and allows for 
control of the buffer gas temperature within 200 – 600 K range.  Several other IM-MS 
instruments with temperature control exist, allowing for work either at cryogenic or 
elevated temperatures.  Often, the mass working range is limited and the above 
mentioned instruments have predominantly been used to study small molecules, peptides 
or monomeric proteins.21,22-25  Recently, Russell et al. reported on capturing hydrated 
peptide ions in their linear drift tube VT-IM mass spectrometer with cryogenic 
capabilities designed for non-covalent complexes and weakly bound cluster ions.26  
Using low temperature (~80 K) in the drift region allowed for preservation of short lived 
hydrated gramicidin S and bradykinin ions.  The results suggested that the number of 
water clusters retained and hydration process might be peptide specific.26  Studies as 
such, illustrate the importance of VT-MS and VT-IM-MS experiments and how these 
new approaches can be used to address fundamental questions related to gas phase 
biomolecules.  
The focus of the work presented in this chapter is to extend the capabilities of VT-IM-
MS methodology to the study of multimeric protein complexes.  The motivation to do so 
is based on the fact that most proteins tend to exist as multiple domains; from the 
distribution of oligomeric states in the Protein Data Base (PDB), 86% of proteins exist as 
oligomers.27  The behavior of four commercially available model protein complexes: 
transthyretin (TTR), avidin, concanavalin A (conA) and human serum amyloid P 
component (SAP) was probed at temperatures from 300 K up to 550 K and traced 
thermally induced dissociation (TID) of subunits in the gas-phase with IM-MS.  Unlike, 
solution studies, TID enables the protein complex melting temperature (Tm) to be 
decoupled from the complex dissociation temperature (TGPD).  Moreover, the 
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conformational changes occurring during the dissociation process are revealed.  This 
approach provides fundamental insights into protein folding, subunit interactions and 




4.2.1 Sample preparation 
Ion species selected for this study were four commercially available multimeric protein 
complexes: human transthyretin (TTR, 55kDa), avidin (64 kDa), concanavalin A (conA, 
103 kDa), human serum amyloid P component (SAP, 128 kDa).  Avidin from egg white 
(A9275) and concanavalin A from Canavalia ensiformis (C2010) were obtained from 
Sigma Aldrich (St. Louis, MO, USA).  Human TTR was obtained from SCIPAC 
(Sittingbourne, UK); human SAP was obtained from CalBioChem (Darmstadt, 
Germany).  Amino acid sequences of all four complexes are available in the Appendix 3. 
Ammonium acetate (AmAc) was obtained from Fisher Scientific (Loughborough, UK).  
40µM protein complex solutions (avidin, conA and SAP) were prepared in 200 mM 
AmAc (pH 6.8) and stored at -25 ̊C.  The buffer was exchanged to 100 mM AmAc on the 
day of analysis, using micro Bio-Spin Chromatography columns (Micro Bio-Spin 6 
Columns, Tris) following the instructions specified by the manufacturer.  The desalting 
procedure was performed twice to achieve desired sample purity.  High purity water was 
obtained from an Arium 611 water purification unit (Sartorius, Göttingen, Germany) 
fitted with a 0.2 µm filter.   
 
4.2.2 Variable temperature mass spectrometry and variable 
temperature ion mobility mass spectrometry  
 
30 µM samples were ionised using positive nESI as described in Chapter 2, section 
2.1.2.  IM-MS data were acquired on the MoQToF, quadrupole time-of-flight mass 
spectrometer modified in-house to include 5.1 cm drift cell, detailed in section 2.2.1.20  
Voltages along the mass spectrometer were adjusted to preserve non-covalent 
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interactions and native like structures.  The capillary potential was held at 1.5 - 1.8 kV, 
the source temperature was set to 80 °C, and the cone voltage was set to 80 V.  The 
injection energy used was between 31 and 36 V.  Other instrumental settings for the 
MoQToF IM mass spectrometer are listed in Chapter 2, Table 2.3.  The drift cell was 
filled with helium as the buffer gas at a pressure of 3.7 – 3.8 Torr and the pressure 
measured using a capacitance manometer (MKS Instruments, UK); the precise pressure 
was recorded for each and every drift voltage and used in the calculations of CCS.  Ion 
mobility experiments were carried out at several drift cell temperatures ranging from 300 
K to 550 K, as discussed in the results section.  The cell was heated via tantalum wire 
wound ceramic heaters located in both the cell body (8 heaters) and in the end cap (2 
heaters) driven by variable transformers (Variacs).  The temperature of the drift cell was 
monitored using three k-type thermocouples and recorded for each data set.  The electric 
potential across the cell was varied from 60 to 15 V with measurements taken at six 
different drift voltages.  In cases, when the signal intensity was low (SAP, at T ≥ 450 K) 
20 V instead of 15 V was used as the sixth drift voltage data point.  The rotationally-
averaged collision cross-sections (CCS) were determined from a plot of arrival time 
versus P / T and the CCSD were determined as described in Chapter 2, section 2.2.1.4.  
Data was processed using Mass Lynx V.4.1 Build 10, Microsoft Excel 2003 and Origin 
8.5.1 graphing software (OriginLab, Northampton, MA, USA).  The VT-MS experiments 
were repeated in triplicate and the average values are reported.  VT-IM-MS experiment 
on TTR, SAP and avidin (only at 475 K) were performed twice.  Experiments on avidin 
at the remaining temperatures and concanavalin A were performed once.  
 
4.2.3 Calculations of the surface interface area, number of hydrogen 
bonds and salt bridges  
Calculations on the surface interface area, possible number of hydrogen bonds and salt 
bridges of TTR and avidin were carried out using the online ‘Protein interfaces, surfaces 
and assemblies’ service PISA at the European Bioinformatics Institute website 
(http://www.ebi.ac.uk/pdbe/prot_int/pistart.html).28,29  Three structures of TTR (PDB: 
1BMZ, 1DVQ, 3U2I) and avidin (PDB: 1AVE, 1VYO, 1RAV) deposited in the Protein 
Data Bank were used and the average values for each protein are reported.   
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4.3 Results and Discussion 
 
4.3.1 Probing dissociation of protein complexes with VT-MS 
VT-MS experiments were performed on four protein complexes shown in Figure 4.1: 
tetrameric transthyretin (TTR, 55 kDa), avidin (64 kDa) and concanavalin A (conA, 103 
kDa) and a pentameric human serum amyloid P component (SAP, 128 kDa).  30 µM 
protein samples in 100 mM ammonium acetate at pH 6.8 were ionised using nESI and 
data were acquired on the in-house modified IM-MS instrument (MoQToF) shown in 
Figure 2.3.  The selected model protein complexes have been well studied via mass 
spectrometry by other groups,30-38 are commercially available, have easy preparation 
requirements, yield a constant spray, and have been proposed as suitable calibrants for 
TWIMS mass spectrometers.39  In order to preserve complexes’ quaternary structure, key 
source parameters were optimized, in particular the capillary, sample and extractor cone 
and injection energy voltages.   
Mass spectra of complexes under investigation present relatively narrow charge state 
distributions indicating well preserved gas-phase structures (Figure 4.2).  The 
temperature of the drift cell helium gas was raised via ten tantalum wire wound ceramic 
heaters driven by two external variable transformers and the temperature was closely 
monitored by the capacitance manometer.  Mass spectra were recorded at temperatures 
ranging from 300 K to 550 K at 20-50 K intervals.  The time ions spend in the 
temperature controlled region of MoQToF is dependent on the ions’ mass, charge and the 
electric potential applied across the drift cell.  In the experiment at 300 K presented here, 
this time varied from 1.8 ms to 4.2 ms for the 55 kDa TTR where z = 15+ charge and 
from 2.2 ms to 5.2 ms for the 128 kDa SAP where z = 22+ charge, where the potential 
difference  across the drift cell ranging from 60 to 15 V.  The experimental time frame 
does vary somewhat with temperature, however, this was minimised by adjusting the 
pressure as a function of temperature to match the drift time at 300 K.   
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Figure 4.1  Structure of (a) TTR tetramer, (b) SAP pentamer, (c) avidin and (d) concanavalin A 
based on the x-ray crystal structures available in PDB: 1BMZ, 1SAP, 1AVE and 1DQ2 
respectively. 
 
Mass spectra of TTR, SAP, avidin and conA at progressively higher temperatures are 
shown in Figure 4.2.  TTR, a 55 kDa homotetrameric protein, is present in a narrow 
charge state distribution centred at 14+ charge state (~m/z 3950).  A minor amount of a 
higher order species i.e. a dimer of tetramer, is also observed around m/z 5000.  A range 
of sample concentrations and buffer strengths were examined prior to choosing the most 
suitable experimental conditions.  Upon the increase of temperature up to 400 K, the 
TTR complex remains intact as a tetramer in the 1.7 – 4.1 ms (at 60 – 15 V drift voltage) 
it spends in the high temperature environment of the drift cell.  Above 450 K, 
dissociation of this tetrameric complex into monomers is observed.  Several monomeric 
species are now present in the m/z 1200 – 2400 region of the mass spectrum, with 8+ 
charge state (~ m/z 1735) being the most abundant.  Above 550 K, higher order species 
are no longer detected and only small amount of tetrameric species remains.  As can be 
seen in the top mass spectrum in Figure 4.2a, is dominated by 10+ to 6+ TTR monomers.  
Moreover, low charge intermediate trimers, centred on a 6+charge state (~ m/z 5900), 
are present.  
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Figure 4.2  Mass spectra acquired at 300 - 550 K for (a) transthyretin (TTR), (b) human serum 
amyloid P component (SAP) (c) avidin and (d) concanavalin A (ConA) illustrating thermally 
induced dissociation (TID) of in the gas-phase.  As the temperature is increased, the m/z peaks 
become narrower which is attributed to more efficient stripping of salt adducts.  
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At 300 K, the charge is more or less evenly distributed among the subunits at 300 K; 
however, at elevated temperatures when the dissociation occurs, the ejected monomer 
carriers over 50 % of the total charge.  This ‘asymmetric’ charge partitioning suggests 
that the subunit undergoes unfolding prior to dissociation as observed in the CID 
experiments in the past, following the ‘typical’ dissociation route.40 
SAP requires higher temperature for the onset of dissociation into monomers to take 
place.  The 128 kDa SAP presents a slightly broader charge state distribution than TTR, 
present in the m/z 4900 – 5900 region and centred on the 24+ charge state (~ m/z 5330).  
Even with the relatively low 30 µM sample concentration a significant amount decamer 
is present.41  These higher order species remain observable until above 550 K (Figure 
4.2b).  Mass spectra acquired at temperatures between 300 K and 500 K, show a gradual 
decrease of decameric SAP population.  No dissociation of SAP into monomers is 
observed below 500 K.  Above 500 K, SAP begins to dissociate into monomeric species 
centred on the 11+ charge state, ~m/z 2320, as shown in the top spectrum in Figure 4.2b.  
Due to the instrumental layout (drift cell prior to quadrupole analyzer), it is not possible 
to mass select ion species to determine whether the majority of dissociated monomer is 
ejected from SAP pentamer or decamer.  As for TTR, asymmetric charge partitioning is 
observed, implying unfolding of the subunit(s) prior to complex dissociation.  
Furthermore, at temperatures at which dissociation into monomers occurs, additional 
peaks are observed at ~m/z 1147 and ~m/z 1529 corresponding to a peptide with mass of 
~4.58 kDa.  Intensity of those peaks increases as the buffer gas temperature is raised.  
Detected peptide is most likely originating from SAP monomer backbone fragmentation, 
however, further CID experiments have not been carried out to determine its sequence.   
Similar unfolding and dissociation trends are observed for tetrameric avidin shown in 
Figure 4.2c.  Avidin, a 64 kDa homotetrameric protein, is present in a narrow charge 
state distribution (m/z 3700 – 4300) centred at 16+ charge state, ~ m/z 3990.  A minor 
amount of higher order species i.e. a dimer of tetramers, is also observed around m/z 
5500, likely due to the sample concentration.  Upon the increase of temperature up to 
400 K, the avidin complex remains intact as a tetramer.  Similarly to TTR, it is above 
450 K, when the dissociation into monomers is observed.  Dissociation produces 
monomeric species with 9+ charge state (~ m/z 1775) being the most abundant.  Above 
550 K, mass spectrum is dominated by 11+ to 7+ avidin monomers; however, there are 
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still some low charge intermediate trimers, centred at 7+ charge state (~ m/z 6860), 
present.   
Concanavalin A requires higher temperature for the onset of dissociation (Figure 4.2d).  
Under physiological conditions, conA exists as a tetramer (103 kDa), dimer and 
monomer.  The tetrameric population is centred on the 20+ charge state (~m/z 5130), 
dimeric population is centred on the 14+ charge state (~m/z 3670), and monomeric 
population is centred on 9+ charge state (~m/z 2850).  Mass spectra acquired at 300 K 
and 400 K, do not show significant differences apart from narrowing of the tetramer 
peaks at higher temperature due to salt clean up.  Above 470 K, onset of dissociation into 
highly charged monomers centred at 12+ charge state (~m/z 2140) is observed.  
Dissociation increases at temperatures above 500 K.  The mass spectra acquired at 550 
K, still contain significant amounts of intact tetramer and as well as lower charge state 
solution present dimers and monomers.  Data obtained from VT-MS experiments gives 
insight into gas-phase dissociation of multimeric complexes into subunits and the results 
are compared to in-solution complex dissociation data reported in the literature.  
 
4.3.2 Gas-phase protein complex dissociation curves and 
determination of TGPD 
The extent of dissociation into monomeric species was observed to vary with the drift 
time.  Figure 4.3, shows time dependent dissociation of TTR at 475 K.  As the drift 
voltage (DV) across the drift cell is lowered, ions take longer to transverse the drift cell 
and complexes undergo dissociation to greater extend.  For example, change of the DV 
from 60 V to 15 V results in increase of drift time from 1.75 ms to 4.26 ms for the 14+ 
TTR charge state, and significantly affects the dissociation ratio.   
From the previous reports of others42 and VT-IM-MS experiments presented in the 
following sections, it is apparent that the amount of energy required to break the 
dissociation energy barrier is dependent on the ion charge state.  Highly charged ions are 
susceptible to more Coulombic repulsion than lower charge states, and as a result 
dissociate more readily, despite the relatively low z across these native nESI charge 
state distributions.  Considering this fact, summed intensities over all the presented  
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Figure 4.3   Time dependent dissociation of TTR at 475 K.  Mass spectra acquired DV = 60, 45, 
35, 30, 25 and 15 V on the MoQToF mass spectrometer.  
charge states were used to construct dissociation curves such as these shown in Figure 
4.4, to reflect the majority of ion population.  The ratio of the summed intensities of 
charge states corresponding to the intact complex [Icomplex] over the sum of the summed 
intact complex charge state intensities and summed intensities of monomer charge states 
resulting from the thermal dissociation [Icomplex + I monomer] was plotted as a function of 
buffer gas temperature for each protein investigated and the data points were fitted with 
a Boltzmann function (Figure 4.4).  For protein complexes requiring temperatures 
exceeding the instrument capabilities to reach a complete dissociation i.e. conA and SAP, 
the fit was extended for the dissociation ratio to approach 0.  The dissociation process 
occurs in the drift cell region of the instrument, and any detector response factor 
differences between monomers and multimers have been neglected.  The gas-phase 
dissociation temperature (TGPD) for each complex is reported; here, the TGPD is defined as 
the temperature at which 50 % of the complex population has dissociated into 
monomeric species as a result of increased temperature of analysis environment.  TGPD 
were determined at several DV and plotted as function of drift time (Figure 4.5).  The 
TGPD decreases with longer drift times.  Data points were fitted with an exponential 
decay function to determine the dissociation equilibrium temperature (Teq) for each  
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Figure 4.4   Temperature induced dissociation (TID) curves of avidin (grey), TTR (green), conA 
(red), and SAP (purple) used for determination of TGPD, determined near the equilibrium drift 
time (DV = 15 V for TTR, avidin and conA; DV = 25 V for SAP).   
 
Figure 4.5   Determination of the dissociation equilibrium temperature (Teq).  The gas-phase 
dissociation temperature (TGPD) of (a) TTR, (b) SAP, (c) avidin and (d) conA versus drift time 
(ms) at corresponding DV.  Results for TTR and SAP are based on two repeats, and a single 
repeat for avidin and conA.    
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complex.  Measurements taken at the lowest DV are the closest to the Teq as can be 
achieved with the current instrumentation.  Data acquired at these low DV was used to 
construct the dissociation curves shown in Figure 4.4.  Table 4.1 lists TGPD at various 
drift times.  Solution thermal stability techniques, such as differential scanning 
calorimetry (DSC), provide one with the Tm, a melting temperature at which 50 % of the 
protein has undergone a transition which is attributable to loss of structure.  From 
thermal dissociation VT-MS measurements, gas-phase dissociation temperatures (TGPD) 
are determined for four protein complexes and compared to Tm values based on DSC 
measurements (Table 4.1).   
The TGPD of TTR was determined to be 468.2 ± 0.7 K.  Notably, the literature value of 
Tm for TTR is significantly lower (by 21 %) than TGPD.  The reported literature Tm of 
TTR is 370.95 K as determined by DSC,43 which is almost 100 K lower than TGPD 
determined VT-MS experiments.  TGPD increases for complexes with higher molecular 
mass which in similar fashion were determined to be 474.0 K, 520.9 K and 523.2 ± 0.6 
K for avidin, conA and SAP respectively.  This increase is only partially correlated to 
molecular mass.  As conA is known to exist in equilibrium with its dimeric and 
monomeric form, for the purpose of calculating the dissociation ratios only the 15+ to 
11+ monomers (~m/z 1715 – 2340) produced during the TID were considered, as 
opposed to the naturally occurring 10+ to 8+ monomers (~m/z 2560 –3200) (Figure 
4.2d).  Moreover, the TGPD is not only dependent on the mass of the complex, but appears 
to be dependent by the strength on the non-covalent interactions between subunit 
interfaces as will be discussed later. 
The protein complex structure is perturbed at the raised temperatures.  In-solution 
studies allow the measurement of Tm i.e. the protein transformation; however, they 
cannot distinguish between loss of structure and complex dissociation, nor do they 
distinguish in detail the route by which structure is lost.  With use of VT-MS, the TGPD 
can be determined, and we can also differentiate between two competing processes: loss 
of structure and dissociation.  The difference between Tm and TGPD was about 100 K for 
the protein complexes investigated here, illustrating a significant difference in the 
amount of energy required for loss of structure vs. complex dissociation.  In other words, 
the unfolding energy barrier and dissociation energy barrier can be decoupled in the gas- 
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Table 4.1  Average drift time across charge states of for TTR, avidin, conA and SAP at various 
drift voltages; gas-phase dissociation temperature (TGPD) determined at each DV; the 
equilibrium temperature (Teq) and the literature in-solution melting temperature Tm. 
 
phase by VT-MS.  Moreover, VT-MS allows the decoupling of extrinsic (solvent) from 
intrinsic factors on thermal stability of protein complexes. 
The TID charge state dissociation profile of TTR (Figure 4.2a), matches the dissociation 
profile from CID experiments reported by Pagel et al.32.  The TTR tetramer displays a 
narrow charge state distribution centred at 14+ charge state (~m/z 3950).  Upon complex 
activation, either by CID or TID, a highly charged monomer carrying approximately 
Protein 
complex 
Drift time/ms TGDP /K Teq /K Tm /K 
TTR 
1.8 478.2 ± 4.9   
2.1 476.6 ± 4.8   
2.6 473.7 ± 2.9   
2.6 470.7 ± 2.5   
2.9 470.0 ± 0.0   
4.2 468.2 ± 0.7 467.8 370.943 
Avidin 
1.7 474.8   
2.0 474.5   
2.2 474.4   
2.5 474.1   
2.7 474.1   
3.9 474.0 474.0 356.744 
ConA 
1.9 531.0   
2.2 526.1   
2.5 525.3   
2.8 524.7   
3.1 527.8   
4.5 520.9 520.9 338.0 ± 6.545 
SAP 
2.0 528.7 ± 0.1   
2.3 526.3 ± 1.0   
2.9 524.1 ± 0.0   
3.3 523.2 ± 0.6 521.6 359.2 – 363.2 
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50 % of overall charge (here, 8+ (~ m/z 1735) being the most abundant dissociated 
monomer) is released from the complex.  CID and TID mass spectra of SAP, avidin and 
ConA, display similar dissociation pattern.34,37  Based on the matching charge state 
profiles and IM-MS data, it may be postulated that CID and TID activate the complexes 
in a very similar fashion.  Currently, TID experiments can only be performed using 
custom modified mass spectrometers that allow for control and monitoring of the 
temperature within the instrument.  CID is a widely available technique featured in many 
mass spectrometers.  Correlating TID temperatures and CID energies could serve as a 
framework for thermal stability screening, especially useful when the amount of sample 
material is limited to perform the classical DSC measurements.  Here, for example about 
725 eV (Elab, based on data reported by Pagel et al.
32) is required to achieve 50 % 
dissociation of TTR 14+ tetramer occurring at about 468 K as determined via the TID 
experiments.  Moreover, the TID data could also be used to obtain thermodynamic 
parameters (enthalpy (ΔH) and entropy (ΔS)) on the interactions between subunits.  
 
4.3.3 Investigating the TID mechanism with VT- IM-MS  
The in-house modified linear DT-IM mass spectrometer allows not only for the 
determination of TGPD but also enables investigation of structural changes of proteins that 
might occur prior to dissociation as the buffer gas temperature is increased in the drift 
cell.  IM-MS experiments, for the complexes studied here, were carried out at 
temperatures ranging from 300 K to 500 K or 550 K, dependent on the TGPD determined 
earlier.  CCS distributions (CCSD) and their transformations, derived from arrival time 
distributions (ATD) of TTR and SAP acquired at a range of temperatures are presented in 
Figure 4.6.  CCSD of avidin and conA at a range of temperatures are available in the 
Appendix 4.  Changes in the CCS and width of CCSD are clearly visible, indicating 
significant structural changes as an effect of increased analysis environment temperature.  
IM data acquired at 350 K and 400 K show a minor decrease in the CCS of TTR and 
SAP in comparison to CCS determined at 300 K, suggesting a structural collapse.  The 
greatest shift towards larger CCS is observed at and above the TGPD determined with VT-
MS.  In Figure 4.7, median CCS (nm2) of each protein and their dissociated subunits, as 
well the naturally occurring dimers and monomers of conA, are plotted versus buffer gas 
temperature (K).   
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Figure 4.6  Collision cross section distributions (CCSD) of TTR (13+,14+ and 15+ charge states) 
and SAP (22+,24+ and 26+ charge states) acquired at DV=35 V and buffer gas temperatures 
ranging from 300 to 500 K and 550 K, respectively.  CCSD of avidin and conA are available in 





The range of TTR tetramer median CCS across charge states decreases from 31.3 - 
33.5 nm2 to 30.7 - 32.3 nm2 at 350 K and further to 30.5 - 32.3 nm2 at 400 K (the list of 
all median CCS values is available in the Appendix 5).  The extent of the collapse was 
noted to be greater for higher charge states (Figure 4.7a).  As the buffer gas temperature 
is increased to 450 K, the median CCS of higher charge states increase as the subunits 
begin to unfold; however, the 13+ charge state remains still somewhat compact.  Around 
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TTR’s TGPD, a significant increase in CCS is observed and the median CCS range across 
charge states increases to 38.3 - 42.0 nm2 at 475 K and further to 39.5 - 47.0 nm2 at 
500 K.  The relative change in median CCS with respect to CCS at 300 K is more 
extensive for higher charge states reaching +40.3 % for the 15+ charge state.  Moreover, 
the CCS of the expelled highly charged monomer has been calculated at temperatures 
near TGPD and above.  It was found that the dissociated monomer has a large CCS (16.8 - 
22.6 nm2 at 475 K) similar to the CCS of a CID dissociated monomer,32,35 suggestive of 
extensive subunit unfolding prior to dissociation in the TID process.  It has been 
previously reported that highly charged TTR monomers (7+ to 9+) expelled from the 
complex during the CID process, adopt CCS in the range of about 17 nm2 to 27 nm2, or 
even up to 30 nm2. 32,33,35 
The SAP pentamer follows a similar pathway of compaction, unfolding and dissociation.  
At 350 K and 400 K a minor decrease in the median CCS is observed for the 22+ to 25+ 
charge states.  The range of the median CCS for the SAP pentamer across charge states 
changes from 59.1 - 63.7 nm2 to 58.9 - 66.4 nm2 at 350 K, with -3.65 % reduction in 
median CCS for 22+ charge state and only -0.39 % reduction for 25+ charge state.  The 
compaction progresses further at 400 K to 58.8 - 71.9 nm2.  In contrast to TTR, lower 
charge states experience a greater degree of compaction; the 26+ charge state does not 
experience any compaction and the CCS begins to increase already at 350 K (+2.71 %) 
and further at 400 K, where up to +8.20 % change in CCS is noted.  As reported before, 
the compaction behaviour might originate from a collapse of the units of SAP into the 
central cavity.33  This path is likely to be controlled by the subtle stabilizing or 
destabilizing effects of charge interactions on the protein ion’s surface and collapse of 
high charge states might be mitigated by dominating Coulombic repulsions and/or by the 
loss of buffer salts or water.33,37  The CCS for all SAP charge states detected, continues 
to increase above 450 K and the median CCS range reaches 77.4 – 89.7 nm2 at 550 K 
(i.e. an increase of +31.2 % for 22+ charge state CCS and of +44.2 % for the 26+ charge 
state CCS).  CCS of the highly charged ejected monomer is again similar to the one 
determined through CID experiments on SAP, ranging from 25.7 – 34.2 nm2  at 500 K 
for 10+ - 13+ charge states.35 
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Figure 4.7   Median CCS and percentage change in CCS with respect to CCS at 300 K of (a) TTR, 
(b) SAP, (c) avidin, and (d) conA in function of buffer gas temperature.  VT-IM-MS 
measurements illustrate an initial decrease in the CCS associated with complexes’ minor 
collapse and latter significant increase in CCS as protein subunits begin to unfold and 
subsequently dissociate. M = monomer, D = dimer, T = tetramer and P = pentamer.  
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Similarly to TTR and SAP, avidin experiences compaction at 350 K and 400 K and 
subsequent unfolding at temperatures above 450 K shown by the increase in the CCS.  
The range of avidin tetramer median CCS across charge states decreased from 32.8 – 
34.8 nm2 (15+ and 16+ charge states) to 32.3 – 46.3 nm2 (15+ to 17+ charge states) at 
350 K and further to 31.9 – 41.0 nm2 at 400 K.  As for TTR, the initial compaction is 
more extensive for the higher charge states, and so is unfolding.  As the buffer gas 
temperature is increased to 450 K, the CCS of higher charge states are increasing as the 
subunits begin to unfold; however, the 15+ charge state remains still somewhat compact.  
Around avidin’s TGPD, a significant increase in CCS is observed and the median CCS 
range across charge states increases to 35.6 – 43.8 nm2 at 475 K and further to 40.8 – 
47.3 nm2 at 500 K.  Relative change in median CCS with respect to CCS at 300 K is 
more extensive for higher charge states and reaches +27.5 % for the 16+ charge state at 
500 K.  Moreover, CCS of the ejected highly charged monomer near TGPD was found to 
be in range of 17.0 – 22.4 nm2 (at 475 K).   
The ConA tetramer follows a similar dissociation pathway.  The range of conA tetramer 
median CCS across charge states decreased from 47.5 – 50.6 nm2 (19+ to 22+ charge 
states) to 47.4 – 48.7 nm2 at 350 K and further to 46.8 – 48.3 nm2 at 400 K.  The extent 
of the collapse was noted to be greater for the higher charge states.  As the buffer gas 
temperature is increased to 450 K, median CCS of higher charge states are increasing as 
the subunits begin to unfold; however, the 19+ and 20+ charge states remain still 
compact.  The CCS for all conA tetramer charge states detected, continue to increase 
above 450 K and the median CCS range reaches 70.0 – 74.9 nm2 at 550 K (i.e. +47.5 % 
increase in 19+ charge state CCS and +47.9 % in 22+ charge state CCS).  As conA exists 
in dimeric and monomeric forms even before the application of external energy, changes 
in these structures at elevated temperatures were also investigated.  Both, conA dimer 
and conA monomer experience a minor compaction at 350 K and 400 K; this compaction 
is more extensive for higher charge states of dimer, just as for tetrameric conA (for 
median CCS values, see Appendix 5).  At 450 K and above, median CCS begin to 
increase as the protein unfolds and continues to do so up to 550 K.  Interestingly, the 
naturally occurring monomer follows the same pathway of collapse (at 350 K and 400 
K) and unfolding above 450 K, like multimeric systems, suggesting that the collapse is 
not only originating from intra-subunit cavity collapse but also from significant 
compaction within each subunit.  CCS of the highly charged ejected monomer is again 
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similar to the one determined through CID experiments on conA, ranging from 28.2 – 
37.8 nm2 at 550 K for 10+ - 16+ monomers.  
The collected IM data shows that protein complexes undergo initial compaction upon 
temperature increase and subsequent unfolding prior to dissociation similarly to the CID 
process.  As reported by others, the CID process occurs by initial compaction of the 
complex and subsequent unfolding of subunits following the ‘typical’ dissociation 
route.33,46  VT-IM-MS data acquired at 350 K and 400 K displays a minor decrease in 
CCS of all four protein complexes in comparison to CCS determined at 300 K, 
suggesting a structural compaction.  This decrease in CCS is associated with initial loss 
of structure and originates from the collapse of structure into the intra-subunit cavities as 
well as the collapse of the subunits within themselves.  The temperature at which 
maximum compaction occurs is comparable to the Tm obtained from the in-solution 
studies.  
As the temperature is increased to 450 K and higher, an extensive increase in CCS is 
noted associated with subunit unfolding.  The CCS increases accordingly with the energy 
input, either by TID or CID.  Due to statistical reasons, one subunit might carry slightly 
more charge than others.  This asymmetrical charge partitioning results in a marginally 
destabilized subunit, resulting from intramolecular Coulombic repulsions.47  Upon 
collisional activation of the complex, one or possibly multiple subunits begin to unfold.  
As the new surface area is exposed, charge migration occurs to that region and drives 
further unfolding which eventually results in release of highly charged monomer which 
further supports the resemblance of TID mechanism to CID mechanism.48   
Here as an example, the CCS of TTR at 300 K was found to be in a range of 31.3 - 33.5 
nm2 and in close agreement with that reported by Pagel et al. (~31 nm2).32  At 500 K, a 
temperature at which only marginal amount of TTR tetrameric species were detectable, 
CCS has increased to 39.5 – 47.0 nm2 for 13+ - 15+ charge states, which again is in close 
agreement with the most extensive conformations measured for TTR tetramer activated 
by CID (40 - 45 nm2)32.  Moreover, the CCS of the ejected highly charged monomers 
were calculated at temperatures near TGPD and above.  It was found that the dissociated 
monomers of all protein complexes studied here, have large CCS similar to those CCS of 
monomers produced via CID.35  Comparison of computationally determined CCS of 
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monomers clipped from a complex x-ray crystal structures, showed that CID produced 
monomers are in their unfolded state.35   
Although, observed trends are similar among different protein complexes, the degree of 
compaction and unfolding varies across charge states.  Past the compaction stage, as the 
subunits begin to unfold, a gradual increase in CCS is noted across all charge states.  
Some complexes experience close to a 50 % increase in CCS in comparison to those 
found at 300 K.  A common trend was seen; higher charge states experience greater 
degree of extension and require less energy to initiate unfolding.  This phenomenon is 
believed to be influenced by Coulombic effects and has been reported previously for 
monomeric proteins such as cytochrome c and lysozyme, or complexes like SAP. 33,49,50 
The degree of compaction varied among the protein complexes.  Low charge states of 
SAP, a complex with relatively large internal cavity, experience greater compaction, in 
agreement with MD and CID experiments reported by Hall et al..37  At the same time, 
the highest charge state did not undergo any compaction.  The compaction pathway is 
believed to be suppressed due to competing effects from Coulombic repulsion for the 
high charge states; whereas, the lower charge states collapse only presumably into the 
internal cavity.  The other three complexes studied here, display an opposite trend i.e. 
greater extent of compaction for higher charge states.  These complexes have 
significantly smaller intra-subunit cavities in relation to SAP.   It can be speculated that 
the majority of compaction observed must be coming from a collapse/loss of structure 
within the subunits themselves.  An alternative explanation is that lower charge states are 
already quite compact at 300 K, hence the relative decrease appears less extensive.  
Upon exposure to higher temperature, the total change for the lower charge state is 
relatively low whereas higher charge states with marginally larger CCS at 300 K, 
collapse to the same extent as lower charge states; however, the relative change observed 
is greater.   
 
4.3.4 Broadening of the CCSD width as an indicator of multiple closely 
related conformational families  
The CCS discussed in the previous section were the median CCS.  When acquiring IM 
data, one does not simply record a narrow peak corresponding to a precise CCS value, 
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especially when dealing with large multimeric protein complexes, as can be seen in 
Figure 4.6.  The CCSD derived from the experimental ATD provide details on protein 
flexibility and the amount of closely related or interconverting conformations as had 
been shown for immunoglobulins in Chapter 3.  In Figure 4.8 the baseline width of the 
CCSD for all four protein complexes is plotted versus buffer gas temperature ranging 
from 300 K to 550 K.  It is clearly visible, that the higher the charge state, the broader 
the CCSD becomes and the width also varies with the temperature.   
For the 13+ charge state of TTR, the CCSD becomes narrower at temperatures between 
350 K and 450 K (Figure 4.8a).  This correlates with the decrease in the median CCS 
associated with structural compaction.  As the complexes attempts to adopt the most 
compact structure, a limited range of conformational combinations is reflected by a 
narrow CCSD.  The width of the other two charge states fluctuates slightly within the 
discussed temperature range.  At 475 K, a temperature near TTR’s TGPD at which 50 % of 
the complex has dissociated, the CCSD of all three charge states increases significantly 
and nearly doubles for the 13+ charge state.  As the complex dissociates, the protein 
subunits unfold prior to their ejection.  After crossing the temperature associated with the 
dissociation energy barrier, the CCSD begins to decline again (at 500 K).  
Unlike TTR, the CCSD of SAP pentamer does not decrease within the 350 K and 400 K 
range (Figure 4.8b).  The CCSD for the 22+ and 24+ charge states increases gradually 
with temperature and peaks around 550 K i.e. near SAP’s TGPD.  Due to the instrument 
limitations, it was not possible to perform experiments at higher temperatures to 
determine the CCSD widths at temperatures much higher than TGPD energy barrier.  The 
26+ charge state behaves somewhat differently and a decrease in CCSD width is 
observed at 450 K.  As 26+ charge state is the most prone to unfolding, it can be 
speculated that it reaches the dissociation energy barrier at lower temperature after which 
a decrease in CCSD is observed.  It has been shown by Hall et al.33, that lower energies 
in CID experiments are required for higher charge states of SAP to induce unfolding.   
The CCSD width of avidin lower charge states (15+ and 16+) experience narrowing of 
the CCSD at 350 K and 400 K, similarly to TTR (Figure 4.8c).  Past the TGPD energy 
barrier and the maximum CCSD width, the values begin to decline.  The highest charge 
state (17+) CCSD width does not decrease significantly until passing the TGPD barrier.   
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Figure 4.8  Baseline width of collision cross section distributions (CCSD) of (a) TTR, (b) even 
charge states of SAP (c) avidin, and (d) conA acquired at buffer gas temperatures ranging from 
300 K to 550 K.  It is shown, how the CCSD width is dependent on the charge state with higher 
charge states having broader CCSD.  The width of CCSD changes significantly with the 
temperature of analysis environment, as well.  In the TTR plot (a), CCSD width data points at 
475 K for 13+ and 14+ are overlapping; as are CCSD width data points at 500 K for all TTR 
charge states. 
 
All conA charge states experience mostly gradual broadening of CCSD (Figure 4.8d).  
This increase becomes steeper at temperatures above 450 K, and values gently decline 
pass the TGPD of conA. 
The observed broadening of the CCSD along with increasing buffer gas temperature is 
an indicative for presence of multiple closely related conformers produced upon complex 
dissociation.  For all four complexes, it was noted that the higher the charge state, the 
broader the CCSD becomes and the width also varies with the temperature of buffer gas.  
Some of these differences should be attributed to diffusion; however, temperature i.e. 
amount of energy supplied, plays the most important role in the observed CCSD trends.  
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At 350 K and 400 K, the CCSD either slightly decreases or remains almost constant.  At 
these temperatures, each protein complex is losing its quaternary structure, collapsing 
into its internal cavity, adopting a minimum energy gas phase conformation.  The 
structure becomes ‘locked’ and has minimum number of conformers present.  When the 
subunits begin to unfold at 450 K and higher temperatures, there is now a significant 
increase in the CCSD width.  Various subunits are unfolding and/or remaining collapsed 
to a diverse extent, this results in many closely related conformational families.  Pagel et 
al. reported on the presence of five intermediate conformers of TTR at various CID 
activation energies.32  After reaching the TGPD energy barrier and the widest CCSD, the 
values begin to decline.   
 
4.3.5 The TID mechanism might be adopting a more ‘atypical’ 
dissociation route as the analysis temperature increases 
 
Ejection of a highly charged monomer, initial collapse of the complex structure followed 
by subunit unfolding and presence of unfolding intermediates reflected by broad baseline 
CCSD are all supportive of the ‘typical’ dissociation route.34  An interesting observation 
was made, as the analysis temperature is increased during the VT-(IM)-MS experiment, 
the average charge state (zave) of the ejected monomer decreases accordingly.  The zave 
values for all four complexes were calculated across temperatures at which the 
dissociation into subunits is observed i.e. 450 – 550 K for TTR, avidin and conA and 
475 – 550 K for SAP (Figure 4.9).  The zave decreases from 8.8 ± 0.3 to 7.9 ± 0.1 for 
TTR (Δz = 0.91), from 10.6 ± 0.1 to 8.6 ± 0.01 for avidin (Δz = 2.01), from 18.8 ± 0.2 to 
12.8 ± 0.06 for con A (Δz = 6.06) and from 13.26 ± 0.23 to 12.00 ± 0.01 for SAP (Δz = 
1.27).  The charge of conA monomers undergoes greatest change; however, this value is 
likely affected by the presence of monomeric conA species existing already at the 
physiological conditions.  Nevertheless, dissociation of all four complexes at increasing 
temperature results in decreased zave suggesting that the process might be adapting more 
‘atypical’ dissociation route.35,36  Lower zave would be reflective of less asymmetrical 
charge partitioning during the charge migration as the monomer experiences less 
unfolding.  Additionally, the median CCS of high charge state monomers were found to 
be smaller at 500 K than median CCS at 475 K (Figure 4.7, Appendix 5).  It can be  
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Figure 4.9  The average charge state (zave) of the ejected monomer of TTR (green), SAP (purple), 
avidin (grey) and conA (red) versus buffer gas temperature (in K).  zave is noted to decrease at 
higher buffer gas temperatures suggesting that the dissociation mechanism might be on a 
route to resembling SID-like dissociation at very high temperatures. 
 
speculated that at the higher buffer gas temperatures, the dissociation process occurs at a 
shorter time scale leading to ejection of slightly less unfolded monomer with lower zave, 
especially for highly charged species where the dissociation energy barrier is lower.33,34   
 
Moreover, baseline width of CCSD of the ejected monomer decreases at higher 
temperature.  Figure 4.10 presents CCSD of the ejected TTR monomers with charge 
states 7+, 8+ and 9+ at 475 K and 500 K.  It can be clearly seen how the CCSD becomes 
narrower at 500 K in comparison to CCSD at 475 K, especially for the 8+ and 9+ charge 
states.  Narrower CCSD indicate a lesser amount of conformationally related species 
present; here in particular, a lesser amount of monomers unfolded to a various extent. 
 
Currently, the upper temperature working range of the MoQToF instrument is limited to 
about 550 – 600 K, nevertheless it would be interesting to perform experiments at buffer 
gas temperatures above 550 K to determine whether: (a) the zave of the ejected monomer 
decreases further as the analysis temperature raises – suggestive of more symmetrical 
charge partitioning during charge migration, (b) the CCS of the ejected monomer 
decreases further as the analysis temperature raises – suggestive of ejection of slightly  
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Figure 4.10  Collision cross section distributions (CCSD) of the 7+, 8+ and 9+ ejected TTR 
monomer at 475 K and 500 K.  The width of CCSD becomes narrower at 500 K in comparison to 
CCSD width at 475 K.  
 
less unfolded monomer, (c) the width of the CCSD decreases further as the analysis 
temperature raises – suggestive of decreased number of conformationaly related 
monomeric species.  Testing these hypotheses would prove additional evidence for the 
TID dissociation mechanism being temperature dependent.  If all three assumptions 
discussed above were to be confirmed experimentally, it could be speculated that TID 
dissociation initially follows the ‘typical’ dissociation route and adapts more ‘atypical’ 
dissociation route as the analysis temperature in increased. 
 
4.3.6 Insights into strength of non-covalent interactions between 
protein subunits from VT-IM-MS experiments  
Multimeric protein complex dissociation is highly controlled by the strength on the non-
covalent interactions between the subunit interfaces.51  The increase of TGPD with 
increasing molecular mass of the complex was a clear trend observed from VT-MS 
experiments.  The size of the multimeric protein complex will correlate somewhat to the 
interface area in-between the subunits.  Since the TGPD was observed to be influenced by 
the molecular weight; here, two proteins relatively close in mass with similar TGPD: TTR 
(55 kDa, TGPD = 468.2 ± 0.7) and avidin (64 kDa, TGPD = 474.0) are compared.  The 
average interface surface area per subunit, average number of hydrogen bonds per 
subunit and average number of possible salt bridges per subunit was calculated using the 
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‘Protein interfaces, surfaces and assemblies’ service PISA at the European 
Bioinformatics Institute for structures of TTR (PDB: 1BMZ, 1DVQ, 3U2I) and avidin 
(PDB: 1AVE, 1VYO, 1RAV) deposited in the Protein Data Bank.  The average values 
based on three structures for each protein complex are reported in Table 4.2.   
The average interface surface area for each TTR subunit was calculated to be 17.11 ± 
2.28 nm2 with an average of 20 ± 2 hydrogen bonds and 1 ± 1 possible salt bridge.  
Values determined for an avidin subunit were slightly higher, with an interface surface 
area of 25.63 ± 0.50 nm2, average of 36 ± 8 hydrogen bonds and 7 ± 5 possible salt 
bridges.  The large standard deviation on the number of hydrogen bonds and possible salt 
bridges originate from variety in the structures examined.  Despite a higher number of 
non-covalent interactions between the subunits, avidin unfolds to a lesser extent near the 
TGPD prior to ejection in comparison to TTR.  The most abundant, 14+ charge state of 
TTR has increased its CCS by 25.0 % at 475 K in comparison to avidin with only 15.9 % 
increase in CCS of the 15+ charge state.   
 
Table 4.2   Comparison of TTR’s and avidin’s, dissociation temperature TGPD, average interface 
surface area per subunit, average number of hydrogen bonds per subunit, average number of 
possible salt bridges per subunit and the percentage increase in the CCS at 475 K.   
 
Protein complex TTR avidin 
Mass / kDa 55 64 
TGPD / K 468.2 ± 0.7 474.0 
Average interface surface 
per subunit / nm2 
17.11 ± 2.28 25.63 ± 0.50 
Average number of H-
bonds per subunit 
20 ± 2 36 ± 8 
Average number of salt 
bridges per subunit 
1 ± 1 7 ± 5 
Percentage increase in the 
CCS at 475 K 
[13+]   +22.5 % 
[14+]   +25.0 % 
[15+]   +25.4 % 
 
[14+]     +8.7 % 
[15+]   +15.9 % 
 
Avidin has a larger area of the interface between subunits and more non-covalent 
interactions per subunit than TTR.  Interestingly, the extent of unfolding is lesser by 
approximately 10 % in contrast to TTR ions carrying the same amount of charge.  More 
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non-covalent interactions might hinder extensive unfolding and keep the subunit 
compact prior to reaching the dissociation energy barrier.  At the same time, fewer 
interactions and extensive unfolding of TTR subunits, suggests that the non-covalent 
interactions between the subunits must be stronger holding them within the complex 
prior its ejection.  Measuring the extent of unfolding with VT-MS experiments could 
provide insights into the strength of non-covalent interactions between subunits when 
high resolution data is not available/possible.  
 
4.4 Conclusions 
VT-MS and VT-IM-MS methodology was applied to study four multimeric protein 
complexes, their dissociation and related conformational change at elevated temperatures 
ranging from 300 K to 550 K.  The presented data pinpoints the importance of analysis 
temperature for protein structural and thermal stability studies, and highlights the 
difference between gas phase and solution thermal stability.  VT-MS was employed to 
probe dissociation of large multimeric protein complexes and as such decouple gas phase 
complex dissociation temperature (TGPD) from solution melting temperature (Tm).   
VT-IM-MS provided insights into conformational changes occurring during the TID 
complex dissociation process.  Complexes were found to undergo an initial compaction 
at 350 K and 400 K noted by a decrease in median CCS.  At these temperatures, each 
protein complex is losing its quaternary structure, collapsing into more compact 
structures with lower number of conformational possibilities present as reflected by 
narrow CCSD profiles.  Subsequent unfolding and eventual release of a monomer at 
temperatures above 450 K were marked by significant increase in median CCS and 
widening of CCSD associated with a series of unfolding events the protein complexes 
undergo prior to reaching the dissociation energy barrier.  The degree of compaction and 
unfolding was found to vary across charge states; however, a common trend was seen for 
the higher charge states to experience greater degree of extension and having lower 
energy requirement for unfolding initiation.  
The TID mechanism was observed to initially proceed via the so called ‘typical’ (CID) 
dissociation route i.e. a release of a highly charged unfolded monomer as proven by VT-
MS dissociation profiles and extent of unfolding determined via VT-IM-MS.  
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Interestingly, it was found that at higher analysis temperature, slightly less unfolded 
monomer with lower average charge is ejected from the complex, suggesting that the 
TID dissociation process might be adapting more ‘atypical’ dissociation route.  More 
experiments at temperatures above 550 K need to be carried out to confirm this theory.  
Nevertheless, correlating TID temperatures and CID energies could serve as a 
framework for thermal stability screening to be performed on instruments with CID 
capabilities.  The TID experiments provide fundamental insights into the protein folding, 
subunit interactions and fundamental thermodynamic parameters. 
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Probing Antibody Thermal Stability 
with VT-(IM)-MS 
 
Aggregation of biologics such as mAbs can not only affect the efficacy of the therapeutic 
treatment but can also induce adverse effects.  Efforts are made to shift the equilibrium 
away from the aggregation-prone state by increasing the thermodynamic stability of the 
native state protein and improving its conformational stability.  Here, the thermal 
stability of three intact IgGs and two Fc-hinge fragments is probed using VT-MS and 
VT-IM-MS.  These proteins show similar collapse-unfold type of mechanism as non-
covalent complexes investigated in the previous chapter.  The differences in the extent of 
collapse and unfolding are rationalized based on properties attributed to different IgG 
subclasses and their thermal stability. Moreover, VT-IM-MS shows to be promising tool 
for thermal stability comparative studies for proteins of therapeutic interest.  
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5.1 Introduction 
 
Handling of chemical and physical instabilities is one of the obstacles in the 
development of protein based therapeutics such as mAbs and their derivatives.1-8  Along 
with analytical and regulatory aspects, biophysical characteristics such as stability are 
crucial selection criteria for mAbs designed for clinical use.  During manufacturing, 
purification, formulation and storage, antibodies behave differently in terms of their 
sensitivity to pH or temperature, aggregation propensity and vulnerability to 
degradation.9-11  Low stability of mAbs may be problematic with regards to long-term 
storage or consistency of production.  The most serious result of physical instability is 
protein aggregation, which can affect not only the efficacy of the therapeutic treatment 
but also may induce adverse effects such as immunogenicity.12-15  Efforts are made to 
enhance stability of mAbs for example through reengineering of the hinge region16, 
domain exchange17, introduction of specific mutations in the CH3 domain18-20 or within 
the inter LC-CH1 DSB network21. 
 
Thermal stability is increasingly accepted as a convenient measure of global stability.  
The temperature induced unfolding of mAbs measured by differential scanning 
calorimetry (DSC) has become an essential tool used for monitoring production 
consistency, clone selection, protein structure characterisation and formulation 
development.22  A number of studies have been published investigating IgG unfolding 
upon exposure to physical stress (heat) and/or chemical stress (solution pH).  These 
studies are briefly overviewed below.  
 
5.1.1 Temperature induced unfolding patterns in IgGs  
 
One of the structural characteristics of an immunoglobulin molecule is its organisation 
into domains.  An IgG molecule consists of 12 similar in size globular domains – 8 
formed by the heavy chains and 4 by the light chains, as described in Chapter 3.  The 
stability of such multidomain proteins, is commonly probed with DSC, while the 
secondary structure content can be investigated with circular dichroism (CD) 
spectroscopy; providing insights into the global structure as well as behaviour of 
unfolding domains.  Unfolding of IgGs is a complex process, where the denatured state 
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is obtained from the native state via several intermediate states as the domains often 
unfold independently in a non-cooperative manner.23,24   
 
The possibility of partly denatured intermediate states of IgGs upon thermal denaturation 
was first proposed by Rowe and Tanford in 1973.25  Later it was confirmed that Fab and 
Fc fragments in IgGs are thermodynamically independent domains.26  One to three major 
transitions are generally observed in the DSC thermogram, correlated with independent 
unfolding of individual domains: CH2 and CH3 domains of the Fc fragment and the Fab 
domain.9,22,23,27,28  Previous studies showed that CH2 domain of IgG1 undergoes 
structural transitions at lower temperature compared to the CH3 domain.22,29,30  
Tischenko et al.  rationalised this phenomenon in IgG1 molecules based on the strength 
of interdomain interactions; strong interactions between CH3 domains form a 
cooperative block, while CH2 interactions are mediated by the N-linked oligosaccharides 
(at Asn279 position).29  Furthermore, deglycosylation of IgGs was found to result in a 
significant destabilisation of the CH2 domain and lowered the temperature of its melting 
but had no effect on the CH3 domain stability.22,31-36  Kenmert et al. referred to 
thermally-treated  IgG-Fc structure as non-native alternatively folded state rather than a 
molten globule state.37   
 
IgG1-Fc fragment unfolding displays a bimodal DSC distribution, the first transition has 
been associated with CH2 domain unfolding, the second transition represents CH3 
domain melt, while the stability of Fab fragment is significantly affected by the sequence 
of the variable domain.22  Studies of isolated Fab fragments had shown that diversity 
within variable antigen binding domains is responsible for stability variations among 
IgGs of identical subclass; while some Fab fragments may be exquisitely stable others 
may be relatively unstable.4,6,31,38-42  Sometimes, Fc fragment and Fab fragment 
transitions may be overlapping disabling rigours thermodynamic analysis of the 
individual transitions.23   
 
A number of studies have demonstrated that IgG1 is the most thermally stable human 
subclass followed by IgG2 and IgG4.10,31  A study performed on mAbs of the same 
antigen binding specificity had shown lower conformational stability of the IgG4 in 
comparison to IgG1, resulting in increased levels of soluble aggregates formed.43  At 
neutral pH, two transitions were observed for IgG1, while only a single one was noted 
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for IgG4.  Reported results indicate that CH2 and CH3 domains unfold simultaneously 
and weaker non-covalent interactions between the CH3 domains know to exist within 
IgG4 subclass, may be responsible for its lower melting temperature.36,43  Additionally, 
dependent on the nature of denaturation the process may follow different pathways; it 
was reported that the Fab fragment is more sensitive to the thermal stress, whereas the Fc 
fragment is strongly affected by lowering of the solution pH.23   Nevertheless, upon 
application of either physical or chemical stress, a significant fraction of the secondary 
structure has been reported to remain intact.23   
 
Overall, in each antibody subclass, the amino acid sequence of the variable region and 
solution conditions affect the unfolding pattern, the number of transitions and their onset 
temperature observed during heating.31,43  Stability variations between antibodies of the 
same subclass are derived from differences in variable domain sequence.  Introducing 
point mutations or reengineering the DSB network are both methods that have been used 
to increase stability of mAbs making them less prone towards aggregation.16,23  For 
example, Peters et al. report on the generation of a more thermally stable IgG4 by 
altering the inter LC-CH1 DSB arrangement to mimic that of IgG1; what resulted in 
increased Fab fragment stability by up to 6.8 °C.21  In this chapter, three intact mAbs of 
the same antigen binding specificity (IgG1, IgG4 and IgG4 with inserted IgG1 upper and 
core hinge) as well the two Fc-hinge fragments (IgG1 and IgG4) are investigated with 
VT-MS and VT-IM-MS.  Such experiments provide insights to thermal stability along 
with conformational information and may benefit comparative thermal stability studies 
of proteins of therapeutic interest.    
  
 
5.2 Methodology  
 
5.2.1 Sample preparation 
 
Human intact IgG1 ‘C’, IgG4 ‘C’, and IgG4 ‘C’ with IgG1 hinge as well as IgG1 Fc-
hinge and IgG4 Fc-hinge fragments were provided by UCB Pharma; protein samples 
were expressed and purified by Dr Shirley Peters.  The upper and core hinge in IgG4 has 
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been replaced with IgG1 upper and core hinge as shown below, to enhance thermal 
stability of the mAb:  
      upper hinge   core    lower hinge  
IgG1     EPKSCDKTHT CPPC  PAPELLGGP 
IgG4    ESKYGPP  CPSC  PAPEFLGGP 
IgG4 with IgG1 hinge   EPKSCDKTHT CPPC  PAPEFLGGP 
 
The complete amino acid sequences are available in the Appendix 3.  Samples were 
stored in 50 mM sodium acetate (NaOAc): 125 mM sodium chloride (NaCl) at 4 °C.  
IgG1 ‘C’, IgG4 ‘C’, and both of the Fc-hinge fragment samples were diluted to a 
concentration of 30 µM, the stock 6 µM sample the IgG4 ‘C’ with IgG1 hinge was 
used.  On the day of analysis, the buffer was exchanged to 100 mM ammonium acetate 
(Fisher Scientific, Loughborough, UK) pH 6.8, using micro Bio-Spin Chromatography 
columns (Micro Bio-Spin 6 Columns, Tris) following the instructions specified by the 
manufacturer.  The desalting procedure was performed twice to achieve desired sample 
purity.  High purity water was obtained from an Arium 611 water purification unit 
(Sartorius, Göttingen, Germany) fitted with a 0.2 µm filter.   
 
 
5.2.2 Variable temperature mass spectrometry and variable 
temperature ion mobility mass spectrometry  
 
The samples were ionised using positive nESI as described in Chapter 2, section 2.1.2.  
The IM-MS data were acquired on the MoQToF, quadrupole time-of-flight mass 
spectrometer modified in-house to include a 5.1 cm drift cell, as detailed in section 
2.2.1.44  The voltages along the mass spectrometer were adjusted to preserve native like 
structures.  The capillary potential was held at 1.5 - 1.8 kV, the source temperature was 
set to 80 °C, and the cone voltage was set to 80 V.  The injection energy used was 
between 30 and 33 V.  Other instrumental settings for the MoQToF IM mass 
spectrometer are listed in Chapter 2, Table 2.3.  The drift cell was filled with helium as 
the buffer gas at a pressure of 3.7 – 3.8 Torr and the pressure was measured using a 
capacitance manometer (MKS Instruments, UK); the precise pressure was recorded for 
each and every drift voltage and used in the calculations of CCS.  Ion mobility 
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experiments were carried out at drift cell temperatures of 300 K, 350 K, 360 K, 400 K, 
475 K, 500 K and 550 K.  The cell was heated via tantalum wire wound ceramic heaters 
located in both the cell body (8 heaters) and in the end cap (2 heaters) driven by variable 
transformers (Variacs).  The temperature of the drift cell was monitored using three k-
type thermocouples and recorded for each data set.  The electric potential across the cell 
was varied from 60 to 20 V with measurements taken at six different drift voltages.  The 
rotationally-averaged collision cross-sections (CCS) were determined from a plot of 
arrival time versus P / T and the CCSD were determined as described in Chapter 2, 
section 2.2.1.4.  Data was processed using Mass Lynx V.4.1 Build 10, Microsoft Excel 
2003 and Origin 8.5.1 graphing software (OriginLab, Northampton, MA, USA).   
 
 
5.3 Preliminary Results and Discussion  
 
5.3.1 VT-MS of the intact mAbs 
 
VT-MS experiments were performed on three intact antibodies (denoted here as ‘C’) of a 
different antigen binding specificity from the mAbs studied in Chapter 3.  Mass spectra 
of (a) IgG1 C, (b) IgG4 C and (c) IgG4 C with IgG1 hinge are shown in Figure 5.1.  The 
upper and core hinge in IgG4 has been replaced with that of IgG1 to enhance thermal 
stability of the mAb.  Solution based melting temperatures (Tm) were 93.3 °C, 84.4 °C 
and 93.3 °C for IgG1 C, IgG4 C and IgG4 C with IgG1 hinge, respectively.45  30 µM 
(IgG1 and IgG4) and 6 µM (IgG4 with IgG1 hinge) protein samples in 100 mM 
ammonium acetate at pH 6.8 were ionised using nESI and data were acquired on the in-
house modified IM-MS instrument (MoQToF) shown in Figure 2.3.  In order to preserve 
the complexes’ quaternary structure, key source parameters were optimized, in particular 
the source pressure, capillary, sample and extractor cone and injection energy voltages.  
The temperature of the drift cell helium gas was raised via ten tantalum wire wound 
ceramic heaters driven by two external variable transformers and the temperature was 
closely monitored by the capacitance manometer.  Mass spectra were recorded at seven 
discrete temperatures in a range of 300 K to 550 K.  Measurement at 360 K (87 °C) was  
Chapter 5                                                                                                                                          VT-IM-MS: IgGs 
 
 
- 159 - 
 
 
Figure 5.1   nESI mass spectra of intact (a) IgG1 ‘C’, (b) IgG4 ‘C’ and (c) IgG4 ‘C’ with IgG1 hinge 
in 100 mM ammonium acetate at pH 6.8 acquired on the MoQToF mass spectrometer at buffer 
gas temperature of 300 K, 350 K, 360 K, 400 K, 475 K, 500 K and 550 K.   
 
acquired to provide more insights into IgG behavior near the solution-phase Tm.  The 
time ions spend in the temperature controlled region of MoQToF is dependent on the 
ions’ mass, charge and the electric potential applied across the drift cell.  In the 
experiment at 300 K presented here, this time varied from 2.2 ms to 5.1 ms for an intact 
IgG with z = 24+ charge, where the potential difference across the drift cell ranged from 
60 to 15 V.  The experimental time frame does vary somewhat with temperature, 
however, this was minimised by adjusting the pressure as a function of temperature to 
match the drift time at 300 K. 
 
Mass spectra of three intact IgGs at progressively higher temperatures are shown in 
Figure 5.1.  Peaks corresponding to the intact IgG are observed in the ~5800 – 7200 m/z 
range; with the charge state envelope ranging from 21+ to 26+ charge state, centred at 
the 24+ and 23+ charge states.  Upon the increase in drift gas temperature no 
dissociation into subunits or fragmentation of peptide chains is observed.  The chains of 
IgG1 and IgG4 with IgG1 hinge are covalently linked via DSB, hence no dissociation is 
anticipated.  The IgG4 isotype, on the other hand, is capable of forming intra-chain DSB 
in the hinge region leading to dissociation into two half molecules; however, this was not 
noted even at 550 K.  Furthermore, the charge state distribution (CSD) remains invariant 
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at the range of buffer gas temperatures investigated.  At 300 K, IgG1 (a) and IgG4 (b) 
are centred on 24+ and 23+ charge state, while CSD of IgG1 remains constant thought 
the experiment within the 300 – 550 K range, the CSD of IgG4 slightly shifts towards 
23+ charge state at higher temperature.  The CSD of stabilized IgG4 with IgG1 hinge (c) 
remains centred on 24+ charge state thought the experiment. 
 
An interesting feature observed in the mass spectra at elevated buffer gas temperatures is 
the significant narrowing of peaks and shift towards lower m/z, attributed to more 
efficient stripping of salt adducts.  Similar effect has been noted for the non-covalent 
complexes investigated in Chapter 4.  Figure 5.2 shows a close up of the 24+ charge 
state of IgG4 species, which displayed the highest degree of salt clean up, particularly at 
500 K and 550 K.  In combination with in-source salt clean up, VT-MS could serve as a 
method for obtaining an enhanced resolution for proteins difficult to desolvate, such as 




Figure 5.2   Zoom at the 24+ charge state of IgG4 ‘C’ in 100 mM ammonium acetate at pH 6.8 
acquired on the MoQToF mass spectrometer at buffer gas temperature of 300 K, 350 K, 360 K, 
400 K, 475 K, 500 K and 550 K, displaying an enhanced removal of salt adducts at elevated 
buffer gas temperature.     
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5.3.2 VT-MS of the IgG Fc-hinge fragments  
 
VT-MS experiments were also performed on the Fc-hinge fragments of IgG1 and IgG4 
subclasses.  A core hinge mutation S241P was introduced to the IgG4 Fc-hinge fragment 
to prevent formation of the intra-chain DSB and subsequent dissociation of the heavy 
chains.  Mass spectra of 30 µM Fc-hinge fragments in 100 mM ammonium acetate at pH 
6.8 in the 300 K – 550 K temperature range, presented in Figure 5.3, were acquired in a 





Figure 5.3   nESI mass spectra of (a) IgG1 ‘C’ Fc-hinge fragment and (b) IgG4 ‘C’ Fc-hinge 
fragment in 100 mM ammonium acetate at pH 6.8 acquired on the MoQToF mass spectrometer 
at buffer gas temperature of 300 K, 350 K, 400 K, 475 K, 500 K and 550 K.   
 
 
Fc-hinge fragments of both isotypes exhibit narrow CSD (~m/z 3600 – 4500) centred on 
the 13+ charge state.  Similarly to the intact IgGs, Fc-hinge fragments display 
preservation of CSD at progressively increasing buffer gas temperature and lack of 
dissociation into subunits.  At 300 K, IgG4 m/z peaks (b) are significantly broader in 
comparison to the IgG1 (a), while their resolution somewhat improves at higher buffer 
gas temperatures.  
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5.3.3 VT-IM-MS of the intact mAbs 
 
Structural changes due to increased temperature of analysis environment of three intact 
mAbs were investigated.  VT-IM-MS experiments were carried out at seven discrete 
temperatures ranging from 300 K to 550 K.  CCSD landscapes and their transformations, 
derived from arrival time distributions (ATD) of IgG1, IgG4 and IgG4 with IgG1 hinge 
acquired at a range of temperatures are presented in Figure 5.4.  Despite the lack of 
dissociation, structural transformation trends observed for IgGs are similar to those 
reported for non-covalent complexes studied in Chapter 4.  IM data acquired at 350 K, 
360 K and 400 K show a minor decrease in the CCS of IgG1 and IgG4 in comparison to 
CCS determined at 300 K, suggesting a structural collapse.  The extent of the collapse 
was noted to be greater for higher charge states.  As the buffer gas temperature is 
increased to 475 K and above, CCS increase as IgG chains begin to unfold.  
Furthermore, above 400 K CCSD profiles become significantly broader suggesting 
presence of closely related unfolding intermediate states.  Interestingly, no decrease in 
the CCS associated with a thermally induced collapse was observed for the IgG4 with 
IgG1 hinge.  This re-engineered mAb mimics thermal stability of IgG1 in solution (Tm = 
93.3 °C); but does not display the same denaturation pathway in the gas-phase.  
Moreover, the CCSD of the hybrid antibody presents over an even broader 
conformational landscape at temperatures above 300 K.  This data suggests that the 
increased thermal stability correlates to higher structural flexibility.  Another explanation 
is that the re-engineered hinge is less able to preserve a compact configuration of this 
hybrid mAb. 
 
As discussed in Chapter 4, the decrease in the CCS is associated with loss of structure 
and solution Tm.  Figure 5.5 shows CCSD of the most abundant (24+) charge state of all 
three IgGs along with the percentage change in the median CCS with respect to CCS at 
300 K.  It can be seen that the greatest decrease in the CCS, hence the maximum 
collapse, is detected at a higher temperature for IgG1 (400 K) than for IgG4 (360 K).  
This correlates well with the solution phase studies, where IgG1 was found to be more 
thermally stable than IgG4.45  Again, IgG4 with an IgG1 hinge is the outlier from the 
trend as no compaction reflected by a decrease in CCS was noted.  A list of median CCS 
is provided in the Appendix 6. 
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Figure 5.4   Total collision cross section distributions (CCSD) of intact IgG1 ‘C’, IgG4 ‘C’ and 
IgG4 ‘C’ with IgG1 hinge in 100 mM ammonium acetate at pH 6.8 acquired on the MoQToF mass 
spectrometer (DV = 35 V) at buffer gas temperature of 300 K, 350 K, 360 K, 400 K, 475 K, 500 K 
and 550 K.  CCSD of individual charge states have been normalised to spectral intensity.  
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Figure 5.5   Collision cross section distributions (CCSD) of the most abundant charge state 
(24+) of (a) IgG1 ‘C’, (b) IgG4 ‘C’ and (c) IgG4 ‘C’ with IgG1 hinge in 100 mM ammonium acetate 
at pH 6.8 acquired on the MoQToF mass spectrometer (DV = 35 V) at a 300 – 550 K buffer gas 
temperature range; along with percentage change in the median CCS with respect to CCS at 
300 K.  
 
 
Moreover, IgG1 undergoes greater degree of compaction in comparison to IgG4; at 
400 K up to 7.4 % decrease in median CCS of 24+ charge state is noted, compared to 
only 1.8 % decrease for 24+ charge state of IgG4 (Figure 5.5).  This behaviour might be 
related to the intrinsic flexibility of the hinge region.  The hinge of an intact IgG1 is 
know to be more flexible than that of IgG4, hence IgG1 might be capable of adopting 
more compact structures upon heat exposure.46  One would expect similar compaction 
behaviour of the hybrid mAb possessing IgG1 hinge, however, such compaction was not 
observed calling for further investigation.   
 
Worth mentioning are the differences observed in the extent of unfolding among the IgG 
subclasses at high buffer gas temperatures.  The onset of IgG4 unfolding occurs at lower 
temperature and proceeds to a greater extent (+26.6 % at 550 K) in comparison to IgG1 
(+21.6 % at 550 K).  This observation can be rationalized by the strength of non-
covalent interaction between CH3 domains of heavy chains; which is known to be 
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stronger for the IgG1 isotype.18,47-50  Strong interactions between CH3 domains of IgG1, 
hold two heavy chains tightly and prevent extensive unfolding, while weak non-covalent 
interaction between CH3 domains of IgG4 permit the dissociation of these domains 
resulting in enhanced unfolding reflected by higher CCS.  The unfolding of the hybrid 
IgG at 550 K progresses to even higher degree (+34.3 % at 550 K), suggesting that the 
unfolding could be mediated by the strength of non-convent interaction between CH3 
domains (weak non-covalent interactions between CH3 domains of IgG4) as well as the 
hinge flexibility (higher hinge flexibility in IgG1). 
 
Although, VT-IM-MS measurements performed at discrete temperatures will not 
provide an exact Tm as DSC measurements do; this method may serve as a valuable tool 
for comparative studies of mAb stability, especially when very limited amount of protein 
material is available.  Measurements taken at smaller temperature intervals near the Tm 
would certainly improve the assessment of thermal stability and provide a closer 
estimate of the gas-phase Tm. 
 
 
5.3.4 VT-IM-MS of the Fc-hinge fragments  
 
VT-IM-MS experiments were also performed on the Fc-hinge fragments of both the 
IgG1 and IgG4 subclass.  CCSD landscapes and their transformations of both Fc-hinge 
fragments acquired at a range of temperatures are presented in Figure 5.6.  Similarly to 
the intact mAbs, both fragments experience initial structural collapse at 350 K and 400 
K, followed by unfolding at higher buffer gas temperatures.  Here however, the extent of 
compaction was noted to be greater for lower charge states and higher for IgG1 Fc-hinge 
fragment in comparison to IgG4 Fc-hinge fragment.  Unfolding continues to be more 
extensive for higher charge states, similarly to intact mAbs and non-covalent multimeric 
complexes. 
 
As reported in Chapter 3, over 60 % of the 14+ charge state of the IgG4 Fc-hinge 
fragment populates the larger conformational family of the two observed (Figures 3.7 
and 5.6), as a result of destabilised interactions between the CH3 domains of the heavy  
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Figure 5.6   Total collision cross section distributions (CCSD) of IgG1 ‘C’ Fc-hinge fragment and 
IgG4 ‘C’ Fc-hinge fragment in 100 mM ammonium acetate at pH 6.8 acquired on the MoQToF 
mass spectrometer (DV = 35 V) at buffer gas temperature of 300 K, 350 K, 400 K, 475 K, 500 K 
and 550 K.  CCSD of individual charge states have been normalised to spectral intensity.  
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chains.50  In contrast, the 14+ charge state of the IgG1 Fc-hinge fragment occupies 
mainly the smaller conformational family, where CH3 domains are held tightly due to 
strong non-covalent interactions producing a more compact structure.47  The 
crystallographic study reported by Davies et al. revealed how Arg409 within CH3 
domain of IgG4, can adopt two different conformations affecting the stability of the CH3 
interface.50  One of these conformations is similar to those observed in IgG1, whereas 
the other conformation weakens the interface by disrupting the water molecule network 
resulting in reduced hydrogen bonding.  VT-IM-MS experiments show that upon 
increase of buffer gas temperature the distinction between two conformational families 
of IgG4 Fc-hinge fragment becomes less apparent.  The ‘destabilised’ conformation of 
IgG4 Fc-hinge fragment experiences unfolding to larger CCS; while the more compact 
form slowly approaches similar unfolding landscape at 500 K, possibly due to weaker 
CH3 interface interactions resulting from significantly reduced residual solvent content 
at this temperature affecting the hydrogen bond network (Figure 5.3).  At 550 K, both 
Fc-hinge fragments display similar CCSD profiles suggesting that both subclasses have 
unfolded to a comparable degree; a 29.0 % increase in median CCS was noted for the 
13+ charge state of IgG1 Fc-hinge fragment and 31.6 % increase for that of IgG4 Fc-
hinge fragment.  Unfortunately the collected data does not allow distinguishing between 
CH2 and CH3 domain unfolding and relating gas-phase behaviour of these domains to 
the solution-phase unfolding.  Experiments would have to be performed on isolated 
domains in order to compare their relative stability. 
 
The amount of thermal unfolding at high temperatures was also noted to be less 
significant for Fc-hinge fragments than for non-covalent complexes.  The extent of mAb 
fragment (54 kDa) unfolding was compared to unfolding of similar in size non-covalent 
tetramer transthyretin (TTR, 55 kDa).  Both species are composed of four folded 
domains, however while subunits of TTR are held together by non-covalent interactions, 
Fc-hinge fragments are covalently linked via the hinge (at the CH2 domains) and via 
non-covalent interaction at the CH3 domain interface.  TTR’s most abundant 14+ charge 
state experiences about 38.3 % increase in the median CCS at 500 K, while only 16.4 -
16.6 % increase in CCS is noted for the most abundant 13+ charge states of Fc-hinge 
fragments under the same experimental conditions.  At 550 K, unfolding of the Fc-hinge 
fragment was found to be closer to that of non-covalent TTR at 500 K of the same 13+ 
charge state: +29.0 % and +31.6 % at 550 K for IgG1 and IgG4 Fc-hinge fragments 
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respectively, and +26.3 % for TTR at 500 K.  The differences in the amount of external 
energy required to reach similar degree of unfolding illustrate the role of DSB of the 





Thermal stability of therapeutic proteins is a crucial aspect of drug development.  
Enhancing the stability of biologics such as mAbs is aimed to reduce aggregation and 
improve production consistency.  Variable temperature MS and IM-MS was applied to 
probe the thermal stability with respect to conformation of three intact mAbs: IgG1, 
IgG4 and thermally enhanced hybrid IgG4 with IgG1 hinge; as well as two Fc-hinge 
fragments of IgG1 and IgG4.  IgG1, IgG4 and their Fc-hinge fragments follow unfolding 
pathway similar to that of non-covalent complexes investigated in the previous chapter.   
 
Upon temperature increase to 350 – 400 K, IgG1, IgG4 and their Fc-hinge fragments 
undergo an initial compaction noted by a decrease in median CCS.  The hybrid IgG 
displayed somewhat different unfolding which did not follow any of the trends observed 
for the other two intact mAbs requiring further investigation.  For IgG1 and IgG4, the 
temperature at which the maximum collapse occurs, correlates with loss of quaternary 
structure and the solution based Tm.  Above 400 K, unfolding of mAb chains was marked 
by a significant increase in median CCS and widening of CCSD associated with a series 
of unfolding events.  Broader conformational landscapes of the hybrid mAb at 
temperatures above 300 K, suggest higher structural flexibility contributing to increased 
thermal stability.  Diversity in the extent of collapse and unfolding were rationalised by 
differences in the hinge flexibility and strength of non-covalent interactions at the CH3 
domain interface among IgG subclasses.   
 
This initial investigation still leaves a lot of questions with regards to the hybrid IgG.  
Nevertheless, VT-IM-MS has been demonstrated as a promising tool for probing the 
thermal stability of biologics.  As the stability of Fab fragment can greatly influence the 
stability of an intact IgG, if would be worthwhile to apply this method to study mAbs of 
different antigen binding specificity. 
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Application of MS, IM-MS and HDX-
MS for Probing Mechanisms of 
Allosteric Inhibition of Enzymes  
 
Natural feedback allosteric inhibition of metabolic enzymes is one of nature’s ways 
of regulating biochemical pathways.  Here, MtATP-phosphoribosyltransferase 
(MtATP-PRT) is investigated, an enzyme catalysing the first step of the biosynthesis 
of L-histidine in Mycobacterium tuberculosis.  Native MS is applied to provide 
insights into L-histidine binding and the inhibition mechanism of MtATP-PRT.  IM-
MS and analytical ultracentrifugation (AUC) are employed to probe conformational 
changes induced by environmental factors and ligand binding.  Moreover, these 
structural changes are mapped with hydrogen deuterium exchange (HDX) MS. 
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6.1 Introduction  
 
6.1.1 Enzyme activity and inhibition  
 
Enzymes are a category of globular proteins which act as a catalyst in the biochemical 
reaction in the living organisms.  Regulation of these enzymatic activities is crucial for 
proper functioning of cells.    An enzyme’s structure is highly important for its activity 
and may be affected by external factors such as temperature or pH.  Additionally, 
enzyme activity can be influenced by the binding of other molecules such as cofactors 
(non-protein element - metal cation or small organic molecule), activators (molecules 
which increase enzymes activity) or inhibitors (molecules which decrease enzymes 
activity). 
 
The active site of an enzyme (indicated in light blue in Figure 6.1) is where the substrate 
i.e. the reacting molecule binds, and lowers the reaction activation energy resulting in 
product formation at an increased reaction rate.  The activity of the enzyme can be 
blocked or decreased by an inhibitor binding at the active site (competitive inhibition) or 
at the allosteric site (allosteric inhibition) (Figure 6.1).   Binding at the allosteric site 
often induces conformational changes to the enzyme structure that prohibit substrate 
from binding and subsequent product formation.  The ability to undergo such changes 
resulting from ligand binding to sites other that the active site is a powerful way of 
regulating protein function.  Naturally occurring allosteric sites in metabolic enzymes 
controlled through feedback effectors are nature’s way of controlling biochemical 
pathways. 
 
Studying feedback allosteric inhibition mechanisms can not only prove to be useful for 
enzyme regulation but these natural inhibitors may also serve as templates for 
chemically diverse, small molecule inhibitors sought after as regulators for synthetic 
biology, as therapeutics for diseases or as probes in both chemical genetics and chemical 
biology.1-3   Additionally, the allosteric sites become attractive drug targets when the 
active site of an enzyme are “not targetable” or have poor “ligandability”.4-6  Some 
examples of important enzymes that have been successfully targeted at their allosteric  
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Figure 6.1  In their active form, enzymes act as a catalyst in biochemical reactions.  Binding of a 
substrate (dark blue) to an active site (light blue) leads to eventual product formation at an 
increased reaction rate.  Enzymes can be inactivated by binding of an allosteric inhibitor (red) 
to an allosteric site (pink), inducing conformational changes and stopping product formation by 
disabling substrate binding.  Image reproduced from Purves et al.7  
 
 
site include pyruvate kinesin8, mitotic kinesin9 or the Cdc34 ubiquitin-conjugating 
enzyme10.  A classic example of an allosterically regulated enzyme is MtATP-
phosphoribosyltransferase (MtATP-PRT).   
 
6.1.2 Mycobacterium tuberculosis ATP-phosphoribosyltransferase 
(MtATP-PRT): function and structure  
 
 
MtATP-PRT belongs to the phosporibosyltransferase superfamily of enzymes which 
catalyse the condensation of 5-phospo-alpha-D-ribose-1-diphosphate with nitrogenous 
bases in presence of metal ions.11  MtATP-PRT catalyses the first step in the 
biosynthesis of L-histidine in Mycobacterium tuberculosis i.e. condensation of adenosine 
triphosphate (ATP) with phosphoribosyl pyrophosphate (PRPP) in the presence of Mg2+ 
cation.  Being a feedback allosterically regulated enzyme, it is inhibited by the end 
product of the pathway, L-histidine.12-14  Due to its essentiality in the cell, MtATP-PRT 
has been suggested as a potential target for the development of novel anti-tuberculosis 
agents, an infectious disease affecting over 2 billion people and responsible for 2 million 
deaths a year.13,15  No priori toxicity associated with potential inhibitors has been 
suggested as this pathway is absent in humans, making it a suitable drug target.12 
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In terms of the tertiary and quaternary structure, two types of ATP-PRT exist.  The more 
abundant homo-hexameric form encountered in bacteria, fungi and plants13,16 and the 
hetero-octameric form present in some bacteria.17,18  MtATP-PRT is a homohexameric 
protein with a total mass of about 190 kDa.12  A cartoon representation of MtATP-PRT 
x-ray crystal structure along the 3-fold axis (Figure 6.2a) and 2-fold axis where the C-
terminus is shown in the front plane (Figure 6.2b) is illustrated below.13   
 
 
Figure 6.2  Graphical representation of the hexameric apo MtATP-PRT x-ray crystal structure 
along the (a) 3-fold symmetry axis and (b) 2-fold symmetry axis.  Data available in PDB consists 
of MtATP-PRT dimer (PDB:1NH7); here the structure has been assembled into a hexamer using 
the online ‘Protein interfaces, surfaces and assemblies’ service PISA at the European 
Bioinformatics Institute website.19,20  (c) MtATP-PRT monomer consists of three contiguous 
domains indicated with teal circles: I, II and III (PDB:1NH8).  Location of the allosteric site (with 
L-histidine) and the active (with AMP) site are indicated with black arrows.  
 
 
A crystallographic study by Cho et al.13 revealed MtATP-PRT monomer as an elongated 
molecule composed of 10 α-helices and 15 β-strands situated across three continuous 
domains (Figure 6.2c).  Domain I (residues 1-90, 175-184 and 194-211) consists of a 
central β-sheet (four parallel β-strands: β1, β3-5 and two anti-parallel strands: β2 and 
β11) surrounded by three α-helices (α1-3).  Domain II (residues 91-174) has four parallel 
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β-strands (β7-10), one anti-parallel β-strand (β6) and two α-helices (α4-5).  Domain III 
(residues 212-284) is composed of one β-sheet (four anti-parallel β-stands: β12-15) and 
two α-helices (α9-10).  The catalytic core of MtATP-PRT is located in a highly 
negatively charged cavity between domains I and II.  Whereas, L-histidine is held at the 
allosteric site by interactions with the carboxyl group of aspartic acid at position 218 
(Asp218), the hydroxyl group of threonine at position 238 (Thr238) and the backbone 
amide oxygen from alanine at position 273 (Ala273) in domain III.13 
 
6.1.3 Proposed MtATP-PRT allosteric inhibition mechanisms with L-
histidine  
 
Cho et al.13 determined crystal structures of apo MtATP-PRT at pH 6.5; and in complex 
with L-histidine and AMT (a competitive inhibitor to ATP) at pH 5.6.  The authors 
suggested that MtATP-PRT is an active dimer that assembles into an inactive hexamer 
upon L-histidine binding (Figure 6.3a).13  It was found that L-histidine binds ~30Å from 
the active site inducing a significant conformational change and supporting the allosteric 
inhibition model.  The major conformational change in the L-histidine bound form is a 
significant twist of the domain III, where the allosteric site is located, with respect to 
domain I and II causing steric hindrance in the active site.  Residues from two adjacent 
domain III were identified to be involved in binding and bringing three dimers together 
to deactivate the enzyme.  These interactions include an ordered hydrogen bonding 
network with residues Asp218 and Ala273 from one subunit and residues Leu234, 
Glu235, Ser236, Thr238 and Leu253 of the second subunit.  Six L-histidine molecules 
were found to bind to domain III clusters at both ends of three dimers, to stabilize the 
hexameric form.  Binding of L-histidine reorients some of the key residues in the active 
site (Tyr116, Arg135, Asp154 and Arg160).  Additionally, an increase in inhibition was 
noted upon binding of AMP, which establishes additional inter-subunit interactions that 
stabilize the L-histidine bound form.  
 
The other inhibition mechanism was proposed by Pedreño et al.12, and has been 
supported by gel filtration, steady-state and pre-steady-state kinetics, pH studies and 1H 
NMR spectroscopy studies.12  Gel filtration studies showed, that MtATP-PRT is present 
mostly in the hexameric form in solution, independent of protein sample concentration  
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Figure 6.3  Proposed mechanisms of MtATP-PRT allosteric inhibition with L-histidine postulated 
by Cho et al.13 (a) and Pedreño et al.12 (b).  Mechanism 1: (a) MtATP-PRT is an active dimer 
assembling to an inactive hexamer upon L-histidine binding; mechanism 2: (b) MtATP-PRT is a 
functional hexamer and conformational changes have to be invoked to explain the allosteric 
inhibition.  
 
(within 0.1 – 10 mg/mL range), and both in the presence and absence of the L-histidine 
or ATP (Figure 6.3b).  Similarly, no shift in the oligomeric state has been observed for 
the hexameric homologous enzyme from S. enterica.21,22  These findings are in contrast 
with results reported by Cho et al.13  Pedreño et al.12 speculate that the observed 
differences are possibly due to different experimental conditions, and that lower pH 
values can lead to dissociation of MtATP-PRT into dimers as there is no evidence that 
the dimer represents a kinetically competent form of MtATP-PRT (the activity 
drastically drops below pH 8).  Similar loss of activity below pH 8 have been reported 
for ATP-PRT from C. glutamicum.23  A proposed mechanism (Figure 6.3b) envisions 
MtATP-PRT as a functional hexamer where conformational changes have to be invoked 
to explain the allosteric inhibition. 
 
Steady-state kinetic studies indicated that MtATP-PRT has very low activity at neutral 
and acid pH (below pH 8).12  Hence, the experiments were carried out at pH 8 and 
above.  Although studies at high pH have no physiological importance as the cytoplasm 
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will not reach pH 9, the results may hint at potential mechanism for preparing L-
histidine analogues that bind tightly.  Moreover, pre-steady-state analysis revealed that 
binding of ATP, the first substrate, is essential for inhibition by L-histidine.12  
 
The ionic state of L-histidine was also found to influence the inhibition and binding to 
MtATP-PRT.12  L-histidine exists in four ionic states across the pH range.  Three half-
equivalence points (pKas) along the L-histidine titration curve (Figure 6.4) are observed 
at pH 1.82, pH 6.10, and pH 9.17.  1H NMR studies showed that saturation transferred to 
L-histidine when bound to MtATP-PRT is influenced by pH and was found to be 
maximal at high pH.  Neutral imidazole and deprotonated α-amino group favour L-
histidine binding (~pH 9 and above).  On the other hand, the pH dependence of 
inhibition is the opposite of what was observed for binding i.e. inhibition is weaker at 
higher pH values, as deprotonation of α-amino group decreases inhibition potency.  
Therefore, the ionic form of L-histidine that best inhibits MtATP-PRT most effectively 
is different from the form that binds the strongest; suggesting that the protonation state 
of the ligand is highly important in the transmission of the inhibitory signal from the 




Figure 6.4  Ionic states of L-histidine.  Below pH 1.8, all possible sites of L-histidine are 
protonated (net charge = 2+); between pH 1.8 and pH 6.1 carboxylic acid loses its proton 
making L-histidine singly charged (1+); between pH 6.1 and pH 9.2 L-histidine is a zwitterion 
with an overall charge of 0.  Above pH 9.17 L-histidine loses the α-amino proton and now 
carries negative charge (1-). pKCOOH = 1.82; pKR-group = 6.10; pKNH3+ = 9.17.  The pI value (where 
half of the species are in the zwitterion form) of L-histidine is 7.59.   
 
To unambiguously and independently define the mechanism of inhibition other 
experimental methods that probe native conformations and conformational changes need 
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to be employed.  In this chapter, the structure of MtATP-PRT and mechanism of its 
feedback inhibition with L-histidine is explored.  Native mass spectrometry (MS), ion 
mobility mass spectrometry (IM-MS) and analytical ultracentrifugation (AUC) are 
employed to study conformational changes induced by environmental changes (pH) and 
by binding of L-histidine.  These structural changes are subsequently mapped with 
hydrogen deuterium exchange mass spectrometry (HDX-MS), and in agreement the with 
the reported x-ray crystallography data.13   
 
 
6.2 Methodology  
 
6.2.1  Protein expression and purification 
 
The samples were provided by Dr. Luiz de Carvalho from the MRC National Institute of 
Medical Research, Mill Hill, London, UK.  MtATP-PRT was expressed and purified by 
João Pedro Pisco and Gérald Larrouy-Maumus.  The rv2121c (hisG) gene sequence from 
M. tuberculosis H37Rv was codon adapted to E. coli, and its nucleotide sequence was 
synthetically prepared and ligated into the pJ411 plasmid (DNA 2.0).  DNA sequence 
was confirmed by sequencing.  This construct contained a noncleavable N-terminal 
hexahistidine tag to facilitate purification.  The N-terminal hexahistidine tag was shown 
not to affect the structure or activity of MtATP-PRT.  During MtATP-PRT purification, 
all steps were performed at 4 °C.  Frozen BL21(DE3)pLysS (pJ411::hisG) cells were 
thawed on ice, and lysed by sonication, in the presence of buffer A (20 mM 
triethanolamine (TEA) (pH 7.8), 300 mM NaCl, and 50 mM imidazole) containing 
lysozyme and complete EDTA-free protease inhibitor cocktail.  Soluble protein was 
obtained by centrifugation at 25000g for 30 min.  The soluble fraction was loaded into a 
50 mL Ni-NTA column and the protein separated by a gradient using buffer B (20 mM 
TEA (pH 7.8), 300 mM NaCl, and 500 mM imidazole).  Peak fractions were analyzed by 
SDS−PAGE.  Fractions containing only MtATP-PRT were pooled together, 
concentrated, dialyzed in 20 mM TEA (pH 7.8), and stored in 50 % glycerol at −20 °C 
or, alternatively, stored at −80 °C after being flash-frozen in liquid nitrogen. 
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6.2.2 Sample preparation  
 
On the day of analysis, buffer was exchanged to 100 mM ammonium acetate buffer 
(Fisher Scientific, Loughborough, UK) of specified pH, using micro Bio-Spin 
Chromatography columns (Micro Bio-Spin 6 Columns, Tris) following the instructions 
specified by the manufacturer.  The desalting procedure was performed four to five times 
to achieve desired sample quality.  pH of the buffer was adjusted with hydrochloric acid 
or ammonia supplied by VWR International Ltd (UK).  Solution pH readings were taken 
using a pH meter (Jenway 3305).  High purity water was obtained from an Arium 611 
water purification unit (Sartorius, Göttingen, Germany) fitted with a 0.2 µm filter.  L-
histidine and 3-(2-thienyl)-L-alanine were obtained from Sigma-Aldrich.  Charge 
reduction experiments were carried out by addition of 10% (v) triethylamine acetate 
buffer (TEAA) (Fluka, Steinheim, Switzerland) prior to MS analysis. 
 
6.2.3 Native mass spectrometry 
 
Mass spectra were recorded on a Q-TOF mass spectrometer (Ultima API US, Waters, 
Manchester, UK) modified for transmission of high mass molecules.  MtATP-PRT 
samples were ionised using positive nESI as described in Chapter 2, section 2.1.2.  The 
samples were prepared in 100 mM ammonium acetate buffer with pH values of 5, 6.8, 8, 
9, and 10.  The source voltages and pressures were tuned to enable maximum ion 
transmission; the source backing pressure was elevated to ~8.5 × 10-1 mBar.  The sample 
cone voltage was varied from 40 to 200 V and the source temperature was kept at 30 °C 
to prevent sample aggregation in the glass capillary.  Ligand binding experiments with 
L-histidine and 3-(2-thienyl)-L-alanine were performed at different ligand concentrations 
and at a range of incubation time points as described in the Results and Discussion.  
Other instrumental settings for the Ultima API US mass spectrometer are listed in 
Chapter 2, Table 2.1  External calibration of the spectra was achieved using solutions of 
cesium iodide (2 mg.mL-1 in 50 : 50 water:isopropanol).  Data were acquired and 
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6.2.4 Ion mobility mass spectrometry: DT-IM-MS 
 
The samples were ionised using positive nESI as described in Chapter 2, section 2.1.2.  
The IM-MS data were acquired on the MoQToF, quadrupole time-of-flight mass 
spectrometer, detailed in section 2.2.1.24  The samples were prepared in 100 mM 
ammonium acetate buffer at pH 6.8 and pH 9.0.  The capillary potential was held at 1.3 - 
1.7 kV, the source temperature was set to 30 °C, and the cone voltage was set to 80 V.  
The injection energy used was between 33 and 35 V.  Other instrumental settings for the 
MoQToF IM mass spectrometer are listed in Chapter 2, Table 2.3.  The drift cell was 
filled with helium gas at a pressure of 3.5 – 3.6 Torr at temperature of 300 - 302 ± 0.5 K.  
The electric potential across the cell was varied from 60 to 20 V, with measurements 
taken at six different drift voltages.  The rotationally-averaged collision cross-sections 
(CCS) were determined from a plot of arrival time versus P / T and the CCSD were 
determined as described in Chapter 2, section 2.2.1.4.   
 
6.2.5 Ion mobility mass spectrometry: TWIMS-MS 
 
The IM-MS data were acquired on the Synapt G2S HDMS (Waters, Manchester, UK) at 
the Waters Corporation, Floats Road, Manchester, UK.  In-house made nano-capillaries 
were used as described previously.  The samples were prepared in 100 mM ammonium 
acetate buffer at pH 6.8 and pH 9.0.  Gentle conditions were applied to preserve the 
native-like structure: capillary voltage 1.6 kV, sampling cone 99 V, source temperature 
20 °C, trap collision energy 5.6 V, and transfer collision energy 2 V.  The pressure of the 
backing region was 8.3 mbar.  For IM, the helium cell and the IMS gas flows were 180 
and 90 mL/min, respectively, the IMS wave velocity was 617 m/s, and the IMS wave 
height was 40 V. Nitrogen was the carrier gas.  Data were acquired and processed with 
MassLynx software (Waters, Manchester, UK). 
 
6.2.6 Determination of theoretical CCS  
 
The theoretical CCS calculations were carried out by Dr Massimiliano Porrini from the 
Institute Européen de Chimie et Biologie (IECB) in Pessac, France.  The input 
coordinates files were those taken from the crystallographic structures, PDB identifiers 
1NH7 and 1NH8 for apo MtATP-PRT and Mt-ATP-PRT – L-histidine complex, 
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respectively. After adding hydrogen atoms, the x-ray crystal structures were minimized 
in vacuo with the sander module of Amber1125, implementing a radial cut-off of 999 Å 
and Amber99SB-ILDN force field26.  The rotationally averaged CCS were calculated 
with the trajectory method of MOBCAL code27 appropriately modified to handle large 
systems such as MtATP-PRT studied here.   
 
6.2.7 Collision-induced-dissociation mass spectrometry (CID-MS)  
 
The IM-MS data were acquired on the Synapt G2 HDMS (Waters, Manchester, UK) at 
the Manchester Institute of Biotechnology, The University of Manchester, UK.  The 
samples were prepared in 100 mM ammonium acetate buffer at pH 6.8 in the presence 
and the absence of L-histidine and ionised as described previously.  Gentle source 
conditions were applied to preserve the native-like structure: capillary voltage 1.6 kV, 
sampling cone 99 V, source temperature 20 °C.  The pressure of the backing region was 
7.5 mbar.  For the IM, the helium cell and the IMS gas flows were 180 and 90 mL/min, 
respectively, the IMS wave velocity was 550 m/s, and the IMS wave height was 40 V.  
Nitrogen was the carrier gas.  CID activation was induced by elevating the trap collision 
energy.  MS and IM-MS data were acquired at several discrete trap collision energy 
values of 10 V, 30 V, 50 V, 80 V, 100 V, 120 V, 150 V and 180 V.  Data were acquired 
and processed using MassLynx software (Waters, Manchester, UK). 
 
6.2.8 Hydrogen deuterium exchange mass spectrometry (HDX-MS) 
 
HDX-MS experimental set up and data analyses were carried out with help of Dr 
Rebecca J. Burnley at UCB Pharma, Slough, UK.  HDX-MS analysis was achieved 
using a Waters HDX module with nanoAcquity UPLC and Synapt G2 mass 
spectrometer.  Sample handling steps were performed by a LEAP-PAL robotics system.  
30 μM protein solutions were diluted 20 fold into 10 mM phosphate in either H2O or 
D2O, pH/pD 7, and the mixture incubated at 20 °C for 0 minutes (H2O), or 1, 10, 30 or 
120 minutes (D2O), before the quench step.  HDX quenching was achieved by mixing 
the reaction solution 1:1 with cooled 3.4 M Gdn-HCl, 500 mM TCEP, 200 mM 
phosphate (pH 2.5, 0 °C). 37.5 pmol was injected into the HDX module (0 °C), and 
washed over the pepsin column (Applied Biosystems, 3 cm Porozyme immobilised 
pepsin column) with 0.1% HCOOH in H2O, pH 2.5, at 200 μL.min
-1.  Resulting peptides 
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were trapped on a VanGuard C18 trap column.  Peptide separation was achieved on a 
C18 column (BEH C18, 100 × 1.0 mm, 1.7 μM) with the following gradient: 0 min: 8% 
B, 7 min: 32% B, 8 min: 85% B (mobile phase A: 0.1% HCOOH in H2O, pH 2.5; mobile 
phase B: 0.1% HCOOH in MeCN).  The mass spectrometer was operated in ToF only 
mode, with MSe data acquisition (trap collision energy ramp 14-35V).  Calibration was 
achieved from the MS/MS spectrum of GluFib peptide. PLGS v2.5 and DynamX Data 
Analysis v2.0 software (Waters Corporation, Manchester, UK) were used for data 
analysis.  The deuterium update protein maps were created in the PyMOL Molecular 
Graphics System, V1.5.0.4 (Schrödinger, LLC., Portland, OR, USA). 
 
6.2.9 Analytical ultracentrifugation 
 
Sedimentation velocity analysis were carried out by Dr. Thomas Jowitt at the 
Biomolecular Analysis Core Facility, Faculty of Life Sciences, the University of 
Manchester, UK.  His-tagged MtATP-PRT was purified and buffer exchanged by 
running peak fractions twice on a Superdex200 10/300 gel filtration column attached to a 
multi-angle laser light scattering system (MALLS) in ammonium acetate buffer at either 
pH 6.8 or pH 9.0.  The peak fractions for each pH separation corresponding to hexameric 
protein were pooled and the concentration assayed using a spectrometer reading at 280 
nm and a molar extinction coefficient of 20190 M-1 cm-1 for monomeric protein.  The 
final concentrations were ~40 µM (hexamer) and to this 12-fold molar excess L-histidine 
from a 50 mM stock in HCl was added to one 0.5 ml fraction for both pH 6.8 and pH 
9.0.  Samples were loaded (400 µl) into 2-sector sedimentation velocity cells with 
sapphire windows and loaded into a XL-I ultracentrifuge (Beckman).  Sedimentation 
was monitored every 1 minute at 45,000 rpm, 20 °C using interference optics and data 
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6.3 Results and Discussion 
 
6.3.1  MtATP-PRT exists mainly in the hexameric form under 
physiological conditions  
 
Changes in pH which can accompany process undergoing the living cells , may alter 
protein structure and hence its activity.  Firstly, the oligomeric state of apo MtATP-
PRT has been investigated as a function of buffer pH.  nESI-MS of 20 µM MtATP-
PRT (based on hexamer concentration) in 100 mM ammonium acetate at pH 5, pH 
6.8, pH 8, pH 9 and pH 10 acquired on the Ultima API US Q-ToF mass spectrometer 
are shown in Figure 6.5.  Peaks corresponding to the hexameric form of MtATP-PRT 
are observed in the ~6500 – 7500 m/z range; with the charge state envelope ranging 
from 25+ to 29+ charge state, centred at the 27+ charge state.  At pH 6.8, around m/z 
 
Figure 6.5   nESI mass spectra of 20 µM MtATP-PRT (hexamer concentration) in 100 mM 
ammonium acetate at pH 5, pH 6.8, pH 8, pH 9 and pH 10 (from bottom to top) acquired on 
Ultima API US Q-ToF mass spectrometer, showing the effect of pH on the oligomeric state of 
the enzyme. 
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3000 a minor amount of monomeric MtATP-PRT is present.  The population of 
monomeric species increases along with the pH and becomes more prominent at pH 
10 (centred on the 10+ charge state).  Additionally at pH 8, dimeric MtATP-PRT is 
detectable (~3900 – 4600 m/z, centred at 15+ charge state) and similarly increases in 
intensity with increasing basicity of the buffer.  Under deprotonated conditions i.e. 
high pH, carboxyl termini may lose their interaction with an adjacent subunit leading 
to conformational changes or dissociation into subunits.  These MS experiments 
indicate that MtATP-PRT is present in solution mainly in a hexameric form in the 
absence of any ligands, in agreement with results reported by Pedreño et al.12.  Under 
highly basic conditions (around pH 9 and above), the presence of monomeric and 
dimeric MtATP-PRT is noted.  
 
For mass determination experiments, high cone voltages (268 V) were applied.  The 
experimentally determined mass of the MtATP-PRT monomer of 31516 ± 11 Da, 
matches closely the theoretical average mass determined for MtATP-PRT monomer 
(31515.6 Da).  The experimentally determined mass of the MtATP-PRT hexamer is 
189374 ± 23 Da, which is slightly higher than the theoretical mass (189090 Da).  This 
difference is attributed to retention of residual solvent and salt despite the application 
of high source acceleration voltages.   
 
6.3.2 Insights into ligand binding stoichiometry from native MS 
experiments 
 
6.3.2.1 Stoichiometry of L-histidine binding   
 
X-ray crystallography experiments indicated up to 6 L-histidine molecules can bind to 
one MtATP-PRT hexamer.13  12 equivalents of L-histidine were added to 1 equivalent of 
MtATP-PRT hexamer in 100 mM ammonium acetate at pH 6.8 and incubated for 1 hour 
at room temperature (Figure 6.6).  The mass of MtATP-PRT hexamer (189 kDa) exceeds 
by over 1000-fold the mass of L-histidine (155.15 Da). This large discrepancy in mass 
precludes the resolution of bound from unbound species with the instrumentation used 
here.  Despite this, upon addition of L-histidine and application of gentle source 
conditions, a shift in the peak centre of the protein complex peaks is observed.  Mass 
spectra acquired at a cone voltage of 115 V in the presence of the ligand, display a mass 
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shift of ~1.2 kDa, corresponding to binding of 8 L-histidine molecules, a number greater 
than the one determined based on the crystallography data, implying super-
stoichiometric and perhaps non-specific binding (Figure 6.6a).  Nevertheless, under 
gentle dissolvation conditions which allow for preservation of non-covalent interactions 
and retention of the ligand, a significant amount of residual solvent is still present and 
the binding stoichiometry cannot be exactly determined.  Even at higher cone voltages 
which aid the desolvation process, a significant amount of solvent is present what could 
bias the stoichiometry of binding determination.  Efforts to shift charge state distribution 
(CSD) to a higher m/z range by addition of charge reducing agents such as TEAA and 
EDDA28, did not improve resolution sufficiently to determine the binding stoichiometry.  
Additionally, elevated acceleration voltages (up to 268 V) led to in-source ligand 
dissociation.  As shown in Figure 6.6b, at high cone voltages, a significant shift in the 
charge state envelope is observed from 27+ charge state (no ligand) to 24+ charge state 
(1H :12L) at CV = 268 V.  This shift in the CSD was found to be pH dependent and it  
 
 
Figure 6.6   (a) Mass spectra of MtATP-PRT in presence and in absence of 12 equivalents of L-
histidine (1H:12L) in 100 mM ammonium acetate at pH 6.8 acquired on Ultima API US Q-ToF 
mass spectrometer at 115 V and 166 V cone voltage (CV), showing the mass shift associated 
with ligand binding.  Moreover, a shift in charge state envelope is noted at higher CV.  Grey 
lines are used to help visualize the mass shift (based on apex of ‘no ligand’ peaks). (b) 
Dissociation of L-histidine upon increased cone voltage; 1 equivalent of MtATP-PRT incubated 
with 12 equivalents of L-histidine in 100 mM ammonium acetate pH 6.8 acquired at various cone 
voltages ranging from 84 – 268 V on Ultima API US Q-ToF mass spectrometer.   
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can be postulated that as the ligand dissociates from the complex, it takes the charge with 
it, reducing the charge of the protein as will be discussed later. 
 
Binding of a given ligand to its target can be influenced by the presence of other ligands 
already bound to the molecule.  The Hill number (nH) provides a way to quantify the 
degree of cooperativity of ligand binding.29,30  If nH is greater than one, this is termed 
positive cooperative binding, where the binding of the first ligand then increases the 
affinity of the substrate for other ligands.  On the other hand, nH values below one 
indicate negative cooperative binding, where the binding of a given ligand then 
decreases the affinity of subsequent ligands.  L-histidine was found to inhibit MtATP-
PRT with a nH of 1.5.12  This suggests that all six active sites could be inhibited with 
only four L-histidine molecules.31  Nevertheless, MtATP-PRT can still accommodate six 
ligands in the six binding sites.  In some cases were partial occupancy is detected 
different binding affinities can also be observed, therefore, it is possible that the first four 
L-histidine molecules have different affinity from the final two.31    
 
A titration experiment was performed, where 1-40 equivalents of L-histidine were added 
to one equivalent of MtATP-PRT hexamer in 100 mM ammonium acetate at pH 6.8.  
High acceleration voltage (CV = 268 V) was applied during acquisition of all mass 
spectra shown in Figure 6.7.  As mentioned earlier, in-source dissociation leads to a 
charge state shift attributed to the loss of charge from the protein complex as the ligand 
departs.  This observation was exploited here to obtain insights into ligand binding 
affinities.  Interestingly, the amount of ligand present in the sample influences the extent 
of CSD shift observed.  No differences in mass between apo MtATP-PRT and those 
containing L-histidine were noted, suggesting that all L-histidine molecules have 
dissociated during the desolvation process at high acceleration voltage.  For the MtATP-
PRT samples containing 1-4 L-histidine equivalents, only a small shift in the CSD (from 
being centered at 27+ to 26+) is noted and all four mass spectra display the same charge 
state profiles.  As the amount of L-histidine is increased to 5-6 equivalents, protein 
complex is stripped of an additional charge resulting in CSD shift from central 27+ to 
25+ charge state.  When more L-histidine is titrated in, 12 and 40 equivalents, a further 
shift in the CSD is observed to centre on the 24+ and 23+ charge states, respectively.   
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Figure 6.7  Titration of L-histidine into MtATP-PRT at 1-40 L-histidine equivalents to 1 MtATP-
PRT hexamer in 100 mM ammonium acetate pH 6.8 acquired at a constant cone voltage (268 V) 
on Ultima API US Q-ToF mass spectrometer.  A greater shift in the CSD profiles is observed 
along with increasing concentration of L-histidine.  
 
 
Differences in CSD profiles upon ligand dissociation may be deriving from the strength 
of the non-covalent interactions and charge transfer during desolvation.  As reported 
earlier, the ionic form of L-histidine that binds to MtATP-PRT is different from the form 
that inhibits it.12  Kinetic studies suggest that the first four ligands could inhibit all six 
active sites inducing conformational change.12,31  A possible explanation for the observed 
differences in CSD may be the involvement of the first four ligands bound (and in 
particular with the protonated forms) facilitating inhibition by inducing the subsequent 
conformational change as opposed to the remaining two which bind, however may not 
necessarily be crucial for the inhibition.  Upon dissociation of the fifth and sixth ligand, 
more charge is taken from the protein complex during desolvation suggesting that less 
external energy is required for the dissociation of the ligand along with extra protons.  
The presence of excess L-histidine causes additional charge reduction of MtATP-PRT 
and may be associated with non-specific binding. 
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6.3.2.2 The effect of buffer pH and incubation time on L-histidine binding   
 
The ionic state of L-histidine has been found to influence the inhibition of as well as its 
binding to MtATP-PRT.12  The effect of the buffer pH and incubation time on binding to 
MtATP-PRT as well as charge stripping upon ligand dissociation have been investigated.  
20 µM MtATP-PRT was incubated for 30 and 240 minutes at room temperature with 12 
L-histidine equivalents at pH 6.8 (a), pH 8 (b), pH 9 (c) and pH 10 (d).  nESI-MS 
acquired at high acceleration voltage (CV = 268 V) on the Ultima API US Q-ToF mass 
spectrometer are shown in Figure 6.8.   
 
L-histidine exists in four ionic states across the pH range (Figure 6.4).  Three half-
equivalence points along the L-histidine titration curve (Figure 6.4) are situated at pH 
1.82, pH 6.10, and pH 9.17.  Between pH 6.10 and pH 9.17, L-histidine carries an 
average net charge of 0.  Binding experiments carried out within this ionic range i.e. at 
pH 6.8 (a) and pH 8 (b), show a reduction in the CSD by 3 charge states upon L-histidine 
dissociation represented by a shift from the central charge state located at 27+ to 24+, 
this suggests that the ligand is dissociating with a bound proton.  As the basicity of the 
buffer is increased to pH 9 (c) this charge stripping is reduced.  Even though under these 
conditions, L-histidine is still within the 0 net charge bracket, it is now less prone to 
extract additional positive charge from the protein complex upon dissociation, which 
could be explained by a conformational change at the binding site or by the binding site 
no longer containing a labile hydrogen.  As a result less extensive charge stripping, a 
CSD shift from central 27+ to 25+ charge state, is observed.  Upon further increase of 
buffer pH to pH 10 (d), L-histidine crosses the final half-equivalence point and acquires 
average net charge of -1.  Here, the CSD shift becomes even less evident, shifting from 
central 27+ to 26+ charge state and the average charge of MtATP-PRT post L-histidine 
dissociation is reduced by one CS.   
 
It has been reported that the form of L-histidine that best inhibits MtATP-PRT is 
different from the form that binds best; suggesting that the ionic state of the ligand is 
highly responsible for the transmission of the inhibitory signal from the allosteric site to 
the active site.12  This presented MS data also shows a dependence of the buffer pH on 
the amount of charge L-histidine can accommodate and remove from the protein 
complex upon in-source dissociation.  Under basic conditions, a reduction of the protein  
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Figure 6.8   nESI mass spectra of 20 µM apo MtATP-PRT (hexamer concentration) and MtATP-
PRT incubated with 12 equivalents of L-histidine for 30 minutes and 240 minutes in 100 mM 
ammonium acetate at (a) pH 6.8, (b) pH 8, (c) pH 9 and (d) pH 10, acquired on Ultima API US Q-
ToF mass spectrometer (at cone voltage 268 V). 
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charge state post ligand dissociation is less apparent in comparison to the shift 
observed under more neutral conditions.  It could be speculated that α-amino group 
or/and imidazole nitrogen could be responsible for sequestering the charge from the 
MtATP-PRT surface.  Titration experiments (Figure 6.7) had shown that it is mainly 
the L-histidine molecules which bind non-specifically, that are responsible for the 
majority of charge reduction of MtATP-PRT upon dissociation.  At pH 6.8 and pH 8, 
the population of L-histidine with neutral imidazole and deprotonated amino group 
would be more predisposed to accept extra charge, which would result in a greater 
CSD shift as opposed to the same scenario at higher pH.  Furthermore, it is important 
to keep in mind that the pH in the desolvating droplet may be different from that in 
bulk solution, and the change is affected by the solvent composition and initial 
droplet pH as shown by Zhou et al..32  
 
As shown in the previous section, the pH of the buffer solution has an impact on the 
oligomeric state of MtATP-PRT.  MtATP-PRT was mainly present in a hexameric 
form under buffered conditions in absence of any ligands.  Under basic conditions 
(around pH 9 and above), the presence of monomeric and dimeric MtATP-PRT 
species was noted.  Addition of L-histidine reduces the amount of monomeric and 
dimeric species after 240 minutes of incubation at room temperature (Figure 6.8c and 
d).  At pH 9, a significant amount of MtATP-PRT monomer and a marginal amount 
of dimer are present (bottom spectrum in Figure 6.8c).  After 30 minutes of 
incubation with 12 equivalents of L-histidine, the intensity of both lower order 
species decreases and are not detectable after prolonged incubation period of 240 
minutes.  At pH 10, an even greater amount of monomeric and dimeric MtATP-PRT 
is observed.  Here, 30 minute incubation with L-histidine does not reduce population 
of either of the species. A longer incubation period is required to achieve a similar 
effect and a decrease of these low order oligomeric forms is observed only after 240 
minutes.    
 
According to Cho et al. 13, MtATP-PRT is an active dimer which assembles into an 
inactive hexamer upon L-histidine binding which could support the observations at high 
pH reported above.  However, the experiments reported by Cho et al. were carried out at 
pH 6.5 (apo) and pH 5.6 (with L-histidine and AMT), conditions under which MtATP-
PRT is believed to be kinetically inactive.12  Nevertheless, L-histidine appears to have a 
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stabilizing effect on MtATP-PRT at high pH, regardless whether it only binds to and 
does not inhibit the enzyme. 
 
6.3.2.3 MtATP-PRT binding with 3-(2-thienyl)-L-alanine  
 
L-alanine based ligand, 3-(2-thienyl)-L-alanine was found to bind to MtATP-PRT 
however, not to inhibit its activity.31  20 µM MtATP-PRT was incubated with 12 
equivalents of 3-(2-thienyl)-L-alanine at pH 6.8 for 30 and 240 minutes.  nESI-MS 
acquired at high acceleration voltage (CV = 268 V) on the Ultima API US Q-ToF mass 
spectrometer are shown in Figure 6.9.  Similarly as for L-histidine, due to over 1000-fold 
mass difference between the ligand (171.22 Da) and MtATP-PRT hexamer, again it is 
not possible to resolve bound and unbound species.  Application of high acceleration 
voltage induces in-source dissociation.  Here in contrast to L-histidine, charge stripping 
and reduction of protein charge state upon ligand dissociation is not present.  A minor 
shift towards higher charge states (centered at 28+) is observed instead.  Differences in  
 
 
Figure 6.9   nESI mass spectra of 20 µM apo MtATP-PRT (hexamer concentration, bottom 
spectrum) and MtATP-PRT incubated with 12 equivalents of 3-(2-thienyl)-L-alanine for 30 
minutes and 240 minutes in 100 mM ammonium acetate at pH 6.8, acquired on Ultima API US Q-
ToF mass spectrometer (CV = 268 V). 
 
Chapter 6                                                                                                            Allosteric inhibition of MtATP-PRT  
 
 
- 192 - 
the dissociation behavior of the two ligands investigated may be arising from their 
structural and composition differences.  The imidazole nitrogen, suggested to be 
responsible for charge stripping apparent in experiments with L-histidine by sequesting 
surface charge upon dissociation is absent in 3-(2-thienyl)-L-alanine.  Hence, these 
results hint towards the imidazole nitrogen to be implicated more in the charge reduction 





6.3.3 Probing conformational changes induced by ligand binding and 
environmental changes (pH) with IM-MS 
 
Cho and colleagues reported on a large shift of MtATP-PRT domain III with respect to 
domains I and II in the dimeric form compared with the hexameric MtATP-PRT formed 
in presence of L-histidine and AMP.13  Although the dimeric form, observed by Cho et 
al. is not present under experimental conditions applied here (lower pH), the domain 
shift could still take place, generating an alternative hexamer which could be inhibited.  
Gel filtration studies by Pedreño et al.12 showed MtATP-PRT to be present mostly in the 
hexameric form which undergoes subtle conformational changes upon L-histidine 
addition.  Here, IM-MS, both DT-IM-MS and TWIMS-MS, is employed to probe native 
conformations and conformational changes of MtATP-PRT. 
 
6.3.3.1 Determination of CCS: linear DT-IM-MS 
 
nESI-IM-MS of 30 µM MtATP-PRT and MtATP-PRT in presence of 12 equivalents of 
L-histidine in 100 mM ammonium acetate at pH 6.8 were acquired on the MoQ-ToF ion 
mobility mass spectrometer.  Source conditions were optimized and low acceleration 
voltages were applied to preserve protein native-like structure and non-covalent 
interactions.  Arrival time distributions (ATD) were recorded following mobility 
separation at 300 K and converted into CCSD as described in Chapter 2 section 2.2.1.4.  
Figure 6.10 shows the CCSD of 27+, 28+ and 29+ charge states of apo MtATP-PRT and 
MtATP-PRT with L-histidine bound, purple dotted lines are used to help visualize the 
subtle changes in the CCSD.  In the presence of L-histidine, MtATP-PRT CCS become 
somewhat smaller, suggesting conformational tightening upon ligand binding which may  
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Figure 6.10   Collision cross section distributions (CCSD) of 27+, 28+ and 29+ charge states of 
30 µM MtATP-PRT in presence (bottom) and in absence (top) of L-histidine in 100 mM 
ammonium acetate at pH 6.8, acquired on the MoQToF instrument at DV = 35 V.  Purple lines are 
added to help visualize the subtle changes in CCSD profiles.  
 
be associated with a shift of domain III with respect to domains I and II.  No AMP was 
used in these experiments suggesting that its presence might not be necessary for the 
allosteric inhibition to take place.  Changes in the median CCS from 75.2 nm2 to 73.6 
nm2, from 76.6 nm2 to 73.5 nm2, and 76.4 nm2 to 72.4 nm2 were determined upon L-
histidine binding for 27+, 28+ and 29+ charge states, respectively.  The reported CCS 
values are based on one experimental repeat.  New batch of samples was used to perform 
replicate experiments; however, these subtle changes in the CCS were no longer 
observed.  Despite many efforts in sample purification and instrumental condition 
optimization, as will be described later, the results obtained from the first experiment 
could not be reproduced.  Repeat experiments will be performed once the protocol has 
been optimized.  Additionally, dependence of the protein conformation on pH and the 
effect of ATP on L-histidine binding will be investigated to provide insights into the 
allosteric inhibition mechanism of MtATP-PRT. 
 
6.3.3.2 Tracing ligand binding and pH dependent conformations: TWIMS-MS 
 
Enzyme activity and structure is dependent on the environmental factors such as 
temperature or pH of the buffer.  Conformational changes of MtATP-PRT due to ligand 
binding as well as changes due to buffer pH were explored with TWIMS-MS.  nESI-IM-
MS of 20 µM MtATP-PRT in presence and in absence of L-histidine in 100 mM  
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Figure 6.11   Drift time distributions of 27+, 28+ and 29+ charge states of MtATP-PRT in 
presence and in absence of L-histidine in 100 mM ammonium acetate at pH 6.8 and at pH 9, 
acquired on the SynapthG2S instrument at wave height of 40 V and wave velocity of 617 m/s.  
 
 
ammonium acetate at pH 6.8 and pH 9 were acquired on SynaptG2S instrument at 
Waters Corporation, Manchester.   Arrival time distributions for 27+, 28+ and 29+ 
charge states of apo MtATP-PRT and MtATP-PRT with L-histidine at pH 6.8 and at pH 
9 are shown in Figure 6.11.  Apo MtATP-PRT at pH 6.8 presents over two 
conformational families in the ion mobility space.  The relaxed conformation with longer 
drift time (28+ charge state centred at 51.2 ms) is significantly higher in abundance 
when compared to the tense conformation observed at shorter drift time (28+ charge 
state centred at 44.1 ms) which constitutes to about 12 % of the total ion population for 
each charge state.  Upon addition of 12 equivalents of L-histidine, the relaxed form of 
MtATP-PRT is no longed observed.  The total ion population shifts to shortened drift 
times and matches (28+ charge state centred at 44.2 ms) the drift time profile of the tense 
conformation of apo MtATP-PRT at pH 6.8.  This conformational tightening upon 
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ligand binding is in agreement with results reported here earlier with DT-IM-MS and 
those found in the literature based on gel filtration and x-ray crystallography studies.12,13  
Interestingly, under the same instrumental conditions, apo MtATP-PRT at pH 9 appears 
to be already in the more compact (tensed) form observed at shorter drift time (28+ 
charge state centred at 44.0 ms) and matches drift time of the L-histidine bound MtATP-
PRT at pH 6.8.  Upon addition of L-histidine, the drift time remains constant (28+ 
charge state centred at 44.1 ms), suggesting absence of the conformational change.  This 
trend is observed across all charge states.   
 
According to the kinetic studies, the enzyme is in its active form at pH 9.12  The lack of 
conformational change under these conditions could be arising for the lack of inhibition.  
Earlier it was proposed that activation or lack of inhibition is dependent on the correct 
binding and position of the six phosphates from both substrates.31  However, these 
substrates are not present in the experiments reported here, revealing that the 
tightening/activation is independent of substrates and is influenced by the protonation 
state of the protein and the ligand.  Nevertheless, the experiments should be performed in 
presence of substrates.  Attempts to repeat experiments reported here were also not 
successful, as will be described later, MtATP-PRT appears in the more compact form 
independent of pH or ligand presence.  
 
6.3.3.3 Conformational differences derived from the x-ray crystal structures: 
theoretical CCS 
 
The conformational change of MtATP-PRT was confirmed by the theoretical CCS 
calculated from the available x-ray crystal structures.  The input coordinates files were 
taken from the crystallographic structures, PDB identifiers 1NH7 and 1NH8 for apo 
MtATP-PRT and Mt-ATP-PRT:L-histidine:AMT complex, respectively.  Dimeric form 
of apo MtATP-PRT available in the PDB was assembled into the hexameric form using 
the online ‘Protein interfaces, surfaces and assemblies’ service PISA at the European 
Bioinformatics Institute website.19,20  After adding hydrogen atoms, the x-ray structures 
were minimized in vacuo.  The rotationally averaged CCS were calculated with the 
trajectory method (TJM) of MOBCAL code27 appropriately modified to handle large 
systems such as MtATP-PRT.   
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The theoretical CCS of hexameric apo MtATP-PRT and Mt-ATP-PRT:L-histidine:AMT 
complex were found to be 94.0 nm2 and 90.7 nm2, respectively.  The experimentally 
determined CCS are significantly smaller than the theoretical CCS by about 23 %.  
Although, MtATP-PRT is not as flexible as the immunoglobulin molecules presented in 
Chapter 3, one could still anticipate structural compaction to a certain degree if the x-ray 
structures were subjected to gas phase molecular dynamics (MD).  While, the theoretical 
CCS values and the experimentally derived CCS are not in close agreement, the trends 
displayed are similar.  The theoretical CCS of apo MtATP-PRT is larger than CCS of 
inhibited MtATP-PRT by 3.3 nm2.  Similarly, the average change in CCS across charge 
states as determined with DT-IM-MS measurements (Figure 6.10) was 2.9 nm2.  
Nevertheless, it would be worthwhile to subject MtATP-PRT to gas phase MD in order 
to determine whether its structure undergoes gas phase contraction. 
 
6.3.3.4 Obstacles encountered, proposed solutions and further directions  
 
New batches of sample were used to perform replicate IM-MS experiments; however, no 
changes in the CCSD upon ligand binding or change of pH were observed.  Apo 
MtATP-PRT at pH 6.8 has shown to occupy the same conformational landscape as 
MtATP-PRT in presence of L-histidine at pH 6.8 or at pH 9.  The very first TWIMS-MS 
experiments were performed on a Synapt G2S HDMS instrument (at Waters 
Corporation, Manchester) whilst the repeats were run on three different Synapt G2 
HDMS instruments in different laboratories.  Initially, it was though that the lack of 
changes might be due to structural collapse of MtATP-PRT occurring during the 
desolvation process which could have been originating from differences in the source 
design between the two instruments (Chapter 2, section 2.2.2.).  Careful optimisation of 
source conditions (elevated pressure and low voltages) did not result in detection of any 
changes in CCSD.  Experiments were performed afresh on the SynaptG2S (at Waters 
Corporation, Manchester) and MoQToF instruments, however, this time no structural 
changes were observed upon L-histidine binding.  Unsuccessful efforts to replicate the 
preliminary results by using several different instruments hinted at the fact, that lack of 
conformational change might be due to the sample itself rather than the instrument 
and/or conditions utilized.  
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Purification of MtATP-PRT is facilitated by inclusion of a non-cleavable hexa-histidine 
tag (HisTag) at the N-terminal.  Although, the allosteric site is located within domain III 
near the C-terminal and far from the HisTag, histidine is the allosteric inhibitor of 
MtATP-PRT and presence of the HisTag could be affecting its activity.  Our collaborator 
at MRC NIMR, conducted kinetic studies and shown that HisTag does not to affect the 
structure or activity of MtATP-PRT.  Nevertheless, wild type MtATP-PRT was 
expressed in order to exclude any potential binding of the HisTag histidine to the 
allosteric site.  IM-MS experiments performed on Synapt G2 HDMS instrument, showed 
no conformational change upon L-histidine addition at pH 6.8.  All experiments reported 
in this chapter, unless otherwise stated, were performed on the HisTag MtATP-PRT.  
Removal of the histidine tag causes MtATP-PRT to be more prone towards aggregation 
and maintenance of a stable nano-electrospray becomes challenging.   
 
Another hypothesis proposed explaining lack of conformational changes observed was 
possibility of enzyme deactivation over time.  Potentially, a disulfide bond could be 
formed between cysteine residues at positions 73 and 175 over time and storage which 
would alter enzyme activity.  These residues are far away from the allosteric site and 
seem to be distant enough to not form a disulfide bond.  Nevertheless, in order to 
exclude any possible disulfide bond formation, dithiothreitol (DTT) was added to 
MtATP-PRT sample.  Addition of this thiol reducing agent did not alter the structure (as 
determined with gel filtration) nor activity, indicating that sample did not contain 
oxidized cysteine residues or disulfide bonds that could inhibit activity.31  IM-MS 
experiments were performed on Synapt G2 HDMS instrument on samples treated with 
DTT, however, still no changes in drift time were noted upon L-histidine addition at pH 
6.8.  
 
During sample purification, MtATP-PRT is eluted into buffer containing 500 mM 
imidazole and subsequently dialyzed into triethanolamine (TEA) buffer prior to storage.  
Imidazole ring of L-histidine is a crucial structural motif in the inhibition of MtATP-
PRT and transmission of the inhibitory signal from the allosteric site to the catalytic site, 
therefore, presence of imidazole in the buffer solution could have an effect on the 
conformation of the enzyme.  Prior to IM-MS, the buffer is exchanged into 100 mM 
ammonium acetate using micro Bio-Spin chromatography columns; the procedure is 
repeated 4-5 time to achieve desired purity.  Additionally, MtATP-PRT was purified by 
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running gel filtration (Superdex 200 10/300) to remove any imidazole present.  
Nevertheless, no conformational changes were observed upon L-histidine addition post 
the extensive buffer exchange procedure.  Currently, efforts are being made to purify the 
MtATP-PRT without the use of imidazole.  
 
Whether the first IM-MS measurements were one time artefact, the conformational 
change and enzyme activity across different batches is observed in gel filtration 
experiments and also hydrogen deuterium exchange (HDX) MS experiments as will be 
discussed later.  Once the conditions, either instrumental or involving sample 
preparation, allowing for differentiation of the tensed and the relaxed form of MtATP-
PRT in IM space are re-established, several additional experiments should be carried out.  
Firstly, the pH scan experiment which would track the transformation between tensed 
and relaxed form of MtATP-PRT as a function of buffer pH.  Secondly, a titration of L-
histidine into MtATP-PRT would help to determine binding stoichiometry and a number 
of L-histidine molecules necessary to induce conformational change.   
 
6.3.4 Effect of L-histidine on MtATP-PRT dissociation: CID  
 
Disruption of protein structure can provide insights into complex stoichiometry, subunit 
interactions or complex topology.33-36  One of the protein activation methods leading to 
complex dissociation is collision induced dissociation (CID).  MtATP-PRT, apo and in 
complex with L-histidine at pH 6.8, was subjected to CID activation on a Synapt G2 
HDMS instrument.  The most intense 27+ charge state (m/z 7142) was chosen as a 
precursor ion.  CID activation was induced by elevating the trap collision energy.  MS 
and IM-MS data were acquired at several discrete trap collision energy values of 10 V, 
30 V, 50 V, 80 V, 100 V, 120 V, 150 V and 180 V.  Mass spectra and drift time 
distributions of apo MtATP-PRT (a,b) and MtATP-PRT in presence of L-histidine (c,d) 
are shown in Figure 6.12.   
 
As the trap collision energy is increased, onset of apo MtATP-PRT dissociation into 
monomers (m/z 1500 – 3500) is observed around 80 V (Figure 6.12a).  As the complex 
undergoes dissociation, loss of structure is indicated by shift towards longer drift times  
Chapter 6                                                                                                            Allosteric inhibition of MtATP-PRT  
 
 
- 199 - 
 
 
Figure 6.12   Trap CID of 27+ charge state of MtATP-PRT (a,b) and MtATP-PRT in presence of L-
histidine (c,d).  Mass spectra and drift time distributions were acquired on Synapt G2 HDMS 
instrument at trap cell voltages of 10 V, 30 V, 50 V, 80 V, 100 V, 150 V and 180 V.  Increase in the 
trap voltage leads to conformational changes associated with subunit unfolding and charge 
stripping of the MtATP-PRT : L-histidine complex (c).  
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and broadening of the drift time distribution (Figure 6.12b).  Upon increasing trap 
energy to higher values, the dissociation into subunits becomes more extensive and 
MtATP-PRT undergoes several intermediate unfolding transitions until finally, at 180 V, 
only a marginal amount of apo MtATP-PRT hexamer is present over one conformational 
family with significantly longer drift time (~ 130 ms).  It is worth noting, that 
experiments presented in this section as opposed results reported in section 6.3.3.2 were 
performed on a different version of the instrument (Synapt G2 and Synapt G2S, 
respectively) and under application of different ion mobility parameters, hence, the 
differences is the drift times observed in Figure 6.12 and Figure 6.11.  Moreover, the 
CID experiment was performed on a batch of sample where no conformational 
difference was observed upon addition of L-histidine, as described earlier.   
 
The presence of L-histidine leads to a different dissociation pattern.  At 50 V, charge 
stripping occurs which has previously been interpreted as due to L-histidine dissociation 
(Figure 6.12c).  A significant amount of MtATP-PRT in lower charge states is detected.  
As the trap collision energy is increased further to 80 V, charge stripping progresses and 
the population of lower charge states increases along with a decrease in the intensity of 
the precursor ion.  The CSD continues to shift towards lower charge states and becomes 
centred at 24+ charge state (at 100 V), similarly to the in-source dissociation 
experiments (Figure 6.6).  Interestingly, the dissociation into monomers appears to be 
facilitated by ligand induced charge stripping.  Population of monomers ejected from 
MtATP-PRT in presence of L-histidine is higher than that of monomers originating from 
the apo MtATP-PRT.  Dissociation ratios have been calculated (following the procedure 
presented in Chapter 4, section 3.2) as a function of trap collision energy and are listed in 
Table 6.1.  Upon application of 80 V to the trap cell, about 66 % of apoATP-PRT 
remains intact as a hexamer in comparison to only 37 % of MtATP-PRT in presence of 
L-histidine.  In conjunction with a titration experiment, inducing such dissociation could 
facilitate a comparison of binding strength of the first four L-histidine molecules, which 
have been suggested as being required for the onset of a conformational change, versus 
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Table 6.1 Trap CID based dissociation ratios of apo MtATP-PRT and MtATP-PRT in presence of 
L-histidine.  The ratio of the summed intensities of charge states corresponding to the intact 
complex [Icomplex] over the sum of the summed intact complex charge state intensities and 
summed intensities of monomer charge states produced via CID [Icomplex + I monomer] listed as a 
function of trap collision voltage.  
Trap collision 
voltage /V 
Dissociation ratio of 
MtATP-PRT 
Dissociation ratio of 
MtATP-PRT + L-
histidine 
10 1.00 1.00 
30 1.00 1.00 
50 0.98 0.93 
80 0.66 0.37 
100 0.55 0.33 
120 0.25 0.18 
150 0.04 0.05 
180 0.02 0.02 
 
 
6.3.5 Mapping of conformational changes and binding site with HDX-
MS 
 
Conformational changes of MtATP-PRT initially observed by means of IM-MS, were 
further investigated with HDX-MS.  The rate and extent of exchange of labile hydrogen 
atoms at the backbone amide positions of the protein with deuterium atoms in a 
surrounding buffer can be measured to provide insights into ligand binding, structural 
changes as well as protein dynamics.  HDX-MS analysis on MtAPT-PRT was achieved 
using a Waters HDX module with nanoAcquity UPLC and Synapt G2 HDMS equipped 
with a LEAP-PAL robotics system for sample handling. 
 
6.3.5.1 Sequence coverage  
 
Firstly, MtATP-PRT prepared in ammonium acetate buffer was injected into a pepsin 
digestion column to determine the sequence coverage.  The non-specific cleaving nature 
of pepsin produces overlapping peptides and increases the sequence coverage of the  
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Figure 6.13   MtATP-PRT amino acid sequence coverage highlighted in blue, after digestion with 
pepsin.  85 peptides have been identified covering 90 % of the sequence.   
 
 
studied protein.  Resulting peptides were separated by UPLC, further fragmented and 
identified by MS.  85 peptides have been identified (list available in Appendix 7) 
covering 264 out of 294 amino acid residues of the MtATP-PRT sequence i.e. 90 % 
sequence coverage (or 94 % if not considering the polyhistidine tag, residues 1-11).  
Figure 6.13, highlights residues of MtATP-PRT sequence covered by peptides resulting 
from pepsin digestion.  Residues not converted included MAHHHHHHAAM (1-11), 
RRRTDSKD (36-43), A (189), M (224), and ASDIRFCRF (286-294).  Differences in 
the numbering system between x-ray crystal structure and HDX data presented here 
exist, as the HisTag residues in the x-ray crystal structure are not numbered.  HDX 
residue numbers correspond to x-ray residue number plus 10 (HDX residue number = 
PDB residue number + 10) and will be used throughout the discussion.  
 
6.3.5.2 Changes in deuterium uptake due to L-histidine binding and buffer pH   
 
HDX experiments were carried out on MtATP-PRT in the presence and absence of L-
histidine (12 ligand equivalents to 1 hexamer) at pH 6.8 and pH 9 to obtain insights into 
ligand induced and environment induced subtle conformational changes observed via 
other characterisation techniques.  After addition of L-histidine, MtATP-PRT samples 
were incubated for at least 30 minutes at room temperature and subsequently diluted 20 
fold into phosphate buffer in either H2O (control) or D2O.  The mixtures were incubated 
at 20 °C for 0 minutes (H2O), or 1, 10, 30 or 120 minutes (D2O), prior to exchange 
quench step and automated injection onto the pepsin column.  The D uptake was 
calculated for each peptide identified at all four labeling time points and compared 
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Figure 6.14   Example deuterium uptake curves of four chosen peptides of MtATP-PRT in 
presence (red) and in absence (green) of L-histidine at pH 6.8 (left) and pH 9 (right).  Deuterium 
uptake was determined at four exposure time points: 1 minute, 10 minutes, 30 minutes and 120 
minutes.  D uptake data for all peptides identified is provided in the Appendix 7.  
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Highly dynamic and disordered protein regions or those with increased solvent 
accessibility undergo rapid deuteration, whereas less solvent accessible regions or buried 
by the ligand binding may be protected within the complex and exchange at a slower 
rate.  Example D uptake curves of four chosen peptides of MtATP-PRT (green) and 
MtATP-PRT : L-histidine complex (red) are shown in Figure 6.14.  The amount of D 
uptake varies along the MtATP-PRT sequence.  Peptides L44-N51, V165-A179 and 
P242-A259 of which all are located on the surface of domains I, II and III , respectively, 
experience higher extent of deuteration on a short time scale (1 min) in comparison to 
peptide M120-L129 which is somewhat buried within domain II.  Upon addition of L-
histidine at pH 6.8, the amount of D uptake instantly decreases in the region within 
domain III (P242-A259, Figure 6.14 bottom plot) recognized as the allosteric site of L-
histidine binding.  As L-histidine binds, amide hydrogen atoms become protected from 
the deuterated solvent which significantly slows down the HDX reaction, hence the 
difference in D uptake is observable within the first minute of reaction.  Although, the D 
absolute uptake increases with the HDX reaction time, the relative difference between 
two species remains constant, suggesting it is protection of a particular residue/s that is 
responsible for the decrease in observed uptake.  
 
Changes in HDX between ligand free and ligand bound MtATP-PRT are also observed 
on long time scales (120 min of HDX).  Peptide M120-L129, located near the AMP 
binding site and proposed ATP and PRPP binding site, shows no significant change in D 
uptake at 1 minute of HDX.  At longer HDX times, however, a decrease in D uptake is 
noted for L-histidine bound form.  Such differences originate from conformational 
changes induced by ligand binding which restrict protein dynamics and limit deuteration 
at extended exposure times rather than from direct interaction with the binding molecule.   
 
Interestingly, no differences in D uptake were observed between apo and L-histidine 
bound MtATP-PRT at pH 9.  No significant changes were observed around the allosteric 
region due to L-histidine binding nor near the active site, suggesting that the 
conformational changes observed at pH 6.8 are not present at pH 9, in agreement with 
conclusions drawn from IM-MS data (section 6.3.3.).  Average D uptake values along 
with standard deviation values (based on three experimental replicas) across four 
samples and four time points for each peptide identified are provided in Appendix 7.   
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Figure 6.15  Difference in the absolute D uptake between L-histidine free and L-histidine bound 
MtATP-PRT at pH 6.8 (a) and pH 9 (b), measured at four deuterium exposure time points: 1 
minute (red), 10 minutes (yellow), 30 minutes (green) and 120 minutes (blue); providing 
information about regions of ligand binding and conformational changes. 
 
 
HDX experiments were also carried out on the WT MtATP-PRT (no HisTag present) 
showing the same trends.  Due to a large number of peptides, the collected data is better 
represented in form of butterfly plots.  The difference in absolute D uptake between apo 
MtATP-PRT and MtATP-PRT in presence of L-histidine at four exposure time points is 
plotted in Figure 6.15 for each peptide along x-axis from N- to C- terminal, at pH 6.8 (a) 
and pH 9 (b).  It becomes clearly visible how changes occurring on a fast timescale 
(observable < 1 min, red trace) associated with direct L-histidine binding take place 
within domain III (peptides 70-85) at pH 6.8 (Figure 6.15a); whereas the other changes 
occur on longer timescales (most obvious at 120 minutes, blue trace), suggesting an 
induced conformational change near the active site (peptides 35-60, 80-85) proceeding at 
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a slower rate.  Anand et al. have suggested HDX changes at different time points as a 
way of differentiating between small molecule binding and protein structural events.37,38 
At pH 9, the differences in D uptake upon L-histidine are more subtle (Figure 6.15 b).  A 
minor variation in D uptake is noted around domain III (peptides 63-85) indicating some 
binding is occurring; however, no significant changes on longer time scale associated 
with conformational changes are observed around the active site.  The datasets obtained 
under different buffer conditions cannot be compared to each other, due to the pH 
dependence of the intrinsic HDX rate.39,40  Nevertheless, data obtained under identical 
buffer conditions serve to map regions of ligand binding and conformational 
changes.41,42  
 
When high resolution structural data is available for a given protein, HDX information 
can be transposed onto the structure to help visualize and understand structural changes 
and dynamics.43  The percentage differences in D uptake between apo and L-histidine  
bound MtATP-PRT at pH 6.8 were calculated and applied onto available x-ray crystal 
structures 1NH7 (apo MtATP-PRT) and 1NH8 (MtATP-PRT + AMP + L-histidine) as 
shown in Figure 6.16.  Residues D226-A259 located in the region of significant changes 
within the first minute of HDX are highlighted in red, and encompass residues identified 
to be involved in direct binding with L-histidine: D228, L244, S246, T248, L263, and 
A283 (black).  Residues, for which differences in HDX were found on a longer time 
scale (120 min), are highlighted in three shades of blue of increasing intensity 
corresponding to greater changes.  The greatest change (difference of 20 % and higher) 
in HDX between L-histidine free and L-histidine bound MtATP-PR evident on a longer 
time scale were located near the allosteric site (V210-L223 and L275-L285).  Slightly 
less extensive but still notable (10 to 20 %) changes where found in regions surrounding 
the active site positioned in the cavity between domains I and II (L44-F55, L117-L129, 
I152-D164); which in Figure 6.16 are marked in teal-green for residues involved in 
direct binding of AMP and lime-green for residues proposed to be involved in ATP and 
PRPP binding.  Cho et al.13 reported on a major conformational change upon L-histidine 
binding originating from a significant twist of the domain III with respect to domain I 
and II causing steric hindrance in the active site.  HDX data supports this hypothesis 
owing to over 30 % change in HDX detected within the α-helix between domains I and 
III (R212-L223); and envisions conformational changes induced by allosteric inhibitor 
binding, resulting in limited access to the active site and/or reorienting residues  
Chapter 6                                                                                                            Allosteric inhibition of MtATP-PRT  
 
 
- 207 - 
 
 
Figure 6.16  Percentage differences in deuterium uptake visualized on the PDB: 1NH7 and  
1NH8 crystal structures and the MtATP-PRT monomer sequence.  Residues with significant 
changes in HDX on short time scale are highlighted in red, residues where changes occur on a 
longer time scale (120 min) are highlighted in shades of blue.  Residues involved in direct 
interactions with L-histidine, residues involved in binding of AMP and residues proposed to be 
involved in ATP and PRPP binding as reported by Cho et.al.13 are shown in black, teal-green 
and lime-green, respectively. 
 
 
responsible for interactions with both of the substrates: ATP and PRPP.  Table 6.2 lists 
residues and peptides experiencing notable changes in D uptake between ligand free and 
ligand bound MtATP-PRT states; as well as residues involved in interactions with 
inhibitors and substrates determined by Cho et al..13 
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Table 6.2   List of MtATP-PRT residues with altered D uptake due to L-histidine binding 
determined via HDX experiments; along with list of MtATP-PRT involved in binding with L-
histidine, AMT and residues predicted to interact with ATP and PRPP. 
 
HDX DATA  
 
Residues Change in D uptake 
Peptide 
number 
L44-F55 long time scale: 120 min 7-9 
L117-L129 intermediate time scale: 30 min 39-41 
V130-E151 intermediate and long time scale: 30-120 min 44-45 
I152-D164 intermediate and long time scale: 30-120 min 48-53 
V210-L234 intermediate and long time scale: 30-120 min (significant) 63-71 
D226-A259 instant within 1 minute 72, 73, 75, 78 
Y227-K235 intermediate and long time scale: 30-120 min 74 
V258-L285 intermediate and long time scale: 30-120 min 80-85 
 
X-RAY CRYSTALLOGRAPHY DATA13 
 
Residues  (HDX numbering) 
 
Type of interaction 
D228, L244, S246, T248, L263, A283 L-histidine 
D40, D43,D80, S100, Y126,D164-T171 AMP 
K19, K42, R59, R170 ATP and PRPP (predicted)  
 
One of the factors affecting the HDX rate is the solvent accessibility.  Amide hydrogen 
atoms on the surface of protein are more prone to undergo exchange at faster rates; 
therefore, residues at the subunit interfaces would be expected to incorporate lower 
amounts of deuterium on a short time scale.  The percentage of absolute D uptake was 
calculated for MtATP-PRT in the presence and absence of L-histidine at pH 6.8 at 1 
minute and 120 minutes exchange time points and was applied onto the MtATP-PRT 
monomer structure.  The MtATP-PRT monomer is presented in Figure 6.17, at various 
angles: three snapshots along the 3-fold axis and one along 2-fold symmetry plane.  An 
increased percentage of absolute D uptake is visualized with increasing intensity of blue.  
Additionally, the interface residues were identified using the online ‘Protein interfaces, 
surfaces and assemblies’ service PISA19,20 based on the 1NH7 (violet) and 1NH8 
(purple) crystal structures as shown in the top row of Figure 6.17.  Some of the crucial 
residues at the subunit interfaces were not covered by peptides resulting from pepsin 
digestion (brown).  Nevertheless, it is seen that a lower amount of D is incorporated into  
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Figure 6.17  Percentage D uptake of MtATP-PRT in presence and in absence of L-histidine at pH 
6.8 after 1 minute and 120 minutes of exposure to deuterated buffer represented on MtATP-PRT 
monomer (PDB:1NH7) viewed from different angles.  The top row highlights interface residues 
based on PDB:1NH7 (violet) and PDB:1NH8 (purple).  The increasing intensity of blue correlates 
with increase in D uptake.  Residues not covered during the HDX experiment are highlighted in 
brown.  
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the surface residues facing the intra-subunit cavity i.e. ‘inner surface’, as opposed to the 
residues on the ‘outer surface’ within the first minute of HDX.  Such pattern is observed 
both, in the presence and absence of L-histidine, and is supportive of the mechanism 
proposed by Pedreño et al.12 which envisions MtATP-PRT as a functional hexamer 
where conformational changes have to be invoked to explain the allosteric inhibition 
(Figure 6.3b).  Moreover, upon the addition of L-histidine , the percentage of absolute D 
uptake on a long time scale at the ‘inner surface’ is lower in comparison to D uptake in 
the absence of ligand further supporting conformational rearrangement to a more 
compact structure and reducing solvent penetration of the intra-subunit cavity.   
 
 
6.3.6 Conformational changes probed with solution-phase technique: 
AUC 
 
Analytical ultracentrifugation (AUC) is a powerful method for analysis of 
macromolecules in solution.44-46  Sedimentation velocity analysis is an AUC method via 
which the movement of molecules through high centrifugal fields is explored to define 
their size, shape and interactions.  Sedimentation velocity experiments determine 
sedimentation coefficient (s20,w) expressed in Svedberg (1 S = 10
−13 s) and defined as 
ratio of a particle's sedimentation velocity to the acceleration that is applied to it.  The 
sedimentation coefficient depends on the molecular weight of the protein where larger 
species sediment faster, but also on their molecular conformation.  Unfolded proteins or 
ones with highly elongated conformations will experience more hydrodynamic friction, 
and thus will have smaller sedimentation coefficients than folded, globular proteins of 
the same molecular weight. 
 
Sedimentation coefficient distributions of MtATP-PRT acquired at pH 6.8 (a) and pH 9 
(b) are shown in Figure 6.18.  The sedimentation coefficient values (s20,w) of MtATP-
PRT at pH 6.8 in presence and in absence of L-histidine were determined to be 8.22 ± 
0.26 S and 8.58 ± 0.14 S, respectively (Figure 6.18a).  An increase in s20,w upon binding 
of L-histidine is indicative of conformational changes and the adoption of a more 
compact structure.  Furthermore, the width of s20,w distribution can reflect on the protein 
dynamics and population of closely related structures.  The minimum width of the 
sedimentation boundary is related to the diffusion coefficient of the molecule; however,  
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Figure 6.18  Sedimentation coefficient distributions (s20,w) of MtATP-PRT in 100 mM ammonium 
acetate at pH 6.8 (a) and pH 9 (b), in presence (blue trace) and in absence of L-histidine (black 
trace).  More compact proteins experience less hydrodynamic friction, and thus have larger 
sedimentation coefficient.   
 
presence of multiple species with similar sedimentation coefficients will cause the 
boundary to be broader.  A narrowing of the s20,w  distribution is observed upon L-
histidine addition, suggesting that its presence may be causing MtATP-PRT to be more 
structurally constrained.  
 
The sedimentation coefficient values of MtATP-PRT at pH 9 in presence and in absence 
of L-histidine were determined to be 8.09 ± 0.18 S and 8.15 ± 0.14 S, respectively 
(Figure 6.18 b).  Here, the difference in s20,w between ligand free and ligand bound 
MtATP-PRT is significantly smaller, suggesting close structural resemblance of the two 
species.  In agreement with IM-MS and HDX-MS results, under these conditions 
MtATP-PRT does not appear to undergo conformational tightening upon L-histidine 
addition.  Minor differences in s20,w of apo MtATP-PRT at pH 6.8 and pH 9 is most 
likely due to an affect of the buffer pH on the hydrodynamic friction during the 
sedimentation process rather than conformational changes.  It is worth nothing that 
the small population of lower order species at s20,w = 6.41 S observed at pH 9, is no 
longer detected after the addition of L-histidine.  Native MS experiments showed, 
monomeric and dimeric MtATP-PRT present at pH 9 to similarly decrease in intensity 
after incubation with L-histidine (Figure 6.8 c).  In summary, AUC data is in agreement 
with results obtained from IM-MS and HDX-MS studies i.e. detection of subtle 
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conformational tightening of MtATP-PRT at pH 6.8 upon L-histidine addition noted, 




A set of MS based techniques has been employed to investigate allosteric inhibition 
mechanism of MtATP-PRT, a 190 kDa homohexameric enzyme catalysing the first step 
of the biosynthesis of L-histidine in Mycobacterium tuberculosis.  Native MS revealed 
MtATP-PRT to exist in the hexameric state under physiological conditions.  The binding 
stoichiometry could not be conclusively determined from the mass shift due to a 
significant mass difference between the ligand and the protein as well as a considerable 
amount of residual solvent and buffer present under the gentle desolvation conditions 
used to preserve non-covalent interactions.  Nevertheless, in-source dissociation MS 
experiments suggest that the first four L-histidine molecules binding may have different 
affinity from the subsequent two. 
 
Conformational changes induced by L-histidine binding and the influence of buffer pH 
were probed with IM-MS, HDX-MS and AUC.  Results obtained from all three 
techniques support the occurrence of subtle conformational changes upon ligand binding 
at pH 6.8.  Linear drift-tube IM-MS experiments showed a decrease in the median CCS 
from 76.6 nm2 to 73.5 nm2 (for the 28+ charge state) and this change was also confirmed 
by the theoretical CCS calculated from the available crystal structures.  No such changes 
in conformation were found to take place at pH 9.  Sedimentation velocity analysis 
confirmed the conformational tightening upon ligand binding observed in vacuo.   
 
Furthermore, HDX was used for mapping of the conformational changes and the results 
are in agreement with x-ray crystallography data.  Changes in the deuterium uptake 
between apo MtATP-PRT and L-histidine bound MtATP-PRT occurring on a short time 
scale were found within domain III and are associated with L-histidine binding to the 
allosteric site.  Changes occurring on longer time scales related to conformational 
changes induced by ligand binding were identified around the active site and near the 
residues involved in AMT binding and residues proposed to be involved in binding of 
ATP and PRPP substrates.  
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The collected data supports the mechanism proposed by Pedreño et al., which envisions 
MtATP-PRT as a functional hexamer where conformational changes have to be invoked 
to explain the allosteric inhibition.  Still, more experiments need to be carried out for 
further elucidation of the inhibition mechanism and determination of the binding 
stoichiometry (such as IM- and CID-based titration).  In future, a combination of 
methods employed here, will be used to scan libraries of MtATP-PRT inhibitor ligands 
with the aim to discover potential novel anti-tuberculosis agents.   
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Mass spectrometry in conjunction with  ion mobility and hydrogen deuterium exchange 
have been used to probe structure, dynamics, interactions and stability of several large 
proteins and multimeric protein complexes.  Conformational changes of these proteins 
induced by ligand binding or elevated temperature or pH were probed. This chapter 
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Mass spectrometry evolved into a powerful tool for the analysis of protein architecture, 
dynamics and interactions with significant benefits for structural biology and drug 
discovery.  Intact proteins and their complexes can be analysed with molecular weight 
even on a mega Dalton scale, and the results can be related to data obtained via other 
biophysical techniques to create a fuller picture of their structure.  In the presented work, 
mass spectrometry in conjunction with ion mobility and hydrogen deuterium exchange 
was used to investigate a broad spectrum of protein behaviour ranging from gas-phase 
dynamics of therapeutic antibodies, temperature induced dissociation mechanism of non-
covalent protein complexes, through probing of thermal stability of mAbs to mapping of 
conformational changes in enzymes upon allosteric inhibition.  Proteins and protein 
complexes studied here ranged in mass from 55 kDa to 190 kDa.  The key conclusions 
derived from the described studies are summarized below and directions for further 
research are proposed.  
 
In Chapter 3, higher order structure and dynamics of intact monoclonal antibodies 
(mAbs) and their fragments were explored with IM-MS and MD.  In comparison to other 
protein complexes of similar size, mAbs displayed significantly broader conformational 
landscape attributed to their intrinsic flexibility and structural dynamics.  MD 
simulations revealed dynamics between linked folded domains of mAbs and indicated 
that desolvation causes a contraction mainly in the hinge region and loss of cavities 
between the folded domains of mAbs; while much of the secondary structure as well as 
the tertiary fold are retained.  Experimentally observed differences in IM-MS data 
among the two IgG subclasses (IgG1 and IgG4) were rationalized based on the distinct 
features in the hinge region and the non-covalent interactions at the CH3-CH3 domain 
interface.  While significant gas-phase contraction is observed during nESI process 
raising caveats about the use of MS to probe higher order structure in flexible proteins;  
presented data have shown that the linked folded domains of mAbs ‘dance’ in the 
absence of solution as they do in the condensed phase.  In future, it would be worthwhile 
to explore dynamic behaviour of other IgG subclasses to further pinpoint the effect of 
structural differences on the conformational landscapes derived from IM-MS 
experiments.  Moreover, performing IM-MS experiments at low buffer gas temperature 
would allow ‘freezing’ mAb molecules and potentially provide more insights into their 
conformational diversity.  
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In Chapter 4, four non-covalent protein complexes were examined at several discrete 
temperatures ranging from 300 K to 550 K.  Increased buffer gas temperature leads to 
complex dissociation and structural changes occurring along the way.  Variable 
temperature MS (VT-MS) measurements allowed decoupling of melting temperature 
(Tm) associated with loss of structure in solution measurements, from the protein 
complex gas-phase dissociation temperature (TGPD).  The thermally induced dissociation 
(TID) mechanism was found to follow a ‘typical’ CID-like dissociation route.  VT-IM-
MS data have shown that complexes undergo an initial collapse at 350 K and 400 K.  
Subsequent unfolding and eventual release of a highly charged monomer from the 
complex at temperatures above 450 K were marked by increase in median CCS.  
Broadening of the CCSD was associated with a series of unfolding events prior to 
complex dissociation.  Interestingly, at higher analysis temperature, the ejected monomer 
carrying lower average charge, was slightly less unfolded and had a narrowed CCSD 
profile, suggesting that the TID dissociation process might be adopting more ‘atypical’ 
dissociation route.  In future, experiments at temperatures above 550 K shall be carried 
out to confirm this hypothesis.  Within the temperature range where the initial loss of 
structure and dissociation occurs, the TID process was shown to follow the ‘typical’ CID 
route, hence correlating the TID temperature and CID energies would allow for TGDP to 
be performed on commonly available instruments with CID capabilities.  The presented 
data portrays the importance of analysis temperature for protein structural, and 
highlighted the difference between gas phase and solution thermal stability.   
 
The VT-IM-MS  methodology employed in Chapter 4, was further applied to probe 
thermal stability of mAbs, albeit without dissociation.  Chapter 5 describes 
conformational changes occurring in intact mAbs and their fragments at elevated 
temperatures up to 550 K, aimed to predict thermal stability of therapeutic proteins.  
IgG1, IgG4 and their Fc-hinge fragments followed unfolding mechanism similar to that 
of non-covalent protein complexes.  Although no dissociation of these covalent 
molecules is present, mAbs were noted to undergo initial collapse at 350 - 400 K and 
subsequent unfolding of domains as the buffer gas temperature is increased.  The 
temperature at which the maximum collapse was observed is speculated to be correlated 
to the solution Tm.  Differences in the extent of collapse and unfolding among IgG 
subclasses occur to be controlled by the differences in the hinge flexibility and strength 
of non-covalent interactions at the CH3 domain interface.  A hybrid IgG (IgG4 with 
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IgG1 hinge) engineered for enhanced thermal stability, displayed an unfolding pathway 
which did not resemble the one of other IgGs investigated.  No compaction was noted 
and broader conformational landscapes of this hybrid mAb at temperatures above 300 K 
acquired suggest higher structural flexibility contributing to increased thermal stability.  
The unanswered questions about the gas-phase behaviour and unfolding route of this 
hybrid IgG leave room for further investigation.  Nevertheless, VT-IM-MS is a 
promising tool for probing thermal stability of therapeutic proteins and benefit drug 
development process aimed at enhancing stability of biologics to reduce aggregation.  
Furthermore, VT-(IM)-MS methodology could be applied to study extremophile proteins 
such as thermophilic or antifreeze proteins.   
 
The final results Chapter 6, sets out to probe conformational changes of metabolic 
enzymes induced by natural feedback allosteric inhibition, and to further elucidate the 
inhibition mechanism.  MtATP-phosphoribosyltransferase (MtATP-PRT) inhibition with 
L-histidine was probed using native MS, IM-MS and HDX-MS.  MtATP-PRT was 
found to exist in the hexameric state under physiological conditions and to undergo 
subtle conformational changes upon ligand binding and changes in pH.  Ligand induced 
changes were found to occur only at pH 6.8 as opposed to pH 9.  This conformational 
tightening observed in vacuo was further confirmed via SV-AUC experiments.  HDX-
MS methodology was employed to map the conformational changes and the results were 
found in agreement with x-ray crystallography data.  Changes in the deuterium uptake 
between apo MtATP-PRT and L-histidine bound MtATP-PRT occurring on a short time 
scale were associated with L-histidine binding to the allosteric site while changes 
occurring on longer time scales were caused by conformational changes induced by 
ligand binding.  The predicted inhibition mechanism envisions MtATP-PRT as a 
functional hexamer where conformational changes have to be invoked to explain the 
allosteric inhibition.  Once the protein purification protocol has been established, more 
experiments will need to be performed to further investigate binding stoichiometry, 
importance of substrate presence on the inhibition and influence of the buffer pH.  In the 
near future, a combination of MS, IM-MS and HDX-MS, will be applied to scan 
libraries of MtATP-PRT inhibitor ligands with the aim to discover potential novel anti-
tuberculosis agents.   
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MS has proved to be a valuable tool for investigation of protein structures in solvent-free 
environment with clear application and benefits to medical and pharmaceutical research.  
Further method development will help to understand and provide more insight into 
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Appendix 1: Amino Acid Abbreviations and Properties  
 














Glycine Gly G C2H5NO2 75.03203 75.06660 
Alanine Ala A C3H7NO2 89.04768 89.09318 
Serine Ser S C3H7NO3 105.0426 105.0926 
Proline Pro P C5H9NO2 115.0633 115.1305 
Valine Val V C5H11NO2 117.0790 117.1463 
Threonine Thr T C4H9NO3 119.0582 119.1192 
Cysteine Cys C C3H7NO2 S 121.0197 121.1582 
Leucine Leu L C6H13NO2 131.0946 131.1729 
Isoleucine Ile I C6H13NO2 131.0946 131.1729 
Asparagine Asn N C4H8N2O3 132.0535 132.1179 
Aspartic Acid Asp D C4H7NO4 133.0375 133.1027 
Glutamic Acid Gln Q C5H9NO4 147.0532 147.1293 
Lysine Lys K C6H14N2O2 146.1055 146.1876 
Glutamine Glu E C5H10N2O3 146.0691 146.1445 
Methionine Met M C5H11NO2S 149.0510 149.2113 
Histidine His H C6H9N3O2 155.0695 155.1546 
Phenylalanine Phe F C9H11NO2 165.0790 165.1891 
Arginine Arg R C6H14N4O2 174.1117 174.2010 
Tyrosine Tyr Y C9H11NO3 181.0739 181.1885 
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Appendix 2: Amino Acid R Groups 
 









Electrically Charged Amino Acids 
 
 
Figure taken from the website of the Department of Biology, Pennsylvania State 
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Appendix 3: Sequences and Theoretical Masses of Proteins 
Studied in this Thesis 
 
 
(variable domains of IgGs provided below are indicated in black) 
 
IgG ‘A’  anti-TNF 
 




























      Intact IgG1 A    Intact IgG4 A 
Average  mass   147 199.13 Da   146 868.42 Da 
Monoisotopic mass  147 106.78 Da   146 776.18 Da 
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IgG ‘B’  anti-Her 
 




























      Intact IgG1 B    Intact IgG4 B 
Average  mass   145 337.32 Da   145 006.61 Da 
Monoisotopic mass  145 246.13 Da   144 915.53 Da 
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IgG ‘C’  anti-KC1 
 







































      Intact IgG1 C   Intact IgG4 C       Intact IgG4 C 
             w/IgG1 C hinge 
Average  mass   145 255.38 Da           144 924.67 Da       145 649.44 Da 
Monoisotopic mass  145 164.37 Da           144 833.77 Da       145 558.16 Da 
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IgG ‘C’  anti-KC1 Fc-hinge fragment  
 














     Fc-hinge IgG1 C     Fc-hinge IgG4 C 
Average  mass  52 167.16 Da    51 510.16 Da 
Monoisotopic mass 52 134.11 Da    51 477.49 Da 











      Monomer    Tetramer 
Average  mass   13 761.41 Da   54 991.58 Da 
Monoisotopic mass  13 752.89 Da   54 957.52 Da 
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Avidin 
 






cabrohydrate moiety 1640 (4-5 x mannose + 3 x N-acetylglucosamine)  
 
Monomer    Tetramer + carbohydrate  
Average  mass   14343.17 Da  63 932.68 Da 
Monoisotopic mass  14334.25 Da  63 870.00 Da 
Theoretical pI   10.281 
 
 
Concanavalin A (conA) 
 








      Monomer    Tetramer 
Average  mass   25 572.38 Da   102 235.48 Da 
Monoisotopic mass  25 556.76 Da  102 172.95 Da 
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Serum Amyloid P Component (SAP) 
 







      Monomer    Pentamer 
Average  mass   23 358.53 Da  116 220.58 Da 
Monoisotopic mass  23 243.95 Da  116 147.71 Da 
Theoretical pI    6.291  
 
 
His-Tag Mt-ATP-phosphoribosyltransferase  
 









      Monomer    Hexamer  
Average  mass   31 648.04 Da  189 798.15 Da 
Monoisotopic mass   31 628.31 Da  189 679.80 Da 
Theoretical pI    5.557    
 
 
* Theoretical pI values were calculated using the online protein isoelectric point calculator 
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Appendix 5: Median Collision Cross Sections of Protein 
Complexes at Various Analysis Temperatures 
 
 
Median collision cross sections (CCS) of transthyretin (TTR) and serum amyloid P 
component (SAP) at various buffer gas temperatures (T / K) along with relative change 
in CCS (Δ) for each charge state (CS) with respect to CCS at 300 K.  Reported values 
are averages based on two experimental repeats. 
P = pentamer, T = tetramer, M = monomer  
 
 TTR SAP 






T [13+] 31.28 ± 0.15 - P [22+] 59.08  ± 1.01 - 
T [14+] 32.02 ± 0.52 - P [23+] 61.41 ± 0.86 - 
T [15+] 33.50 ± 1.30 - P [24+] 62.86 ± 0.76 - 
- - - P [25+] 63.26 ± 1.02 - 








T [13+] 30.73 ± 0.01 -1.74 P [22+] 58.86 ± 0.22 -3.65 
T [14+] 31.39 ± 0.13 -1.97 P [23+] 61.39 ± 0.70 -3.27 
T [15+] 32.30 ± 0.15 -3.60 P [24+] 63.24 ±0.37 -1.86 
- - - P [25+] 63.99 ± 0.26 -0.39 






T [13+] 30.57 ± 0.06 -2.25 P [22+] 58.77 ± 0.16 -1.08 
T [14+] 31.12 ± 0.01 -2.81 P [23+] 60.27 ± 1.23 -2.66 
T [15+] 32.28 ± 0.11 -3.64 P [24+] 63.76 ± 2.56 -0.38 
- - - P [25+] 65.47 ± 2.74 +1.09 






T [13+] 30.80 ± 0.13 -1.52 P [22+] 60.05 ± 0.88 +0.73 
T [14+] 32.10 ± 0.13 -0.25 P [23+] 64.70 ± 0.18 +3.06 
T [15+] 35.94 ± 0.29 +7.27 P [24+] 69.02 ± 0.11 +6.81 
- - - P [25+] 71.82 ± 0.03 +11.05 
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T [13+] 38.31 ± 0.34 +22.49 P [22+] 66.00 ± 0.22 +12.61 
T [14+] 40.02 ± 0.13 +24.98 P [23+] 68.63 ± 0.16 +11.23 
T [15+] 42.01 ± 0.54 +25.40 P [24+] 71.76 ± 0.01 +14.80 
M [7+] 16.83 ± 0.06 - P [25+] 74.14 ± 0.33 +18.38 
M [8+] 20.94 ± 0.28 - P [26+] 77.79 ± 0.43 +25.15 






T [13+] 39.48 ± 2.19 +26.24 P [22+] 70.76 ± 0.32 +19.07 
T [14+] 44.28 ± 1.15 +38.29 P [23+] 73.34 ± 0.41  +18.14 
T [15+] 47.02 ± 1.14 +40.34 P [24+] 76.14 ± 0.19 +20.43 
M [7+] 16.90 ± 0.08 - P [25+] 76.43 ± 0.25 +21.76 
M [8+] 19.60 ± 0.01 - P [26+] 80.66 ± 1.12 +28.05 
M [9+] 21.31 ±0.01 - M [10+] 25.77  ± 0.54  
M [10+] 21.59 ± 0.95 - M [11+] 29.75 ± 0.33  
- - - M [12+] 32.65 ± 0.42  






- - - P [22+] 77.35 ± 0.80 +31.16 
- - - P [23+] 76.56 ± 0.52 +23.98 
- - - P [24+] 81.83 ± 0.04 +29.99 
- - - P [25+] 77.51 ± 1.07 +23.19 
- - - P [26+] 89.70 ± 0.86 +44.21 
- - - M [10+] 28.35 ± 0.01 - 
- - - M [11+] 29.92 ± 0.02 - 
- - - M [12+] 32.22 ± 0.05 - 
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Median collision cross sections (CCS) of avidin and concanavalin A (conA) at various 
buffer gas temperatures (T / K) along with relative change in CCS (Δ) for each charge 
state (CS) with respect to CCS at 300 K.   
T = tetramer, D = dimer, M = monomer  
 
 Avidin ConA 






T [15+] 32.78 - T [19+] 47.47 - 
T [16+] 34.76 - T [20+] 47.98 - 
- - - T [21+] 48.20 - 
- - - T [22+] 50.66 - 
- - - D [13+] 32.45 - 
- - - D [14+] 33.19 - 
- - - D [15+] 35.82 - 








T [15+] 32.34 -1.34 T [19+] 47.42 -0.11 
T [16+] 33.77 -2.85 T [20+] 48.14 +0.33 
T [17+] 46.33 - T [21+] 48.44 +0.50 
- - - T [22+] 48.69 -3.89 
- - - D [13+] 31.98 -1.45 
- - - D [14+] 33.17 -0.06 
- - - D [15+] 34.66 -3.24 






T [15+] 31.86 -2.81 T [19+] 46.76 -1.50 
T [16+] 33.75 -2.91 T [20+] 47.50 -1.00 
T [17+] 40.95 - T [21+] 47.73 -0.98 
- - - T [22+] 48.34 -4.58 
- - - D [13+] 31.58 -2.68 
- - - D [14+] 32.52 -2.02 
- - - D [15+] 34.32 -4.19 
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T [15+] 32.62 -1.65 T [19+] 46.63 -1.77 
T [16+] 35.79 +2.96 T [20+] 47.47 -1.06 
T [17+] 41.23 - T [21+] 50.38 +4.52 
- - - T [22+] 54.25 +7.09 
- - - D [13+] 32.16 -0.89 
- - - D [14+] 34.46 +3.83 
- - - D [15+] 38.26 +6.81 






T [15+] 35.62 +8.66 T [19+] 52.20 +9.96 
T [16+] 40.29 +15.91 T [20+] 54.54 +13.67 
T [17+] 43.81 - T [21+] 58.33 +21.02 
M [7+] 16.95 - T [22+] 62.36 +22.90 
M [8+] 19.28 - D [13+] 37.18 +14.58 
M [9+] 21.66 - D [14+] 39.35 +18.56 
M [10+] 22.60 - D [15+] 42.02 +17.31 






T [15+] 40.81 +24.50 T [19+] 61.13 +28.78 
T [16+] 44.33 +27.53 T [20+] 64.57 +34.58 
T [17+] 47.33 - T [21+] 69.28 +43.73 
M [7+] 17.14 - T [22+] 72.10 +42.32 
M [8+] 18.31 - D [13+] 41.36 +27.46 
M [9+] 20.08 - D [14+] 42.05 +26.69 
M [10+] 20.65 - D [15+] 45.88 +28.08 
M [11+] 20.99 - M [9+] 25.06 +20.08 
- - - M [10+] 27.84 - 
- - - M [11+] 29.38 - 
- - - M [12+] 31.20 - 
- - - M [13+] 33.18 - 
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CS CCS /nm2 Δ/% CS CCS /nm2 Δ/% 
- - - M [15+] 35.26 - 
- - - M [16+] 28.47 - 






- - - T [19+] 70.01 +47.48 
- - - T [20+] 71.12 +48.23 
- - - T [21+] 73.05 +51.56 
- - - T [22+] 74.93 +47.91 
- - - D [13+] 43.31 +33.47 
- - - D [14+] 44.00 +32.57 
- - - D [15+] 47.45 +32.47 
- - - M [9+] 26.72 +28.03 
- - - M [10+] 28.15 - 
- - - M [11+] 29.69 - 
- - - M [12+] 32.72 - 
- - - M [13+] 34.86 - 
- - - M [14+] 38.37 - 
- - - M [15+] 40.43 - 
- - - M [16+] 37.79 - 
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Appendix 6: Median Collision Cross Sections of IgGs and Fc-
hinge Fragments at Various Analysis Temperatures 
 
 
Median collision cross sections (CCS) of IgGs ‘C’ at various buffer gas temperatures (T 
/ K) along with relative change in CCS (Δ) for each charge state (CS) with respect to 
CCS at 300 K, based on one experimental repeat.  *CS = charge state 
 
 
 IgG1 IgG4 IgG4 + IgG1 hinge 






22 60.99  58.20  58.57  
23 63.42  60.26  59.83  
24 67.43  63.77  61.98  
25 72.58  67.21  65.11  






22 58.40 -4.25 57.10 -1.89 57.42 -1.96 
23 60.21 -5.06 59.31 -1.58 60.47 1.07 
24 63.58 -5.71 62.91 -1.35 65.24 5.26 
25 67.34 -7.22 68.01 1.19 71.73 10.17 






22 56.57 -7.25 58.16 -0.07 58.25 -0.55 
23 60.16 -5.14 58.99 -2.11 60.90 1.79 
24 63.00 -6.57 62.60 -1.83 66.47 7.24 
25 67.02 -7.66 67.97 1.13 72.55 11.43 






22 56.66 -7.10 54.62 -6.15 57.02 -2.65 
23 59.44 -6.28 59.59 -1.11 60.70 1.45 
24 62.42 -7.43 63.92 0.24 66.05 6.57 
25 65.63 -9.58 70.76 5.28 72.45 11.27 






22 60.49 -0.82 64.13 10.19 64.17 9.56 
23 67.90 7.06 68.85 14.25 68.67 14.78 
24 71.45 5.96 71.91 12.76 72.23 16.54 
25 73.39 1.12 74.96 11.53 75.89 16.56 






22 69.67 14.23 71.06 22.10 71.03 21.27 
23 73.49 15.88 74.11 22.98 73.76 23.28 
24 76.76 13.84 76.80 20.43 77.12 24.43 
25 79.26 9.20 80.30 19.48 80.02 22.90 






22 73.18 19.99 76.33 31.15 72.69 24.11 
23 76.51 20.64 78.40 30.10 77.76 29.97 
24 82.02 21.64 80.72 26.58 83.26 34.33 
25 83.74 15.38 83.38 24.06 86.74 33.22 
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Median collision cross sections (CCS) of Fc-hinge fragments at various buffer gas 
temperatures (T / K) along with relative change in CCS (Δ) for each charge state (CS) 














 12 30.26  29.44  
13 30.28  30.67  






 12 29.52 -2.45 28.89 -1.87 
13 29.64 -2.11 30.39 -0.91 






 12 29.12 -3.77 28.45 -3.36 
13 29.45 -2.74 30.20 -1.53 






 12 29.88 -1.26 28.43 -3.43 
13 30.85 1.88 31.71 3.39 






 12 32.51 7.44 30.43 3.36 
13 35.30 16.58 35.70 16.40 






 12 36.44 20.42 34.38 16.78 
13 39.05 28.96 40.36 31.59 
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Appendix 7: MtATP-PRT HDX data 
 










1 12 27 13 LRVAVPNKGALSEPAT 
2 12 28 14 LRVAVPNKGALSEPATE 
3 12 30 16 LRVAVPNKGALSEPATEIL 
4 13 28 13 RVAVPNKGALSEPATE 
5 13 30 15 RVAVPNKGALSEPATEIL 
6 29 35 6 ILAEAGY 
7 44 51 6 LTVIDPVN 
8 44 52 7 LTVIDPVNN 
9 44 55 10 LTVIDPVNNVEF 
10 45 55 9 TVIDPVNNVEF 
11 46 55 8 VIDPVNNVEF 
12 47 55 7 IDPVNNVEF 
13 56 62 5 FFLRPKD 
14 56 64 7 FFLRPKDIA 
15 57 65 7 FLRPKDIAI 
16 63 71 8 IAIYVGSGE 
17 63 73 10 IAIYVGSGELD 
18 63 74 11 IAIYVGSGELDF 
19 65 74 9 IYVGSGELDF 
20 66 73 7 YVGSGELD 
21 66 74 8 YVGSGELDF 
22 66 80 14 YVGSGELDFGITGRD 
23 67 80 13 VGSGELDFGITGRD 
24 72 80 8 LDFGITGRD 
25 73 79 6 DFGITGR 
26 73 80 7 DFGITGRD 
27 81 88 7 LVCDSGAQ 
28 81 91 10 LVCDSGAQVRE 
29 84 93 9 DSGAQVRERL 
30 89 102 13 VRERLALGFGSSSF 
31 92 102 10 RLALGFGSSSF 
32 94 101 7 ALGFGSSS 
33 94 102 8 ALGFGSSSF 
34 96 102 6 GFGSSSF 
35 102 111 8 FRYAAPAGRN 
36 103 111 7 RYAAPAGRN 
37 103 117 13 RYAAPAGRNWTTADL 
38 112 119 7 WTTADLAG 
39 117 129 11 LAGMRIATAYPNL 
40 120 129 8 MRIATAYPNL 
41 121 129 7 RIATAYPNL 













43 130 141 11 VRKDLATKGIEA 
44 130 142 12 VRKDLATKGIEAT 
45 142 151 9 TVIRLDGAVE 
46 143 149 6 VIRLDGA 
47 143 151 8 VIRLDGAVE 
48 152 159 7 ISVQLGVA 
49 152 160 8 ISVQLGVAD 
50 152 161 9 ISVQLGVADA 
51 154 161 7 VQLGVADA 
52 157 163 6 GVADAIA 
53 157 164 7 GVADAIAD 
54 160 179 19 DAIADVVGSGRTLSQHDLVA 
55 162 179 17 IADVVGSGRTLSQHDLVA 
56 164 179 0 DVVGSGRTLSQHDLVA 
57 165 179 14 VVGSGRTLSQHDLVA 
58 180 186 5 FGEPLCD 
59 180 188 7 FGEPLCDSE 
60 190 209 19 VLIERAGTDGQDQTEARDQL 
61 191 199 8 LIERAGTDG 
62 192 209 17 IERAGTDGQDQTEARDQL 
63 210 218 8 VARVQGVVF 
64 210 221 11 VARVQGVVFGQQ 
65 210 222 12 VARVQGVVFGQQY 
66 210 223 13 VARVQGVVFGQQYL 
67 212 218 6 RVQGVVF 
68 212 221 9 RVQGVVFGQQ 
69 212 223 11 RVQGVVFGQQYL 
70 225 233 7 LDYDCPRSA 
71 225 234 8 LDYDCPRSAL 
72 226 246 18 DYDCPRSALKKATAITPGLES 
73 226 259 28 
DYDCPRSALKKATAITPGLESPTIAPLADPD
WVA 
74 227 234 6 YDCPRSAL 
75 235 246 10 KKATAITPGLES 
76 235 259 0 KKATAITPGLESPTIA 
77 237 245 7 ATAITPGLE 
78 242 259 14 PGLESPTIAPLADPDWVA 
79 249 257 6 IAPLADPDW 
80 258 273 14 VAIRALVPRRDVNGIM 
81 260 273 12 IRALVPRRDVNGIM 
82 260 275 14 IRALVPRRDVNGIMDE 
83 276 285 9 LAAIGAKAIL 
84 277 285 8 AAIGAKAIL 







- 239 - 
D uptake – MtATP-PRT at pH 6.8 
 
Average relative D uptake at 1 minute, 10 minutes, 30 minutes and 120 minutes of 
exposure along with standard deviation values (SD). 
pH 6.8 D UPTAKE /Da 
peptide 
# 
1 min SD 10 min SD 30 min SD 120 min SD 
1 3.04 0.04 3.04 0.05 3.38 0.08 4.08 0.09 
2 3.06 0.04 3.04 0.03 3.38 0.05 4.07 0.10 
3 2.86 0.05 2.84 0.04 3.12 0.05 3.79 0.08 
4 3.05 0.03 3.02 0.05 3.30 0.06 4.01 0.10 
5 2.98 0.08 2.99 0.07 3.27 0.08 3.95 0.14 
6 0.30 0.04 0.33 0.05 0.46 0.04 0.75 0.04 
7 1.77 0.09 2.17 0.16 2.43 0.09 2.96 0.09 
8 1.90 0.06 2.48 0.04 2.86 0.06 3.39 0.08 
9 1.85 0.03 2.29 0.05 2.69 0.04 3.27 0.09 
10 1.73 0.12 2.08 0.05 2.25 0.09 2.43 0.24 
11 1.19 0.03 1.50 0.06 1.70 0.04 1.89 0.06 
12 1.10 0.08 1.42 0.05 1.54 0.05 1.69 0.08 
13 0.91 0.02 1.04 0.02 1.21 0.02 1.39 0.02 
14 1.18 0.11 1.62 0.05 1.86 0.03 2.12 0.03 
15 1.06 0.10 1.62 0.11 1.94 0.09 2.21 0.11 
16 1.16 0.10 1.51 0.06 1.87 0.07 2.37 0.06 
17 0.61 0.03 0.93 0.03 1.18 0.07 1.73 0.04 
18 0.48 0.06 0.69 0.05 1.02 0.07 1.57 0.13 
19 0.62 0.04 0.91 0.03 1.27 0.03 1.74 0.04 
20 0.53 0.01 0.84 0.02 1.20 0.03 1.65 0.07 
21 0.68 0.03 1.05 0.02 1.45 0.03 2.02 0.06 
22 0.94 0.12 1.69 0.12 2.12 0.02 2.54 0.15 
23 1.13 0.09 1.63 0.10 2.05 0.03 2.34 0.04 
24 0.92 0.07 1.16 0.06 1.23 0.06 1.32 0.15 
25 0.72 0.02 0.92 0.01 1.00 0.01 1.06 0.01 
26 0.74 0.11 0.86 0.07 1.04 0.10 1.03 0.06 
27 1.96 0.03 1.96 0.03 2.05 0.07 2.23 0.04 
28 3.00 0.04 3.54 0.12 3.72 0.15 3.72 0.08 
29 2.51 0.14 2.70 0.16 2.83 0.12 2.91 0.18 
30 2.28 0.20 2.54 0.13 3.02 0.28 3.40 0.19 
31 1.86 0.03 2.16 0.01 2.50 0.06 3.05 0.03 
32 1.97 0.03 2.04 0.07 2.17 0.02 2.57 0.04 
33 1.24 0.03 1.49 0.04 1.86 0.06 2.39 0.07 
34 1.60 0.01 1.74 0.01 1.86 0.02 2.00 0.02 
35 2.25 0.06 2.41 0.06 2.56 0.05 3.05 0.13 
36 2.31 0.04 2.46 0.01 2.56 0.03 2.87 0.02 
37 3.69 0.04 4.02 0.02 4.42 0.05 5.17 0.08 
38 1.17 0.05 1.30 0.02 1.62 0.07 2.15 0.04 
39 0.55 0.08 0.88 0.06 1.70 0.12 3.17 0.08 
40 0.39 0.16 0.65 0.16 1.13 0.18 2.19 0.18 
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peptide 
# 
1 min SD 10 min SD 30 min SD 120 min SD 
42 1.35 0.04 2.08 0.04 2.37 0.03 2.88 0.05 
43 1.95 0.06 2.79 0.05 3.04 0.05 3.55 0.04 
44 2.08 0.15 3.15 0.19 3.54 0.14 4.33 0.10 
45 2.17 0.09 2.86 0.08 3.47 0.06 4.27 0.13 
46 1.33 0.05 1.56 0.06 1.80 0.08 2.17 0.07 
47 2.01 0.04 2.63 0.06 3.12 0.04 3.75 0.02 
48 1.37 0.03 1.75 0.03 2.07 0.01 2.91 0.03 
49 1.45 0.11 1.83 0.07 2.19 0.06 2.97 0.08 
50 1.70 0.17 2.16 0.36 2.43 0.04 3.29 0.10 
51 0.70 0.03 1.00 0.03 1.27 0.05 1.86 0.05 
52 0.40 0.06 0.38 0.04 0.61 0.07 1.29 0.07 
53 0.45 0.08 0.44 0.02 0.68 0.08 1.48 0.12 
54 6.01 0.07 6.14 0.07 6.72 0.12 7.97 0.11 
55 4.44 0.11 4.84 0.09 5.23 0.10 6.00 0.07 
57 2.83 0.04 3.28 0.12 3.40 0.07 3.64 0.03 
58 0.71 0.03 0.70 0.05 0.82 0.09 1.28 0.04 
59 0.56 0.04 0.66 0.04 0.96 0.05 1.46 0.07 
60 6.35 0.18 6.93 0.10 7.17 0.16 7.62 0.15 
61 1.16 0.09 1.48 0.12 1.87 0.15 2.40 0.08 
62 5.97 0.06 6.40 0.04 6.60 0.13 7.01 0.12 
63 0.24 0.02 0.32 0.02 0.86 0.02 2.02 0.02 
64 0.58 0.05 0.95 0.07 2.31 0.06 3.89 0.06 
65 0.63 0.11 1.19 0.08 2.72 0.03 4.56 0.07 
66 0.61 0.04 1.21 0.05 2.93 0.03 4.82 0.15 
67 0.15 0.03 0.22 0.02 0.69 0.04 1.66 0.03 
68 0.57 0.06 0.99 0.07 1.94 0.07 3.52 0.14 
69 0.49 0.07 1.03 0.07 2.83 0.16 4.75 0.08 
70 0.72 0.05 1.08 0.10 2.02 0.07 2.63 0.08 
71 0.82 0.03 1.26 0.04 2.44 0.03 3.22 0.03 
72 4.31 0.31 5.62 0.18 7.56 0.30 8.65 0.27 
73 6.10 0.18 9.13 0.17 11.32 0.26 13.03 0.31 
74 0.80 0.09 1.17 0.10 2.05 0.09 2.57 0.09 
75 2.55 0.04 3.07 0.17 4.11 0.02 4.83 0.17 
77 1.48 0.06 1.75 0.02 2.35 0.02 2.91 0.05 
78 3.45 0.09 4.65 0.06 5.29 0.17 6.06 0.15 
79 1.20 0.03 1.82 0.14 2.07 0.14 2.38 0.07 
80 1.49 0.08 1.81 0.09 3.28 0.07 5.24 0.16 
81 1.53 0.03 1.77 0.04 2.84 0.03 4.24 0.07 
82 1.68 0.13 2.00 0.17 3.29 0.18 4.65 0.18 
83 0.53 0.02 1.50 0.03 2.86 0.02 4.32 0.03 
84 0.50 0.02 1.38 0.03 2.61 0.03 3.92 0.04 
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D uptake – MtATP-PRT + L-histidine at pH 6.8 
 
Average relative D uptake at 1 minute, 10 minutes, 30 minutes and 120 minutes of 
exposure along with standard deviation values (SD). 
pH 6.8 D UPTAKE /Da 
peptide 
# 
1 min SD 10 min SD 30 min SD 120 min SD 
1 3.05 0.03 3.00 0.03 3.25 0.03 3.67 0.06 
2 3.03 0.04 2.97 0.04 3.22 0.02 3.60 0.05 
3 2.84 0.03 2.77 0.02 2.94 0.03 3.25 0.06 
4 3.03 0.04 2.97 0.03 3.26 0.03 3.60 0.06 
5 2.95 0.08 2.89 0.09 3.09 0.08 3.43 0.10 
6 0.36 0.06 0.31 0.06 0.41 0.03 0.65 0.04 
7 1.80 0.05 2.07 0.13 2.17 0.04 2.38 0.04 
8 1.95 0.05 2.43 0.04 2.61 0.04 2.78 0.04 
9 1.89 0.11 2.23 0.05 2.41 0.10 2.62 0.06 
10 1.76 0.08 2.02 0.17 2.20 0.05 2.13 0.12 
11 1.21 0.02 1.53 0.04 1.66 0.05 1.67 0.02 
12 1.10 0.06 1.39 0.06 1.48 0.08 1.51 0.06 
13 0.87 0.02 1.03 0.02 1.23 0.02 1.32 0.03 
14 1.12 0.05 1.58 0.05 1.89 0.05 2.03 0.05 
15 1.06 0.08 1.66 0.14 1.96 0.06 2.12 0.09 
16 1.04 0.03 1.37 0.02 1.64 0.04 1.87 0.05 
17 0.56 0.04 0.83 0.06 1.13 0.03 1.47 0.02 
18 0.42 0.07 0.67 0.09 0.93 0.07 1.29 0.06 
19 0.61 0.03 0.86 0.03 1.23 0.03 1.62 0.03 
20 0.53 0.02 0.80 0.03 1.13 0.01 1.54 0.03 
21 0.65 0.03 1.00 0.02 1.42 0.02 1.93 0.04 
22 1.05 0.05 1.63 0.04 2.18 0.11 2.67 0.05 
23 1.10 0.11 1.61 0.10 2.06 0.09 2.42 0.05 
24 0.90 0.05 1.11 0.06 1.21 0.06 1.21 0.07 
25 0.69 0.02 0.89 0.01 0.98 0.01 0.98 0.02 
26 0.76 0.11 1.02 0.11 1.03 0.11 1.05 0.12 
27 1.96 0.02 1.93 0.03 2.01 0.04 2.07 0.04 
28 3.33 0.16 3.40 0.05 3.64 0.01 3.66 0.08 
29 2.56 0.18 2.80 0.10 2.94 0.08 2.96 0.15 
30 2.35 0.07 2.45 0.15 2.68 0.13 3.28 0.14 
31 1.89 0.05 2.04 0.02 2.35 0.05 2.83 0.06 
32 2.14 0.14 2.38 0.06 2.17 0.07 2.47 0.03 
33 1.20 0.04 1.37 0.03 1.68 0.04 2.21 0.06 
34 1.59 0.04 1.64 0.03 1.80 0.02 1.93 0.06 
35 2.21 0.06 2.40 0.07 2.40 0.03 2.37 0.05 
36 2.31 0.04 2.40 0.03 2.43 0.04 2.41 0.04 
37 3.64 0.04 3.89 0.02 4.14 0.02 4.46 0.08 
38 1.18 0.05 1.21 0.04 1.49 0.03 1.81 0.04 
39 0.45 0.04 0.69 0.05 0.99 0.04 1.28 0.04 
40 0.32 0.17 0.41 0.17 0.61 0.17 0.85 0.17 
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peptide 
# 
1 min SD 10 min SD 30 min SD 120 min SD 
42 1.30 0.03 2.03 0.03 2.20 0.03 2.23 0.04 
43 1.90 0.04 2.76 0.04 2.89 0.05 2.93 0.05 
44 2.02 0.10 3.10 0.15 3.32 0.18 3.51 0.22 
45 2.13 0.08 2.80 0.07 3.23 0.06 3.73 0.07 
46 1.30 0.03 1.52 0.06 1.71 0.09 1.83 0.07 
47 1.96 0.02 2.53 0.02 2.94 0.03 3.36 0.03 
48 1.33 0.01 1.69 0.01 1.75 0.02 1.86 0.03 
49 1.46 0.05 1.84 0.06 1.90 0.03 2.09 0.06 
50 1.68 0.31 1.99 0.03 2.11 0.04 2.27 0.06 
51 0.65 0.03 0.91 0.01 0.98 0.01 1.02 0.01 
52 0.35 0.03 0.29 0.03 0.31 0.03 0.33 0.04 
53 0.45 0.02 0.36 0.02 0.42 0.07 0.48 0.05 
54 5.88 0.09 6.05 0.04 6.40 0.05 6.96 0.12 
55 4.39 0.11 4.78 0.08 5.15 0.07 5.58 0.10 
57 2.84 0.03 3.23 0.03 3.38 0.03 3.34 0.05 
58 0.57 0.05 0.57 0.04 0.64 0.04 0.84 0.05 
59 0.52 0.02 0.55 0.03 0.71 0.04 1.09 0.04 
60 6.58 0.16 7.01 0.16 7.22 0.11 7.52 0.13 
61 1.21 0.06 1.32 0.10 1.67 0.11 2.17 0.07 
62 5.99 0.03 6.42 0.03 6.69 0.03 6.98 0.10 
63 0.22 0.01 0.21 0.01 0.24 0.01 0.31 0.01 
64 0.49 0.03 0.60 0.03 0.87 0.02 1.24 0.03 
65 0.49 0.04 0.62 0.05 0.96 0.02 1.37 0.04 
66 0.45 0.05 0.67 0.04 0.90 0.10 1.26 0.09 
67 0.13 0.03 0.11 0.03 0.11 0.02 0.18 0.02 
68 0.51 0.08 0.63 0.07 0.82 0.07 1.22 0.06 
69 0.52 0.11 0.65 0.07 0.82 0.11 1.16 0.07 
70 0.66 0.05 0.90 0.03 1.30 0.03 1.92 0.06 
71 0.76 0.03 1.00 0.03 1.43 0.03 2.08 0.05 
72 3.16 0.13 4.43 0.34 5.37 0.10 7.08 0.17 
73 3.87 0.18 5.65 0.17 7.26 0.21 10.01 0.20 
74 0.81 0.08 1.02 0.07 1.41 0.07 2.02 0.09 
75 1.50 0.07 2.30 0.07 2.78 0.06 3.26 0.26 
77 1.43 0.06 1.76 0.02 2.12 0.06 2.55 0.08 
78 1.77 0.04 2.74 0.08 3.44 0.13 4.28 0.11 
79 1.24 0.05 1.83 0.05 2.03 0.06 2.24 0.06 
80 1.54 0.14 1.60 0.15 2.04 0.10 2.72 0.15 
81 1.54 0.02 1.69 0.03 2.07 0.03 2.77 0.05 
82 1.75 0.13 2.03 0.12 2.55 0.13 3.30 0.14 
83 0.80 0.01 1.61 0.01 1.99 0.03 2.29 0.03 
84 0.76 0.01 1.45 0.01 1.72 0.01 1.80 0.03 
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D uptake – MtATP-PRT at pH 9 
 
Average relative D uptake at 1 minute, 10 minutes, 30 minutes and 120 minutes of 
exposure along with standard deviation values (SD). 
pH 9 D UPTAKE /Da 
peptide 
# 
1 min SD 10 min SD 30 min SD 120 min SD 
1 4.13 0.13 4.31 0.13 4.88 0.13 5.56 0.39 
2 4.30 0.04 4.40 0.09 5.03 0.11 5.74 0.13 
3 4.40 0.02 4.60 0.05 5.24 0.06 6.05 0.14 
4 4.01 0.15 4.25 0.12 4.81 0.18 5.44 0.22 
5 4.71 2.24 4.82 1.85 5.39 1.55 6.08 1.05 
6 0.82 0.13 0.96 0.05 1.09 0.17 1.59 0.09 
7 2.21 0.15 2.42 0.08 2.83 0.19 2.97 0.16 
8 2.43 0.11 2.75 0.12 3.19 0.11 3.47 0.12 
9 3.79 0.27 4.01 0.25 4.27 0.23 4.53 0.22 
10 2.24 1.09 2.45 0.81 2.82 1.35 3.01 1.51 
11 1.55 0.04 1.85 0.05 2.06 0.06 2.34 0.06 
12 1.44 0.08 1.72 0.06 1.86 0.08 2.12 0.09 
13 1.06 0.02 1.24 0.02 1.39 0.02 1.54 0.03 
14 1.49 0.03 1.89 0.03 2.14 0.03 2.41 0.04 
15 1.51 0.08 1.99 0.08 2.27 0.07 2.56 0.08 
16 1.60 0.26 1.98 0.44 2.37 0.38 2.68 0.23 
17 0.89 0.17 1.26 0.15 1.59 0.25 2.13 0.45 
18 0.91 0.12 1.31 0.08 1.68 0.15 2.38 0.15 
19 1.12 0.04 1.49 0.04 1.94 0.04 2.36 0.06 
20 0.89 0.02 1.25 0.03 1.61 0.01 2.03 0.02 
21 1.20 0.03 1.64 0.02 2.12 0.04 2.53 0.02 
22 1.69 0.24 2.67 0.17 3.42 0.23 3.82 0.24 
23 1.75 0.27 2.35 0.24 2.87 0.21 3.33 0.30 
24 1.38 0.03 1.49 0.14 1.66 0.16 1.92 0.17 
25 0.97 0.03 1.13 0.03 1.23 0.06 1.42 0.08 
26 1.05 0.03 1.20 0.12 1.31 0.07 1.54 0.11 
27 2.20 0.04 2.10 0.06 2.17 0.09 2.27 0.16 
28 3.68 0.22 3.80 0.12 3.96 0.13 4.07 0.34 
29 2.90 0.19 3.18 0.22 3.40 0.22 3.46 0.27 
30 2.62 0.18 2.92 0.08 3.37 0.12 3.99 0.27 
31 2.26 0.05 2.60 0.60 3.16 0.76 3.55 0.67 
32 2.30 0.09 2.24 0.02 2.36 0.03 2.65 0.07 
33 1.53 0.04 1.74 0.04 2.04 0.05 2.48 0.07 
34 1.64 0.02 1.68 0.03 1.77 0.07 1.88 0.04 
35 2.80 0.07 2.86 0.06 3.11 0.10 3.54 0.11 
36 2.76 0.06 2.80 0.07 2.94 0.07 3.16 0.09 
37 4.80 0.25 4.86 1.18 5.48 1.48 6.04 1.69 
38 1.70 0.44 1.97 0.75 2.20 0.58 2.59 0.63 
39 1.72 0.23 2.32 0.26 3.08 0.27 4.05 0.21 
40 1.24 0.40 1.81 0.45 2.28 0.41 3.30 0.42 
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peptide 
# 
1 min SD 10 min SD 30 min SD 120 min SD 
42 2.18 0.04 2.59 0.05 2.91 0.03 3.34 0.07 
43 2.81 0.05 3.19 0.03 3.46 0.02 3.93 0.06 
44 3.23 0.15 3.73 0.14 4.17 0.16 4.86 0.12 
45 2.69 0.10 3.18 0.06 3.78 0.07 4.32 0.14 
46 1.60 0.09 1.72 0.06 1.89 0.06 2.17 0.07 
47 2.45 0.03 2.82 0.02 3.32 0.02 3.70 0.06 
48 1.90 0.18 2.26 0.13 2.68 0.13 3.47 0.16 
49 2.00 0.51 2.55 0.50 3.01 0.46 3.69 0.49 
50 2.31 0.14 2.65 0.13 3.17 0.22 3.95 0.15 
51 1.12 0.06 1.38 0.03 1.78 0.11 2.31 0.05 
52 0.62 0.11 0.83 0.06 1.61 0.36 1.71 0.08 
53 1.10 0.13 1.09 0.10 1.52 0.08 2.11 0.10 
54 6.82 0.07 7.00 0.11 7.72 0.10 8.69 0.19 
55 5.00 0.03 5.21 0.07 5.67 0.07 6.22 0.15 
56 5.05 0.03 5.22 0.05 5.47 0.07 5.83 0.14 
57 3.27 0.03 3.48 0.04 3.62 0.04 3.82 0.10 
58 0.67 0.04 0.77 0.05 0.94 0.04 1.23 0.06 
59 0.73 0.10 0.91 0.06 1.19 0.06 1.66 0.09 
60 7.13 0.13 7.29 0.08 7.51 0.13 7.98 0.16 
61 1.33 0.07 1.66 0.11 1.94 0.13 2.32 0.06 
62 6.65 0.05 6.70 0.07 6.84 0.10 7.15 0.15 
63 0.97 0.05 1.31 0.05 2.10 0.08 3.02 0.17 
64 1.84 0.07 2.56 0.08 3.85 0.07 4.84 0.10 
65 2.09 0.59 2.85 0.50 4.56 0.31 5.62 0.34 
66 2.19 0.47 3.07 0.52 4.68 0.27 5.81 0.26 
67 1.13 0.19 1.34 0.21 1.67 0.19 2.28 0.07 
68 1.40 0.11 1.99 0.19 3.24 0.08 4.19 0.06 
69 1.87 0.39 2.63 0.48 4.22 0.33 5.55 0.32 
70 1.09 0.03 1.61 0.04 2.41 0.04 2.64 0.07 
71 1.57 0.73 2.39 0.71 3.25 0.60 3.86 0.81 
72 5.51 0.14 6.81 0.11 8.42 0.27 8.53 0.37 
73 8.21 0.23 10.36 0.22 12.37 0.18 13.18 0.38 
74 1.01 0.11 1.49 0.12 2.21 0.11 2.48 0.13 
75 3.72 0.46 4.17 0.48 4.68 0.60 4.82 0.70 
76 5.58 0.05 6.71 0.04 7.77 0.09 8.31 0.17 
77 1.77 0.11 2.12 0.08 2.53 0.13 2.86 0.11 
78 4.32 0.16 4.95 0.20 5.22 0.26 5.52 0.08 
79 1.81 0.63 2.19 0.59 2.23 0.47 2.48 0.56 
80 1.74 0.08 2.41 0.20 4.29 0.14 5.67 0.20 
81 1.76 0.04 2.18 0.06 3.60 0.11 4.57 0.12 
82 1.94 0.13 2.53 0.18 4.03 0.19 5.10 0.32 
83 1.11 0.06 2.13 0.08 3.75 0.09 4.67 0.11 
84 1.02 0.05 1.94 0.07 3.31 0.12 4.29 0.09 
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D uptake – MtATP-PRT + L-histidine at pH 9 
 
Average relative D uptake at 1 minute, 10 minutes, 30 minutes and 120 minutes of 
exposure along with standard deviation values (SD). 
pH 9 D UPTAKE / Da 
peptide 
# 
1 min SD 10 min SD 30 min SD 120 min SD 
1 4.09 0.03 4.26 0.04 4.71 0.05 5.42 0.28 
2 4.23 0.02 4.33 0.06 4.82 0.18 5.57 0.05 
3 4.33 0.04 4.50 0.06 4.98 0.07 5.87 0.07 
4 4.00 0.13 4.18 0.08 4.60 0.20 5.28 0.20 
5 4.75 2.40 4.75 1.90 5.00 0.75 5.95 1.58 
6 0.80 0.06 0.80 0.14 1.13 0.05 1.36 0.07 
7 2.23 0.14 2.49 0.16 2.64 0.14 3.06 0.09 
8 2.33 0.05 2.58 0.13 3.20 0.16 3.39 0.09 
9 3.67 0.24 3.98 0.25 4.24 0.24 4.45 0.18 
10 2.45 1.11 2.48 0.84 2.78 1.32 2.96 1.06 
11 1.55 0.04 1.85 0.04 1.99 0.06 2.25 0.05 
12 1.41 0.06 1.67 0.07 1.82 0.07 2.05 0.07 
13 1.04 0.01 1.22 0.02 1.37 0.02 1.54 0.02 
14 1.46 0.02 1.89 0.04 2.12 0.02 2.37 0.02 
15 1.47 0.04 1.91 0.11 2.18 0.07 2.50 0.04 
16 1.49 0.23 1.85 0.10 2.23 0.18 2.57 0.13 
17 0.90 0.10 1.24 0.13 1.62 0.14 2.14 0.24 
18 0.90 0.08 1.24 0.07 1.60 0.07 2.37 0.23 
19 1.09 0.02 1.45 0.03 1.90 0.03 2.35 0.02 
20 0.85 0.02 1.22 0.03 1.58 0.03 1.95 0.02 
21 1.17 0.03 1.61 0.02 2.08 0.03 2.54 0.02 
22 2.08 0.24 2.80 0.12 3.50 0.16 4.04 0.12 
23 1.75 0.27 2.42 0.24 3.03 0.26 3.50 0.18 
24 1.29 0.07 1.55 0.09 1.62 0.15 1.85 0.13 
25 0.94 0.03 1.13 0.04 1.23 0.07 1.31 0.05 
26 0.94 0.06 1.12 0.05 1.23 0.08 1.41 0.10 
27 2.17 0.02 2.09 0.02 2.15 0.03 2.31 0.06 
28 3.70 0.11 3.82 0.13 3.93 0.15 4.02 0.27 
29 3.01 0.27 3.09 0.29 3.27 0.23 3.55 0.14 
30 2.73 0.10 2.96 0.16 3.28 0.11 4.12 0.10 
31 2.38 0.60 2.46 0.04 2.77 0.04 3.41 0.53 
32 2.34 0.15 2.31 0.10 2.38 0.02 2.72 0.05 
33 1.49 0.03 1.70 0.03 1.96 0.04 2.42 0.06 
34 1.60 0.02 1.66 0.02 1.73 0.03 1.86 0.01 
35 2.76 0.11 2.84 0.06 2.93 0.11 3.47 0.10 
36 2.74 0.05 2.83 0.08 2.90 0.09 3.18 0.08 
37 4.86 1.31 4.55 0.12 5.30 1.86 5.85 0.79 
38 1.57 0.51 1.79 0.68 2.15 0.65 2.46 0.69 
39 1.81 0.24 2.14 0.27 2.62 0.21 4.08 0.16 
40 1.42 0.25 1.65 0.25 2.12 0.24 3.48 0.28 
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peptide 
# 
1 min SD 10 min SD 30 min SD 120 min SD 
42 2.14 0.04 2.63 0.13 2.77 0.03 3.31 0.04 
43 2.75 0.04 3.15 0.02 3.35 0.04 3.86 0.07 
44 3.17 0.13 3.70 0.13 3.99 0.12 4.79 0.14 
45 2.69 0.10 3.17 0.07 3.71 0.08 4.41 0.10 
46 1.58 0.09 1.67 0.07 1.87 0.09 2.15 0.05 
47 2.43 0.01 2.83 0.02 3.29 0.06 3.70 0.02 
48 1.88 0.12 2.19 0.13 2.43 0.15 3.39 0.11 
49 1.96 0.68 2.29 0.67 2.80 0.71 3.46 0.63 
50 2.34 0.19 2.62 0.18 2.99 0.22 3.94 0.19 
51 1.09 0.06 1.33 0.03 1.58 0.10 2.23 0.15 
52 0.71 0.04 0.76 0.04 0.97 0.09 1.65 0.05 
53 0.96 0.10 1.12 0.05 1.26 0.08 2.00 0.14 
54 6.77 0.05 6.99 0.07 7.46 0.07 8.58 0.17 
55 4.83 0.10 5.22 0.06 5.57 0.06 6.16 0.07 
56 5.03 0.02 5.22 0.04 5.45 0.04 5.82 0.07 
57 3.23 0.05 3.46 0.03 3.56 0.05 3.76 0.04 
58 0.71 0.03 0.81 0.11 0.88 0.19 1.28 0.09 
59 0.69 0.08 0.79 0.06 1.03 0.08 1.62 0.08 
60 7.20 0.15 7.35 0.08 7.52 0.11 7.97 0.14 
61 1.40 0.05 1.72 0.12 1.91 0.11 2.44 0.04 
62 6.65 0.03 6.75 0.05 6.93 0.04 7.15 0.03 
63 0.90 0.06 1.12 0.06 1.70 0.06 2.90 0.08 
64 1.69 0.17 2.20 0.04 3.30 0.07 4.80 0.05 
65 1.85 0.65 2.43 0.53 3.79 0.57 5.42 0.35 
66 2.04 0.51 2.64 0.55 4.15 0.34 5.75 0.17 
67 1.16 0.26 1.24 0.24 1.53 0.20 2.28 0.11 
68 1.28 0.06 1.70 0.08 2.77 0.04 4.15 0.08 
69 1.75 0.37 2.41 0.42 3.66 0.41 5.26 0.14 
70 1.03 0.04 1.46 0.08 2.19 0.02 2.66 0.06 
71 1.51 0.68 2.06 0.81 2.85 0.71 3.61 0.67 
72 5.13 0.09 6.48 0.18 7.99 0.19 8.79 0.31 
73 7.38 0.22 9.82 0.23 11.84 0.21 13.24 0.16 
74 0.98 0.12 1.42 0.12 2.07 0.13 2.50 0.12 
75 3.59 0.47 3.97 0.49 4.58 0.49 4.60 0.56 
76 5.00 0.09 6.42 0.04 7.40 0.03 8.29 0.05 
77 1.73 0.08 2.13 0.06 2.52 0.10 2.91 0.09 
78 3.86 0.07 4.73 0.09 5.07 0.19 5.40 0.26 
79 1.56 0.70 2.03 0.64 2.08 0.65 2.46 0.75 
80 1.64 0.17 2.06 0.18 3.39 0.17 5.56 0.23 
81 1.71 0.03 2.03 0.02 2.97 0.08 4.53 0.08 
82 1.80 0.18 2.25 0.14 3.37 0.16 5.10 0.31 
83 1.05 0.03 1.95 0.03 3.14 0.02 4.78 0.03 
84 0.98 0.03 1.78 0.01 2.82 0.02 4.32 0.05 
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Appendix 8: Metric System Unit Prefixes    
 
Prefix    Symbol  Factor 10n 
tera    T   1012 
giga    G   109 
mega    M   106 
kilo    k   103 
hector    h   102 
deca    da   101 
deci    d   10-1 
centi    c   10-2 
milli    m   10-3 
micro    μ   10-6 
nano    n   10-9 
pico    p   10-12 
femto    f   10-15 
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Appendix 9: Journal Publications and Work Presented at 
Conferences and Meetings   
 
 
Journal publications  
 
 
The application of ion mobility mass spectrometry and hydrogen deuterium exchange 
mass spectrometry for probing mechanisms of allosteric inhibition of enzymes.  
Pacholarz, K.J., Jowitt, T., Burnley, R.J., Ordsmith, V., Porrini, M., Larroy-Maumus, G., 
Pisco, J.P., Garlish, R.A., Taylor, R.J., de Carvalho, L.P., Barran, P.E.. Manuscript in 
preparation 
 
Insights into disorder–order transitions using variable temperature ion mobility mass 
spectrometry.  Dickinson, E.R., Jurneczko, E., Pacholarz, K.J., Reeves, M., Clarke, D.J., 
Ball, K., Hupp, T., Nikolova, P.V., Campopiano, D., Barran, P.E.. Manuscript submitted 
 
Distinguishing loss of structure from subunit dissociation for protein complexes: a gas-
phase route for microcalorimetry.  Pacholarz, K.J., Barran. P.E. Manuscript submitted 
 
A mass spectrometry based framework to define structural order in proteins. Beveridge, 
R., Covill, S., Pacholarz, K.J., Kalapothakis, J., McPhee, C., Barran, P.E. Anal. Chem., 
2014, 86, 10979-10991.  
 
Dynamics of intact immunoglobulin G explored by drift-tube ion-mobility mass 
spectrometry and molecular modeling.  Pacholarz, K.J., Porrini, M., Garlish, R.A., 
Burnley, R.J., Taylor, R.J., Henry, A.J., Barran, P.E. Angew. Chem., 2014, 53, 7765-
7769.  
 
Mass spectrometry based tools to investigate protein-ligand interactions for drug 
discovery.  Pacholarz, K.J., Garlish, R.A., Taylor, R.J., Barran, P.E.  Chem. Soc. Rev., 
2012, 41, 4335-4355.  
 
 
Work presented at conferences and meetings  
 
62nd Conference of American Society of Mass Spectrometry, (15-19/06/2014) 
Baltomore, USA  
“Probing protein stability, unfolding and dissociation with variable temperature mass 
spectrometry and variable temperature ion mobility mass spectrometry” (Talk) 
 
Native Mass Spectrometry and Ion Mobility Workshop (8-9/04/2014) Strasbourg, 
France 
“The application of native MS, IM-MS and HDX-MS to study mechanisms of allosteric 
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UCB PhD Student Science Day (03/10/2013) Oxford, UK  
“Signature dynamic of the intact immunoglobulin G isotype revealed by drift-tube ion-
mobility mass spectrometry and molecular dynamics” (Talk) 
 
Ion Mobility Mass Spectrometry Special Interest Group Inagural Meeting (16/04/2013) 
Slough, UK 
“Variable temperature ion mobility mass spectrometry: the effect of temperature on the 
gas-phase protein complex structure” (Talk) 
 
10th International Congress of Young Chemists - YoungChem (10-14/10/2012) Gdansk, 
Poland 
“Mass Spectrometry for Drug Discovery: Conformation, inhibition and stability studies 
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